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Abstract 
The pathogenic bacteria Streptococcus pneumoniae is one of the major 
causes of morbidity and mortality in humans in the world today. A Gram-
positive facultative anaerobe, under natural conditions it exists as a 
commensal bacteria residing in the nasopharynx. Upon invasion of the body, 
S. pneumoniae can cause a number of diseases, which range in severity from 
acute otitis-media to pneumonia, septicaemia and meningitis. 
The main virulence factor of S. pneumoniae has been identified as the 
polysaccharide capsule, which coats the outside of the cell. S. pneumoniae 
can be categorised into 92 distinct serotypes based on capsular composition. 
Current available vaccines utilise a mixture of polysaccharides from the most 
prevalent capsular serotypes, or capsular polysaccharide conjugated to a 
carrier protein. Vaccine coverage is therefore serotype specific. 
Furthermore, vaccine efficiency is lower in those groups most at risk of 
infection; namely infants, the elderly and the immuno-compromised. As a 
result investigation is ongoing into a next generation of protein-based 
vaccines that can provide increased coverage and efficiency. 
A novel family of proteins termed Pneumococcal Histidine Triad (Pht) 
proteins were identified from a whole genome antigen-screen as potential 
candidates for inclusion in a novel protein-based pneumococcal vaccine.1 
Animal models of infection have shown that immunisation with the Pht 
protein Pneumococcal Histidine Triad D (PhtD) confers protection against 
invasion of S. pneumoniae. 
PhtD was cloned, expressed, purified and subjected to crystallisation trials in 
an attempt to uncover the function of PhtD through determining the protein 
structure by macromolecular X-ray crystallography, which yielded some 
rudimentary crystallographic data. Biophysical analysis of PhtD using a variety 
of techniques including limited proteolysis and circular dichroism revealed 
that PhtD exclusively bound the divalent-cation Zn2+ and that Zn2+-binding 
induced a major conformational change in the protein structure, which 
proved to be a reversible process. A rationalised, targeted analysis of PhtD 
protein structure by limited proteolysis, Nuclear Magnetic Resonance (NMR), 
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N-terminal sequencing and mass-spectrometry revealed localised, ordered 
regions of structure within the protein sequence that were highly stable. 
These identified protein fragments were subsequently cloned, expressed, 
purified and subjected to crystallisation trials. Due to their smaller and more 
ordered nature, it was postulated that these PhtD fragments may prove more 
readily crystallisable than the full-length molecule. Initial crystals have been 
obtained for these protein fragments and are being optimised to improve 
crystal size and quality. Evaluation of the PhtD proteolysis products by 
Western blotting with anti-PhtD antibody has revealed the dominant epitope 
for the PhtD protein, localised to a 15 kDa region in the C-terminal half of the 
PhtD protein sequence. This could be a major advancement in development 
of a protein based vaccine as only the 15 kDa epitope-containing region need 
be included in order to elicit an antibody reaction. Furthermore, the small 
size of the protein fragment is highly conducive to structural determination 
by a variety of methods. This 15 kDa epitope fragment has been cloned into 
an expression plasmid allowing recombinant protein expression in order to 
investigate further. 
Additionally, as training for handling of PhtD X-ray diffraction data, 
macromolecular X-ray crystallography was attempted with a variety of 
different proteins from Gram-positive bacteria. Two proteins  -a novel cis-
trans isomerase PpmA from S. pneumoniae, and the transketolase TktA from 
Lactobacillus salivarius- were successfully crystallised. Diffraction quality 
crystals of TktA were grown that produced X-ray diffraction to 2.3Å 
resolution. The structure of TktA was successfully determined using the 
molecular replacement method. Diffraction quality crystals of PpmA were 
grown that show X-ray diffraction to 2.5Å resolution, and optimisation of 
crystallisation conditions should yield better X-ray diffraction, allowing the 
structure of PpmA to be determined. The data pertaining to these proteins is 
also included as part of this thesis. 
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Chapter 1 : Introduction 
1.1  Streptococcus pneumoniae 
1.1.1  Morphology 
The bacterial human pathogen Streptococcus pneumoniae (commonly 
referred to as the pneumococcus) is one of the leading causes of disease in 
the world today, causing an estimated 1 million deaths per year in children 
alone. A Gram-positive facultative anaerobe, S. pneumoniae, lacks the 
presence of flagellae, rendering it non-motile. It occurs as a diplococcus, 
which forms chains during growth, as illustrated in figure 1.1 
 
Figure 1.1: Scanning electron micrograph of S. pneumoniae at x14,500 magnification2 
 
Although normally present asymptomatically as a commensal of the 
nasopharyngeal flora, S. pneumoniae can cause a variety of diseases as a 
result of relocating to a different ecological niche of the body. These 
diseases can range from the mild- such as otitis-media, to the life-
threatening such as meningitis.  
The pneumococcus produces a highly antigenic extracellular capsule 
comprised of a variety of polysaccharides, which aids the bacteria in evading 
opsonophagocytosis through masking of Complement C3b deposition sites.3, 4 
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At present more than 90 different strains of pneumococcus have been 
identified, based on polysaccharide immunohistochemistry. However, due to 
cross-reactivity between antibodies used to identify different serotypes, 
nomenclature has been altered to include sub-grouping, where closely 
related serotypes are clustered into serogroups. Clinical identification of S. 
pneumoniae has traditionally been performed through the Quellung reaction 
utilising capsular-polysaccharide specific antibodies,5, 6 and by sensitivity to 
Optochin antibiotic when cultured on blood agar plates- techniques that are 
still employed in the laboratories of today.  
1.1.2 Pneumococcal Carriage 
The pneumococcus is a common commensal bacteria which colonises the 
nasopharynx. In addition to the pneumococcus, the nasopharynx is a 
competitive environment, being the ecological niche for a diverse range of 
organisms and including such species as Haemophylus influenzae, 
Staphylococcus aureus and Neisseria meningitidis.7 The pneumococcus is able 
to produce hydrogen peroxide (H2O2), which has been shown to inhibit the 
growth of other microflora of the nasopharynx, providing the pneumococcus 
with a selective advantage.8 It is thought that every person will be colonised 
with these organisms at least once during their lifetime. Pneumococcal 
carriage varies due to factors such as age, geographical location, and genetic 
background of the population.9-11 In developed countries, it is estimated that 
virtually every child will have been colonised with S.pneumoniae within their 
first year of life. 
Colonisation is thought to be key to any subsequent presentation of invasive 
pneumococcal disease (IPD). However due to variation between the current 
92 different serotypes, not all serotypes are equally pathogenic,12 with a 
number of serotypes known for their high incidence of invasive disease, 
whilst others appear to favour colonisation over invasion. Although 
pneumococcal carriage studies are rare, it has been shown that the most 
common pneumococcal serotypes in Europe are 6A, 6B, 9V, 14, 18C, 19F and 
23F.7 
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1.1.3 Pneumococcal Disease 
1.1.3.1  Overview 
Although usually present asymptomatically, the pneumococcus can cause a 
variety of diseases if it migrates from the nasopharynx to an atypical 
ecological niche within the body. The diseases that present are dependant on 
the resultant niche to which the pneumococcus migrates. There are a broad 
range of diseases which result from pneumococcal invasion which present 
symptoms of varying severity. It is thought that post-colonisation, the 
pneumococcus is able to transmigrate across the epithelial barrier in the 
nasopharynx and disseminate throughout the host, although the mechanism 
by which this process occurs is yet to be determined.13 As a result of this 
transmigration and dissemination process, the pneumococcus can invade a 
variety of niches within the host. 
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1.1.3.2  Pneumococcal Burden Of Disease 
World Health Organisation (WHO) statistics report that in the year 2000, 
there were an estimated 14.5 million cases of serious IPD.14 
 
Figure 1.2: Incidence of serious pneumococcal disease worldwide 
Global representation illustrating incidence of serious IPD. Figure reproduced from the 
WHO14 
 
Looking at the schematic representation illustrating the incidence of serious 
IPD in figure 1.2, it is evident that the regions worst affected by serious IPD 
are the developing countries; in particular, a large proportion of African 
countries show an incidence of disease of ≥3000 cases per 100,000 children 
under 5 years of age. 
The corresponding rates of mortality illustrated in figure 1.3 compound these 
findings, with the developing nations, in particular Africa exhibiting the 
highest mortality rates. 
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Figure 1.3: Incidence of mortality resulting from serious pneumococcal disease 
Global representation illustrating incidence mortality as a result of serious IPD. Figure 
reproduced from the WHO14 
 
Recent estimates suggest that there is a mortality rate of 700,000 – 1 million 
deaths per year for children below 5 years of age every year worldwide.15 Of 
these mortalities, an estimated 91,000 were in HIV+ children and an 
estimated 735,000 were in HIV- children. Of the deaths in HIV- children, over 
61% occurred in 10 African and Asian countries. These statistics illustrate the 
severity of the disease burden caused by the pneumococcus. 
 
1.1.3.3  Acute Otitis-Media (AOM) 
Acute otitis-media is the most common complaint for which antibiotics are 
prescribed for children in the US.16 The most common pneumococcal disease, 
AOM is a relatively benign condition characterised by growth of the 
pneumococcus in the middle-ear cavity resulting in inflammation of the 
tympanic membrane.17 It is thought that AOM occurs in co-infection with 
other diseases, such as viral-respiratory diseases which can alter Eustachian 
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tube function, leading to negative middle-ear pressure predisposing bacterial 
middle-ear infection.18 Of the incidence in cases of AOM, 40-60% are 
attributed to the pneumococcus,19-21 with the other major disease-causing 
agent being identified as H. influenzae. In the UK, around 30% of children 
each year are diagnosed with AOM, of which 97% are prescribed antibiotic 
treatment.22 Although not a life-threatening disease, the number of 
incidences of AOM cause a serious burden on the current healthcare system 
through outpatient treatment, and would therefore benefit from prevention 
through vaccination which would also result in reduction in the use of 
antibiotics, potentially helping to reduce the spread and proliferation of 
antibiotic-resistant pneumococci. 
1.1.3.4  Pneumococcal Pneumonia 
The pneumococcus is the leading cause of pneumonia in the world today.14 Of 
the estimated 14.5 million incidences of IPD in the year 2000, 95% of cases 
were attributed to pneumonia.14 Pneumonia is characterised by a build-up of 
fluid in the lung cavity, which reduces the area across which oxygen can pass 
into the bloodstream via the bronchial alvaeoli. Pneumonia is responsible for 
the deaths of an estimated 2 million children each year, attributing to around 
20% of child mortality, of which the pneumococcus is responsible for a high 
proportion (~70%).23 In developed countries where the majority of pneumonia 
cases are as a result of community-acquired pneumonia. With a mortality 
rate of 10-20%, the pneumococcus is the major causal agent of community-
acquired pneumonia. Pneumonia cases in the developed-world are mainly 
prevalent in the “at risk” groups comprising the elderly and immuno-
compromised, where the immune system has been weakened. Although the 
mortality rate for pneumococcal meningitis is greater, the sheer burden of 
disease caused by pneumococcal pneumonia makes it by far the most serious 
of the pneumococcal diseases. 
1.1.3.5 Meningitis & Bacteraemia 
As a consequence of the migration of the pneumococcus to the lungs and the 
onset of pneumonia, it is thought that bacteraemia due to IPD may be caused 
by pneumococcal invasion of the bloodstream across the bronchial alvaeoli. 
As a result of the dissemination and proliferation of the pneumococcus in the 
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bloodstream, it is possible for the pneumococcus to present itself at and 
cross the blood/brain barrier, resulting in meningitis in the host. 
Meningitis is characterised by inflammation of the meninges, which are the 
protective membranes that surround the brain tissue and spinal-cord. 
Symptoms of meningitis include headache, stiff neck, fever, confusion or loss 
of consciousness and intolerance to light.24, 25 Left untreated, meningitis can 
lead to coma and death. In adults, bacterial meningitis has an annual 
incidence of 4 -6 per 100,000 members of the population; 80% of all bacterial 
meningitis cases are caused by S. pneumoniae or N. meningitidis.24 Meningitis 
has a mortality rate of 20-30%26, 27. Complete recovery is rare however, with 
a large number of survivors suffering from residual effects; epilepsy, spinal-
cord dysfunction and hearing loss have been reported.26 In addition to these 
observations, the WHO reports that in sub-Saharan Africa, 40-75% of 
individuals diagnosed with pneumococcal meningitis either die or are 
permanently disabled. 
1.1.4 Pneumococcal Virulence Factors 
1.1.4.1  Overview 
The pneumococcus has a number of virulence factors that have an effect on 
the pathogenicity of the organism. As previously mentioned, the main 
virulence factor of the pneumococcus has been identified as the 
polysaccharide capsule, which coats the surface of the bacteria. In addition 
to the polysaccharide capsule, a variety of other pneumococcal virulence 
factors have been identified and include surface proteins capable of 
performing a variety of functions, pili thought to play a role in cellular 
adherance, and a lytic toxin named pneumolysin (Ply). A selection of these 
virulence factors are illustrated in figure 1.4, and their functions described in 
table 1.1. 
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Figure 1.4: Pneumococcal virulence factors 
Figure illustrating a selection of virulence factors possessed by S. pneumoniae. Figure 
reproduced from Mitchell, T.J. (2003).28 
 
Virulence Factor Function/Effect 
  
Capsule Protection against phagocytosis 
and opsonisation.4, 29, 30 
 
Pneumolysin (Ply) Cytolytic toxin.31, 32 Essential for 
pneumococcal pathogenesis and 
survival in the host.33-36 
 
Autolysin A (LytA) Degrades pneumococcal 
peptidoglycan releasing cell-wall 
products resulting in 
inflammation,37 and allowing 
release of Ply toxin from the inside 
of the cell.38 Also involved in 
migration of pneumococci from 
nasopharynx to lower respiratory 
tract.36 
 
Pneumococcal Surface Protein C (PspC, aka 
CbpA) 
Protects host from opsonisation by 
recruiting complement Factor H to 
the cell surface.39-41 Involved in 
pneumococcal colonisation.42 
 
Pneumococcal Surface Protein A (PspA) Inhibition of Complement binding 
and activation.43-45 Protects 
pneumococcus against killing 
effects of lactoferrin.46 
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Pneumococcal Surface Antigen A (PsaA) Substrate-binding protein of Mn2+ 
ABC transporter.47, 48 Required for 
pneumococcal adherance.49-51 
  
Neuraminidase A (NanA) Cleaves sialic acid from cell 
surfaces, revealing receptors for 
adherence to host.52, 53 
 
Pilus Involved in adhesion of 
pneumococci to host.54-57 A second 
pilus recently discovered also 
appears involved in adhesion.58 
 
Hydrogen Peroxide (H2O2) Kills or inhibits growth of 
competitive nasopharyngeal 
microflora.8 
  
Zinc Metalloprotease (ZmpB) Induces TNF-α production, 
resulting in lower respiratory tract 
inflammation.59 
 
Pneumococcal Histidine Triad (Pht) proteins Unknown function. Proposed 
metal-scavengers for survival 
under environmental stress.60 
Possible role in Factor H binding.61 
  
Table 1.1: Pneumococcal virulence factors and their functions 
 
1.1.4.2  Pneumococcal Polysaccharide Capsule 
The capsule protects the pneumococcus from phagocytosis through blocking 
the sites of Complement C3b binding, which causes opsonisation.4, 29 The 
composition of the pneumococcal capsule is highly variable, which has led to 
the evolution and proliferation of greater than 90 distinct serotypes.62 This 
capsule is laid down on the outer surface of the cell. Due to the high 
variability in capsular composition, differences occur in capsule physiology 
between pneumococcal serotypes (STs); as an example, serotype 3 (ST3) 
pneumococci exhibit a significantly more highly mucoid capsule than other 
serotypes. There has been speculation that the type of capsule expression 
may affect the preference of the bacteria for invasion or colonisation; 
expression of a capsule is important for survival in the blood, and is strongly 
associated with the ability of pneumococci to cause invasive disease. 
Certainly there are differences in invasion and colonisation instances 
between strains possessing different capsule types.63  
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Having been identified as the main pneumococcal virulence factor, the 
polysaccharide capsule is the current target of the developed range of 
pneumococcal vaccines, with a polysaccharide vaccine that targets 23 
different serotypes, an established protein conjugate vaccine targeting 7 
serotypes and a recently introduced protein conjugate vaccine which targets 
10 serotypes. 
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1.2  Pneumococcal Vaccines 
1.2.1  At Risk Groups/Vaccine Coverage 
The main ‘at risk’ groups susceptible to IPD are the young (children under 5 
years of age), the elderly, and the immuno-compromised.64 Children in 
undeveloped countries are particularly at risk from pneumococcal infection. 
In developed countries, the elderly are particularly at risk from 
pneumococcal disease resulting in community-acquired pneumonia. Current 
pneumococcal vaccines are based on the pneumococcal polysaccharide 
capsule. As there are greater than 90 different serotypes of pneumococcus 
based on capsule composition,62 current vaccines are serotype specific. These 
vaccines have been highly successful in providing protection against the 
pneumococcal strains that they target, however due to their serotype-
specific design, this efficiency varies depending on geographical location due 
to varying prevalence of different serotypes around the world.65 Current 
pneumococcal vaccines have shown high efficiency in preventing IPD in 
developed countries such as the USA,65 as the current vaccines were tailored 
for this market, targeting the most prevalent US serotypes. Worldwide 
implementation of the pneumococcal conjugate vaccine is illustrated in 
figure 1.5. 
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Figure 1.5: Worldwide implementation of pneumococcal conjugate vaccine 
From the data above it can be observed that use of the pneumococcal conjugate vaccine is 
largely confined to the developed world. Figure reproduced from the WHO.14 
 
Although implementation of the pneumococcal conjugate vaccine has begun 
to be introduced in developing countries such as regions of South America, 
use of the pneumococcal conjugate vaccine is predominantly still confined to 
regions of the developed world such as the USA and Europe. Possible reasons 
for this could be cost, lack of ease-of-administration (an immunisation-course 
must be administered by a General Practitioner), or possibly due to the 
prevalence of serotypes not covered by the vaccine. 
1.2.2  Evolution of the Pneumococcal vaccine 
Similar to the original smallpox vaccine developed by Edward Jenner, the 
first pneumococcal vaccine was whole-cell based, utilising whole killed 
pneumococci.66, 67 Further investigation lead to the revelation that the 
pneumococcal polysaccharide capsule played a key role in causing IPD. A 14-
valent polysaccharide vaccine comprising the polysaccharide elements for the 
14 most prevalent pneumococcal serotypes was developed and released in 
1977. Subsequently, this 14-valent vaccine was updated to a 23-valent 
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vaccine, which included polysaccharide for an additional 9 serotypes.68 
However, limitations in these polysaccharide vaccines led to the development 
of a new generation of vaccines based on the method of fusing antigens to a 
protein carrier first developed and implemented with success for the 
influenza HiB vaccine.69, 70 Both the pneumococcal polysaccharide vaccine 
and the protein-conjugate vaccines have advantages and limitations, and are 
administered accordingly.  
1.2.3  Pneumococcal Vaccine Types 
As described in chapter 1.2.2, there are currently two distinct types of 
pneumococcal vaccine on the market at present. An overview of these 
currently available vaccines is given in table 1.2. 
Vaccine 
Name 
Type Vaccine 
Coverage (ST) 
Details Manufacturer 
     
PneumoVax® Polysaccharide 1, 2, 3, 4, 5, 6B, 
7F, 8, 9N, 9V, 
10A, 11A, 12F, 
14, 15B, 17F, 
18C, 19A, 19F, 
20, 22F, 23F, 
33F 
 
Polysaccharide 
vaccine comprising 
capsular 
polysaccharide for 
23 pneumococcal 
STs 
Sanofi Pasteur 
MSD 
Prevenar™ 
(PCV7) 
Protein-
conjugate 
4, 6B, 9V, 14, 
18C, 19F, 23F  
 
(Additions for 
PCV13: 1, 3, 5, 
6A, 7F, 19A) 
7 most prevalent 
disease-causing STs 
conjugated to 
CRM17 diphtheria 
toxoid71 (PCV7 has 
recently been 
updated to include 
a further 6 
serotypes and 
named PCV13.72-74 
These additional 
serotypes are 
shown in 
parenthesis) 
 
Wyeth Vaccines 
(Pfizer) 
Synflorix™ Protein-
conjugate 
1, 4, 5, 6B, 7F 
9V, 14, 18C, 
19F, 23F 
10 most prevalent 
disease-causing STs 
conjugated to 
NTHiD75, 76 
GlaxoSmithKline 
     
Table 1.2: Current licensed available pneumococcal vaccines 
 
The 23 serotype-polysaccharides included in the PneumoVax polysaccharide 
vaccine comprise those responsible for 65-86% of pneumococcal disease over 
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the period from 1978-94 in the US.65 PneumoVax is the pneumococcal vaccine 
usually administered to elderly patients. 
Wyeth Vaccines’ pneumococcal conjugate vaccine Prevenar™ utilises 
polysaccharides that recognise the 7 most prevalent pneumococcal serotypes 
in the US. These polysaccharides are conjugated to the CRM17 diphtheria 
toxoid. In contrast to the 23-valent polysaccharide vaccine, Prevenar™ is 
capable of providing protection in young children.77 
Synflorix™ takes the serotype formulation used in Prevenar™ and incorporates 
serotype 7F, along with two serotypes -1 and 5- most prevalent in developing 
countries.14 In addition to these additional serotypes, the polysaccharides are 
conjugated to the Non-typable H. influenzae D protein (NTHiPD) rather than 
the CRM17 carrier utilised in Prevenar™, resulting in a degree of protection 
against H. influenzae.75 
1.2.4  Limitations Of Current Vaccines 
Whilst all the above vaccines have proven to be successful in controlling 
pneumococcal disease, each has their limitations. The 23-valent 
polysaccharide vaccine is ineffective in children under 2 years of age, one of 
the most vulnerable groups susceptible to pneumococcal disease, with the 
poor immunogenic response to the pneumococcal antigens resulting from a 
lack of T-cell involvement that is a prerequisite for high-level antibody 
response and induction of immunologic memory.65, 78, 79 
Whilst Prevenar™ has been shown to provide protection in children where 
PneumoVax® does not, it has the disadvantage of only providing protection 
against the 7 serotypes of pneumococci most prevalent in the US. As a result 
of this, vaccine efficacy in different geographical areas is likely to vary 
significantly, depending on the prevalent serotypes of the region. It is likely 
that this would also occur with the Synflorix™ 10-valent conjugate vaccine, 
although having been recently introduced, it will be some time before 
enough data is available to draw any conclusions. Additionally, with regards 
to the polysaccharide conjugate vaccines covered in this section, there is the 
added complication of economic value for vaccine production; the 
conjugation process becomes progressively more difficult with increasing 
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number of conjugate-antigens, and similarly vaccine production costs also 
increase. It could therefore be foreseen that the difficulties in continuing this 
method of vaccine development would eventually outweigh the merits of 
production of the vaccine. 
A further complication that has been foreseen as a potential problem for the 
current group of pneumococcal vaccines is the possibility of serotype 
replacement occurring.80, 81 It may be that upon successful control of the 
serotypes targeted by the current vaccines, a gap is made available which is 
filled by other pneumococcal serotypes which had previously been relatively 
uncommon in comparison to those targeted by the vaccine, resulting in the 
need for reformulation of the current vaccines to cover the newly emergent 
serotypes.82, 83 This effect has already been observed in regions which have 
implemented the PCV7 vaccine;84-86 successful reduction in the serotypes 
covered by PCV7 has resulted in serotype-replacement of these strains, with 
the subsequent emergence of serotype 19A pneumococci as a virulent strain 
in these areas.87-89 
1.2.5  Next-Generation Vaccine Development 
Although there has been success with administration of the current 
pneumococcal vaccines, the limitations in the vaccine design at present as 
outlined above have encouraged research into development of a next-
generation protein vaccine. As such, investigation has begun in an attempt to 
identify suitable candidate proteins that would satisfy the following criteria: 
• Highly conserved throughout the various pneumococcal serotypes 
• Capability of eliciting an antibody response from the host immune-
system upon exposure to the protein vaccine candidate 
• Ideally, unique to the pneumococcus 
• No homology to any human proteins 
Potentially, a protein candidate which satisfied these criteria could have the 
ability to provide protection against the vast majority of pneumococcal 
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strains, whilst avoiding any cross-reactivity with host proteins which may 
have a detrimental effect to the patient. 
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1.3 Pneumococcal Histidine Triad Proteins 
1.3.1  Identification As A Vaccine Candidate 
In 2001, a whole genome study of a serotype 4 strain of pneumococcus 
(named Norway 4 - isolated from a Norwegian patient with bacteraemia90 and 
subsequently renamed TIGR491) performed by Medimmune Inc. (Gathersberg, 
Maryland US) identified 130 ORFs for proteins encoding secretion motifs or 
showing  similarity to known virulence factors, of which 6 conferred 
protection against pneumococcal infection and showed broad strain 
distribution.1 Utilising flow-cytometry, several of these targets were 
confirmed as surface localised.1 Further investigation revealed the presence 
of a novel family of proteins that localised to the cell-surface,92 which were 
termed Pneumococcal Histidine triad proteins (Pht) after an HxxHxH motif 
repeated several times throughout the amino acid sequence of the Pht 
protein family. These proteins were shown to provide protection against 
pneumococcal disease in a murine model of systemic infection, implying that 
the Pht proteins were possible candidates for inclusion in a protein-based 
pneumococcal vaccine.92 A subsequent study in 2006, performing a whole 
genome screen via a lambda-display library was carried out on the 
pneumococcal strain D39.93 Screening of this library with sera from 
individuals suffering pneumococcal infection, or with sera from mice 
immunised with S. pneumoniae D39 resulted in the identification of a number 
of potential vaccine candidates including the Pneumococcal Histidine Triad 
(Pht) proteins.93 These proteins have also variously been termed 
Pneumococcal Histidine Proteins (Php),94 and BVH proteins.95 Throughout this 
thesis, these proteins will be referred to as Pht proteins, as this is the most 
widely accepted name for these proteins in the current literature. 
In a murine model of pneumococcal infection, immunisation of mice with Pht 
proteins has been shown to confer protection from pneumococcal 
challenge.96 Additionally, flow-cytometry experiments and immunogold-
labelling experiments have shown that the Pht proteins are present on the 
surface of the pneumococcal cell.92, 95 The observations above, and the 
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potential for antibodies generated against one Pht protein to cross-react with 
the other Pht proteins (due to high sequence identity between the different 
Pht proteins) make the pneumococcal histidine triad protein family an 
attractive option for inclusion in a new protein-based pneumococcal vaccine. 
1.3.2 Sequence Variation 
There have been 4 identified Pht proteins in the pneumococcus. These have 
been named PhtA, PhtB, PhtD, and PhtE respectively. To date these Pht 
proteins have been identified exclusively in Streptococci, and are highly 
conserved across all pneumococcal serotypes. Sequence homology between 
the 4 proteins in this family varies from 87%,92 with PhtE bearing the lowest 
sequence identity to the others, being only 37% homologous. Most variation 
between the different Pht proteins is evident at the C-terminal end of the 
molecule, whilst the N-terminal sequence is rather more highly conserved 
with an average of >62% homology between members. In general, the Pht 
proteins show a high degree of sequence homology, as illustrated in figure 
1.6. This sequence homology could be advantageous when considering the 
Pht proteins as potential vaccine candidates, as the high degree of similarity 
in sequence could confer cross-reactivity of antibodies generated from one 
Pht protein with other members of the Pht family. 
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Figure 1.6: Sequence alignment of Pht proteins 
Multiple sequence alignment of the four Pht proteins in the pneumococcal strain Norway4 
(subsequently known as TIGR4). Highly conserved residues are shaded. HxxHxH motifs are 
highlighted by white lettering-on-black. Predicted signal sequences for the Pht proteins are 
also indicated. Figure reproduced from Adamou et al (2001).92 
 
1.3.3 Putative Role 
Previous investigation into the Pht proteins in our laboratory at the University 
of Glasgow resulted in the structural determination of a fragment of 
Pneumococcal histidine triad A (PhtA) through the method of macromolecular 
X-ray crystallography.97, 98 The crystal structure of this fragment of the PhtA 
molecule was determined at high resolution (1.2Å) and revealed the presence 
of a Zn2+ atom bound by the HxxHxH motif present in the fragment for which 
the protein family was named (illustrated in figure 1.7).  
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Figure 1.7: 1.2Å Crystal structure of PhtA fragment 
Crystal structure of the PhtA fragment (residues 166-220).98 The Zn2+ atom is illustrated in 
grey. Image generated using Jmol.99  
 
The Zn2+ atom was revealed to be bound into the crystal structure through a 
novel zinc-binding fold, which is created by the histidines from the HxxHxH 
motif and an additional aspartate residue; the ligating residues and their 
interaction with the zinc are shown in figure 1.8. 
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Figure 1.8: Zn2+ binding in 1.2Å crystal structure of PhtA, illustrating Zn2+-ligating residues 
The coordination of the ligating residues showing their interaction with the Zn2+ atom is 
illustrated. Ligating residues are numbered according to their residue number in the 
determined crystal structure. Corresponding residue numbers in the full protein sequence of 
PhtA are given in parenthesis. Image created using COOT. 
 
The Zn2+ atom is bound by ND1 of His-194, NE2 of His-197, NE2 of His-199 and 
OD2 of Asp-173 at distances of 2.02, 2.03, 2.03 and 1.97Å, forming a 
distorted tetrahedral coordination sphere for the Zn2+ atom, with the three 
histidine residues forming the base of the triangle and the side-chain of 
aspartate 173 forming the apex. The observed distances were shorter than 
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expected; typical distances of protein – Zn2+ atoms are 2.2Å for histidines and 
2.1Å for aspartate residues.98 
Interestingly, crystallisation trials were begun using full-length PhtA protein, 
suggesting either that the PhtA protein had subjected itself to auto-
proteolysis, or a protease contaminant had inadvertently been introduced 
during experimental set-up. Data in this thesis supports the mechanism of 
Zn2+ binding by the Pht proteins, and that PhtD appears to elicit Zn2+ binding 
exclusively. Recent publications have variously suggested that PhtD may play 
a role in protection of the pneumococcus from opsonophagocytosis by the 
recruiting of Complement Factor-H to the cell surface,61, 100 or that the Pht 
proteins function to scavenge Zn2+ or Mn2+ from the environment60, 101, 102 and 
act as a reservoir which can be released in nutrient- depleted conditions, 
effectively playing the role of a siderophore.103, 104  
Although 4 different Pht proteins have been described to date in the 
pneumococcus, the degree of sequence homology outlined above would 
suggest that only one of the Pht proteins may be required in order to provide 
protection, due to the possibility of cross-reaction between generated 
antibodies and the other members of the Pht protein family. To this end, 
PhtD has been singled out as the candidate protein from this family, as it is 
the most highly conserved of the Pht proteins, and has been identified in all 
strains of the pneumococcus that have been analysed to date.60 
A variety of other pneumococcal proteins have been investigated as potential 
vaccine candidates, such as PspA, PspC, and PsaA.49, 105-107 However in 
experiments carried out using lung and nasopharyngeal colonisation models, 
immunisation with the Pht proteins was more successful at preventing 
pneumococcal colonisation than immunisation with other candidates 
including PspC, PspA, and PsaA.96 Additionally, PhtD has been seen to provide 
protection against a variety of different pneumococcal strains including ST3, 
which is becoming increasingly prevalent.108 Furthermore, in a murine model 
of intranasal challenge, mice immunised with PhtD showed significant 
protection against challenge with a lethal dose of pneumococci.96 Ply has also 
been investigated as a possible vaccine candiate.109, 110 Since Ply is a member 
of the cholesterol dependant cytolysins and is toxic, it must be used at 
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extremely low concentrations; a non-lytic version of Ply has been discovered 
which allows greater doses to be administered.111 However, the potential of 
Ply as a vaccine is currently focused on making use of its properties as an 
adjuvant where it is administered in conjunction with another protein as a 
fusion-protein to boost the immunogenicity of its fusion-partner.112, 113 
1.4  Pneumococcal Histidine Triad D (PhtD) 
PhtD is the main antigen of interest from the Pht family of proteins for 
possible inclusion in a protein-based pneumococcal vaccine. Although lacking 
any classical anchoring region such as an LPxTG motif or choline binding 
domain, flow-cytometry and immuno-gold labelling have shown PhtD to be 
located on the cell surface,95 giving rise to PhtD being termed “cell-surface 
associated”. 
The protein sequence of PhtD is illustrated in figure 1.9. The predicted signal 
sequence for targeting PhtD to the surface of the cell,92 and the location of 
the HxxHxH motifs in the amino acid sequence are highlighted. 
 
Figure 1.9: PhtD protein sequence from the S. pneumoniae strain TIGR4 
The figure above shows the protein sequence of PhtD from the S. pneumoniae strain TIGR4. 
HxxHxH motifs are highlighted in pink. Predicted signal sequence for targeting PhtD to the 
pneumococcal cell-surface is highlighted yellow. 
  
Without the signal sequence, mature PhtD protein from the pneumococcal 
strain TIGR4 has a predicted molecular weight of 91.5 kDa114 and contains 5 
of the canonical HxxHxH motifs for which the Pht family is named. 
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Vaccination studies with PhtD have shown the protein to be a promising 
candidate for inclusion in a protein-based pneumococcal vaccine, producing 
an antibody response in mice that provided protection from a lethal 
challenge of pneumococci. The uniqueness of the Pht proteins is another 
advantage for inclusion of PhtD in a protein-based vaccine, as to date the Pht 
proteins are thought to be highly conserved and exclusive to streptococci 
(genome comparisons have predicted the presence of Pht proteins in S. mitis 
and S. pyogenes, which is not surprising, as for example horizontal gene 
transfer is very common between S. mitis and S. pneumoniae). Thus a 
vaccine targeting Pht proteins should be able to provide comprehensive, 
specific protection against pneumococcal disease. 
PhtD is the most prevalent of the Pht proteins, and has been found present in 
100% of pneumococcal strains analysed to date.102 Whilst there has been 
speculation as to the function of the Pht family of proteins in general,61, 100-102 
the definitive understanding of the functions of PhtA, PhtB, PhtD, and PhtE 
are still unknown. As the crystal structure of PhtA showed Zn2+ binding to the 
PhtA fragment through the HxxHxH motifs,98 it was postulated that PhtD 
would also be able to bind metal atoms through the same mechanism. 
1.5  Project Aims 
The primary aim of this project was to attempt structural determination of 
the protein Pneumococcal Histidine Triad D by macromolecular X-ray 
crystallography, in order to use the determined crystal structure for 
elucidating the biological function of the PhtD protein. Structural analysis of 
PhtD was also investigated by a variety of complimentary biochemical 
techniques to uncover regions of the protein that may be conducive to X-ray 
crystallography, with an aim to providing a crystal structure for a fragment of 
the PhtD protein in the event that a crystal structure of the complete protein 
was unattainable. Furthermore, following on from previous work in our 
laboratory which uncovered the metal-binding ability of the HxxHxH motif in 
Pht proteins,98 biophysical characterisation of PhtD and its role as a metal-
binding protein were performed in order to assess the effect of metal-binding 
on protein structure, and the interaction of PhtD with various different 
metals.
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Chapter 2 : Materials And Methods 
2.1  Materials 
2.1.1 Chemicals 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich, 
Gillingham UK or Fisher Scientific, Loughborough UK. Agarose was procured 
from Invitrogen, Paisley UK. Complete™ EDTA-free Protease Inhibitor tablets 
and Proteomics Grade Bovine Trypsin were purchased from Roche 
Diagnostics, West Sussex UK. 
2.1.2 Enzymes 
Restriction enzymes and Phusion® high-fidelity DNA polymerase were 
purchased from New England BioLabs, Hitchin UK. GoTaq® DNA polymerase 
was purchased from Promega UK, Southampton UK. 
2.1.3 Competent Cells 
 Subcloning Efficiency™ DH5α™ cells and MAX Efficiency® DH10B™ cells were 
purchased from Invitrogen, Paisley UK. Stratagene XL10-Gold™ 
Ultracompetent cells were obtained from Aligent Technologies UK, Stockport 
UK. Rosetta™ 2(DE3)pLysS Singles™ and B834 chemically competent cells were 
obtained from Merck Chemicals, Nottingham UK.  
2.1.4 Oligonucleotides 
Oligonucleotides were obtained from Sigma-Aldrich, Gillingham UK or 
Invitrogen, Paisley UK. 
2.1.5 Chromatography Supplies 
Prepacked HisTrap™ HP affinity columns for Immobilised Metal Ion Affinity 
Chromatography (IMAC), HiTrap™ Capto™Q columns for anion exchange, and 
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PD10-Desalting columns were obtained from GE Healthcare, Buckinghamshire 
UK. 
2.1.6 Crystallographic Supplies 
A variety of commercially available crystallisation screens were utilised 
throughout this project. Crystal Screens 1 & 2, PEG/Ion Screen and Grid 
Screen were obtained from Hampton Research, Aliso Viejo, CA USA. JCSG+ 
and Wizard 1& 2 screens were purchased from Emerald Biosystems, 
Bainbridge Island, WA USA. PACT screen was obtained from Qiagen, West 
Sussex UK. Morpheus™ and MemStart/MemSys screens, Cryocaps and vials 
mounted Litholoops™ were obtained from Molecular Dimensions, Suffolk UK. 
Innovaplate™ SD-2 crystallisation plates were obtained from Innovadyne 
Technologies INC, Santa Rosa, CA USA. 
2.2  Media And Buffers 
2.2.1 Molecular Biology Buffers 
Commonly used buffers for molecular biology are listed in table 2.1. 
Buffer Composition Comments 
   
50x Tris-Acetate- 
EDTA (TAE) 
242g Tris base, 
57.1ml glacial 
acetic acid, 100ml 
0.5M EDTA (pH8.0).  
 
Final volume 1L, pH 
adjusted to 8.5. 
Diluted to 1x before 
use 
 
 DNA loading dye 0.25% Orange G 
(Sigma-Aldrich), 
40% (W/V) Sucrose 
 
Made to final vol in 
dH2O 
Tris-EDTA (TE) 10mM Tris HCl 
pH7.5, 
1mM EDTA 
 
N/A 
Table 2.1: Commonly used buffers and their composition 
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2.2.2 Growth Media 
The Escherichia coli (E. coli) bacterial strains DH10B, XL10-Gold, DH5α, B834, 
and Rosetta 2(DE3)pLysS were routinely grown in Luria Broth (LB). For large 
scale protein expression cultures the strains B834 and Rosetta 2(DE3)pLysS 
were routinely grown in Overnight-Express™ Instant TB medium (TB-Onyx; 
Merck Chemicals, Nottingham UK). For growth of E.coli bacterial strains on 
agar plates, solid LB medium was obtained by dissolving 1.5% (w/v) micro-
agar in liquid LB and autoclaving at 121oC for 15 mins. For growth of 
S.pneumoniae on solid media, Blood Agar Base (Oxoid, Hampshire UK) plates 
were obtained by dissolving 40g/L BAB in dH2O and autoclaving at 121oC for 
15 mins. The sterile gar was allowed to cool until warm but still molten then 
supplemented with 5% defibrinated horse blood (E & O Laboratories, 
Bonnybridge, Scotland UK). Liquid culture of S. pneumoniae was performed in 
Brain Heart Infusion (BHI) broth (Oxoid).  Compositions of all growth media 
used are given in table 2.2. 
Media Composition Comments 
   
Luria Broth (LB) Tryptone 10g/L 
Yeast extract 5g/L 
NaCl 10g/L 
20g/L dissolved in dH2O, then 
autoclaved at 121oC for 15 mins 
 
Brain Heart Infusion (BHI) Brain infusion solids 12.5g/L 
Beef heart infusion solids 5.0g/L 
Proteose peptone 10g/L 
Glucose 2g/L 
NaCl 5g/L 
Disodium phosphate 2.5g/L 
pH to 7.4 ± 0.2 @ 25oC 
 
37g/L dissolved in dH2O then 
autoclaved at 121oC for 15 mins 
LB Agar LB media + 1.5% (w/v) micro-agar 
 
N/A 
Blood Agar Base (BAB) Proteose peptone 15g/L 
Liver digest 2.5g/L 
Yeast extract 5.0g/L 
NaCl 5.0g/L 
Agar 12g/L 
pH to 7.4 ± 0.2 @ 25oC 
 
40g/L dissolved in dH2O 
Then autoclaved at 121oC for 15 
mins. 
For blood plates: supplement 
warm, molten BAB with 5% 
defibrinated horse blood 
 
Overnight-Express Instant 
TB Medium 
(TB-Onyx) 
Proprietary formulation 60g/L in dH2O. Microwaved until 
dissolved and simmering. 
N.B. Cannot be autoclaved due 
to presence of sugar 
supplements in formulation 
 
GS96 Medium Proprietary formulation 49.1g/L in dH2O autoclaved at 
121oC for 15mins. Supplemented 
with 0.1% (v/v) glycerol to 
increase plasmid yield.  
   
Table 2.2: Growth media and their composition 
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2.2.3 Antibiotics 
The antibiotics described in table 2.3 were used routinely. Stock solutions of 
these antibiotics were made at 1000x working strength, filter sterilised and 
stored at -20oC until required. Sterile broth media was cooled to ambient 
temperature before addition of antibiotic immediately before starting culture 
growth. When using antibiotic-supplemented agar, required antibiotics were 
added to sterile agar that was hand-warm but still molten immediately prior 
to pouring plates, in order to preserve antibiotic activity. 
Antibiotic Stock 
concentration 
Final 
concentration 
Solvent Sterilisation 
 
Ampicillin 
 
50mg/ml 
 
50µg/ml 
 
dH2O 
 
0.22µm 
syringe filter 
     
Chloramphenicol 34mg/ml 34µg/ml EtOH 0.22µm 
syringe filter 
     
Carbenicillin 54mg/ml 54µg/ml dH2O 0.22µm 
syringe filter 
     
Table 2.3: Antibiotics 
 
2.2.4 Isopropyl β-D-thiogalactopyranoside (IPTG) 
A 1M stock of IPTG for a final working concentration of 1mM was prepared in 
dH2O and filter sterilised with a 0.22µm syringe filter. The 1M IPTG stock was 
stored at -20oC until required. 
2.3  Bacterial Strains And Vectors 
2.3.1 Storage 
All bacterial strains were kept as glycerol stocks for long-term storage at -
80oC. Glycerol stocks were prepared by addition of 0.5ml 80% (w/v) sterile 
glycerol to per 1ml of O/N culture. Glycerol stocks were divided into multiple 
aliquots before storage. 
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2.3.2 Bacterial Strains 
A summary of the bacterial strains utilised is given in table 2.4 For long-term 
storage and preservation, plasmids were transformed into Subcloning 
Efficiency DH5α cells and stored as glycerol stocks at -80oC. Protein 
expression was carried out in Rosetta 2(DE3)pLysS or B834 chemically 
competent cells under control of a T7 promoter. Initially, newly constructed 
plasmids were transformed into XL10-GOLD chemically competent or DH10B 
electrocompetent cells, and subsequently transformed into DH5α cells for 
storage. 
Strain Genotype Reference 
 
XL10-Gold® 
 
TetrΔ(mcrA)183 Δ(mcrCB-
hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F’ proAB 
lacIqZΔM15 Tn10 (Tetr) Amy 
Camr] 
 
 
N/A 
MAX Efficiency® DH10B™ F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZ ΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara, 
leu)7697 galU galK λ - rpsL 
nupG tonA 
Killmann et al (1996)115  
Subcloning Efficiency™ 
DH5α™ 
F-φ80lacZΔM15 Δ(lacZYA-
argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 
thi-1 gyrA96 relA1 λ- 
 
Rogers et al (2000)116 
B834 F- ompT hsdSB(rB-mB-) gal dcm 
met 
 
Wood (1966)117 
Studier & Moffat 
(1986)118 
 
Rosetta™ 2(DE3)pLysS 
Singles™ 
F- ompT hsdSB(rB-mB-) gal dcm 
(DE3) pLysSRARE2 (CamR) 
N/A 
Table 2.4: List of bacterial strains, including genotypes 
 
 
2.3.3 Plasmid DNA 
All expression constructs generated were the result of cloning the desired S. 
pneumoniae TIGR4 gDNA into the expression vector pOPINF119 (Fig 2.1). 
Protein expression is possible through the lac operator under control of a T7 
promoter and can utilise an IPTG-inducible or auto-induction system. In 
addition, pOPINF119 has added versatility in that it can be used for expression 
in multiple hosts without having to shuttle the insert into a different vector. 
Main vector features are described in table 2.5. 
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Vector Features Reference 
 
pOPINF 
 
T7 promoter, lac operator, 
N-terminal His6-Tag, 
HRV-C3 protease site for His6 
cleavage,  
Ampicllin resistance 
 
Berrow (2007)119 
   
Table 2.5: pOPINF expression vector features 
 
 
Figure 2.1: pOPINF expression vector map 
Expression constructs based on the pOPINF vector119 were generated by insertion of the gene 
of interest (GOI) or DNA fragment between KpnI and HindII restriction sites, fusing a His6-tag 
to the N-terminus of the inserted DNA and placing recombinant protein expression under the 
control of the T7 promoter located upstream from the insertion site. Plasmid map was 
generated using CLC Genomics Workbench 4.120 
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2.4  Laboratory Techniques 
2.4.1 General Laboratory Techniques 
Unless otherwise specified, all general laboratory techniques were performed 
as outlined in Sambrook et al (1989)121 or the set of standard operating 
procedures devised or optimised by the Mitchell Lab (relevant SOPs are 
included in appendices). 
2.5 Polymerase Chain Reaction (PCR) 
2.5.1 Preparation Of Genomic DNA 
S. pneumoniae gDNA was prepared from the strain TIGR4 as described in the 
standard protocols devised by the Mitchell Lab (See Appendix A.3.1). Purified 
gDNA concentration was measured using a Nanodrop 1000, standardised to a 
concentration of 100ng/µl and stored at 4oC for use as required. 
2.5.2 PCR Primers 
Primers for PCR were supplied from either Sigma-Aldrich or Invitrogen in solid 
form. Primers were reconstituted in DNase/RNase-free Ultra-pure water 
(Invitrogen) to a final concentration of 100µM. A working stock of 10µM was 
prepared by dilution of the 100µM stock 10-fold with DNase/RNase-free 
water. Both Concentrations of primers were stored at -20oC until required. 
Table 2.6 describes the primers used. 
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Primer Name Primer Sequence Comments 
   
PhtD F/L Fwd AAGTTCTGTTTCAGGGCCCGTCCTA 
TGAACTTGGTCGTCACCAA 
Fwd primer for pMRH1 
PhtD F/L Rev ATGGTCTAGAAAGCTTTACTGTATA 
GGAGCCGGTTGACTTTC 
Rev primer for pMRH1, 
pMRH2 & pMRH4 
PhtD C-Term Fwd AAGTTCTGTTTCAGGGCCCGCCCAG 
CGCAAATCACAAGTCGAAC 
Fwd primer for pMRH2, 
pMRH3 & pMRH6 
PhtD ΔC-Term Rev ATGGTCTAGAAAGCTTTATTTTTCTA 
GCAAGGCCTCCGCATC 
Rev primer for pMRH3 & 
pMRH7 
PhtD 5.3kDa Fwd AAGTTCTGTTTCAGGGCCCGGTAACA 
GATCCTAGTATTAGAC 
Fwd primer for pMRH4 
PhtD 34kDa Rev ATGGTCTAGAAAGCTTTAGTTATGGT 
AATGGTCATAATGAGG 
Rev primer for pMRH6 
PhtD Epitope Fwd AAGTTCTGTTTCAGGGCCCGATCAAA 
TTTGAGTGGTTTGAC 
Fwd primer for pMRH7 
PhtD Internal 1 GTTCTAGTTATAATGCAAATCC Located at 664 – 686bp. 
For fully sequencing PhtD 
PhtD Internal 2 GTCGACAAGTTGATTTTGAGGC Located at 1348 – 1370bp. 
For fully sequencing PhtD 
PhtD Internal 3 CCAAACGAACGTCCGCATTCAG Located at 1986 – 2008bp. 
For fully sequencing PhtD 
PhtD/Plasmid join GCAGAAGTAGATAGTCTCTTGG Sequences from PhtD into 
pOPINF plasmid at C-
terminal join 
Ply Sense (52Q) ATTTCTGTAACAGCTACCAACGA For amplification of Ply 
fragment122 
Ply Anti-sense (52R) GAATTCCCTGTCTTTTCAAAGTC For amplification of Ply 
fragment122 
   
Table 2.6: PCR primers used in DNA cloning and sequencing 
 
2.5.3 dNTPs 
A set of dNTPs (Invitrogen), a source of free nucleotides, for use in PCR 
reaction-mixes was prepared in a ratio of 1:1:1:1 in DNase/RNase-free ultra 
pure H2O to a final concentration of 10µM and stored at -20oC until required. 
2.5.4 PCR 
PCR was performed using a Techgene thermal cycler (Bibby Scientific, 
Staffordshire UK) using 200µl thin-walled PCR tubes (Starlabs, Milton Keynes 
UK). A total reaction volume of 50µl was comprised as shown in table 2.7 
Where PCR products were to be used for cloning into plasmid DNA, Phusion 
high fidelity DNA polymerase and HF reaction buffer were utilised. For 
general PCR, GoTaq DNA polymerase and GoTaq Green reaction buffer were 
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} x35 
utilised. Details of a typical PCR experiment are given in table 2.8 The 
temperature used in the annealing step was varied as required for different 
PCRs; more details are given in the relevant sections. Reactions were 
analysed by agarose gel electrophoresis as described in 2.6.1 An overview of 
the PCR process is given in figure 2.2. 
 
Reaction Component  Volume 
   
Template (100ng/µl)  1.5µl 
FWD primer (10µM stock)  1µl 
REV primer (10µM stock)  1µl 
dNTPs (10µM stock)  1µl 
DNA polymerase  0.5µl 
Reaction buffer (5x stock)  10µl 
DNase/RNase free PCR H20  35µl 
   
 Total vol. 50µl 
Table 2.7: Standard PCR reaction-mix 
 
 
Reaction Step Temperature (oC) Time 
 
Init. denaturation 
 
98 
 
30 seconds 
Melting 98 10 seconds 
Annealing 54 30 seconds 
Extending 72 90 seconds 
Final extension 72 5 minutes 
   
Table 2.8: General PCR experiment parameters 
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Figure 2.2: Outline of a general PCR experiment 
 
2.6 DNA Manipulation 
2.6.1 Agarose Gel Electrophoresis 
PCR products, restriction digests, and plasmid DNA were all analysed using 
agarose gel electrophoresis. In all cases, agarose gels were 0.8% (w/v) 
agarose in TAE buffer. 5µl of SybrSafe® per 100ml agarose was added for 
product staining and visualisation when the agarose had cooled, before 
pouring. All gels were run in 1xTAE buffer at 100V for 20mins. All gels were 
loaded with 0.3µg 1kbp+ DNA standard (Invitrogen, Paisley UK). Gels were 
visualised and imaged using a UVPro Gold gel-documentation system 
(UVtech). 
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2.6.2 DNA Purification 
2.6.2.1  Purification Of PCR Products 
Purification of PCR products was carried out using a Qiagen QIAquick PCR 
Purification Kit123 as described in the accompanying manufacturers protocol 
(see Appendix A.4.1). 
2.6.2.2 Gel Extraction 
Where large concentrations of purified PCR or restriction digest product were 
required, gel extraction was performed using a Qiagen QIAquick Gel 
Extraction Kit124 according to the accompanying manufacturers protocol (see 
Appendix A.4.2). 
2.6.2.3  Restriction Digestion 
Restriction digestion was used to prepare the pOPINF plasmid for insertion of 
desired S. pneumoniae gDNA. 5µg of purified pOPINF plasmid was incubated 
with 50 units each of HindIII and KpnI in the presence of Bovine Serum 
Albumin (BSA) in a total reaction volume of 100µl at 37oC for 3 hours in a 
water-bath. Digests were carried out as double digests using the appropriate 
supplied buffer. The reaction was split over 5 reaction-tubes of 20µl volume 
to increase digestion efficiency, and subsequent purification of the resulting 
products carried out as described in 2.6.2.2 A summary of the restriction 
enzymes used is outlined in table 2.9. 
Restriction 
Enzyme 
Recognition Site Buffer Temperature 
(oC) 
    
HindIII 5'…A↓AGCTT…3' 
3'…TTCGA↑A…5' 
NE Buffer 2 37 
    
KpnI 5'…GGTAC↓C…3' 
3'…C↑CATGG…5' 
NE Buffer 2 37 
    
Table 2.9: Restriction enzymes used to linearise pOPINF plasmid in preparation for insertion 
of required gene or DNA fragment 
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2.6.2.4  Insertion Of S. pneumoniae gDNA Into Expression Vector 
Molecular cloning of the required S. pneumoniae gDNA into the expression 
vector pOPINF was carried out using the ligation-independent In-Fusion® 
System (Clontech, Mountain View, CA USA).125 The required ratio of insert to 
linearised pOPINF was calculated using the online tool ‘In-Fusion Molar Ratio 
Calculator’ (http://bioinfo.clontech.com/infusion/molarRatio.do),126 added 
to 1 vial of In-Fusion drydown mix in a final reaction volume of 10µl and 
reacted at 42oC for 30mins using a Techgene thermal cycler (Bibby Scientific, 
Staffordshire UK). The reaction was diluted immediately post-incubation to a 
final volume of 50µl with TE buffer and immediately transformed into the 
required bacterial cell-line. 
2.6.2.5 Purification Of Plasmid DNA 
When required, plasmid DNA was purified from bacterial culture with the use 
of a Qiagen QIAspin Miniprep Kit127 according to the accompanying 
manufacturers protocol (see Appendix A.4.3)  
2.7 Protein Expression 
2.7.1 Bacterial Transformation 
An overview of the transformation of bacterial strains with plasmid DNA is 
given below. Specifics for each transformation are given in the relevant 
chapters. Briefly, an aliquot of competent cells was incubated on ice in the 
presence of plasmid DNA. Uptake of plasmid DNA was induced by either 
electroporation or the heat-shock method. Growth media was added diluting 
the cells 10-fold and incubated at 37oC for 1hr. Serial dilutions of grown cells 
were plated out on LB agar containing appropriate antibiotics, allowed to dry 
and incubated upside-down at 37oC overnight. 
2.7.2 Large Scale Culture Growth 
A single colony of either Rosetta 2(DE3)pLysS or B834 E. coli cells 
transformed with the appropriate plasmid DNA was used to inoculate 50ml of 
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sterile LB supplemented with appropriate antibiotics and grown in a shaking 
incubator at 37oC, 170 revolutions per minute (rpm) overnight (O/N). Large 
volume cultures of either O/N Express media or LB, supplemented with 
appropriate antibiotics were inoculated with 0.1% of their volume of O/N 
culture. Large volume cultures were grown in a Unitron shaking incubator 
(Infors, Bottmingen Switzerland) at 37oC, 170rpm until O.D600 reached 0.6, 
upon which 1mM IPTG was added (if using LB) and temperature lowered to 
25oC and allowed to grow for the remainder of the 24hr period post-
inoculation. Bacterial cultures were harvested by centrifugation at 4000rpm, 
4oC for 30mins in a Beckman J-6B large volume centrifuge to pellet bacteria. 
Supernatant was discarded and cells were stored at -20oC until required. 
2.7.3 Cell Lysis 
Cells expressing the desired recombinant protein were lysed using a French 
Pressure cell. Cells were resuspended in lysis buffer to a final volume of 
100ml per litre of cultured cells. Resuspended culture was supplemented 
with 2µl DNase1 (Invitrogen, Paisley UK), a Complete EDTA-free protease 
inhibitor tablet and 25µl 0.5M MgSO4 to aid in bacterial DNA breakdown and 
inhibition of undesired protease activity. Lysis was carried out on ice at 
950psi. The sample was passed through the French Press x5 to ensure 
maximum lysis. 
2.8 Protein Purification 
2.8.1 General Notes 
This section is intended to give an overview into the protein purification 
processes used. Specific details pertaining to the various proteins purified are 
given in the subsequent relevant chapters. 
2.8.2 Ni-NTA (nitrilotriacetic acid) IMAC Chromatography 
Ni-affinity chromatography was used as the primary protein purification step. 
Buffers used in the purification process are given in table 2.10 1ml or 5ml 
HisTrap HP (GE Healthcare) nickel affinity columns were equilibrated by 
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washing with 5x column volumes Nickel Wash Buffer using a bench-top 
peristaltic pump (Masterflex C/L) at a rate of 2ml/min. The fractionated 
sample of bacterial cell lysate containing the soluble protein to be purified 
was loaded onto the HisTrap HP nickel column with the peristaltic pump at a 
rate of 2ml/min and allowed to cycle through the column for 30mins to 
ensure maximum binding to the Ni-resin. During this process the sample was 
kept on ice. The column was then washed with 5x column volumes of wash 
buffer to remove any unbound proteins, and transferred to an ÄKTAprime™ 
Plus (GE Healthcare) which was used to run a Nickel Affinity Purification 
program (see Appendix A.5.2). The bound protein was eluted from the 
column using a linear gradient of Nickel Elution Buffer (see table 2.10). 
Fractions were collected and analysed by SDS-PAGE as described in 2.10.1. 
Buffer Name Composition Comments 
   
Nickel Wash Buffer 50mM Tris HCl 
pH7.5 
500mM NaCl 
20mM Imidazole 
 
pH adjusted to 7.5 
with HCl, 
Filter sterilised 
with 0.22µm filter 
 
Nickel Elution 
Buffer 
50mM Tris HCl 
pH7.5 
500mM NaCl 
500mM Imidazole 
 
pH adjusted to 7.5 
with HCl, 
Filter sterilised 
with 0.22µm filter 
 
Lysis Buffer Wash Buffer + 0.2% 
tween 
Filter sterilised 
with 0.22µm filter 
   
Table 2.10: Buffers used in Ni-affinity purification 
 
2.8.3 Ion Exchange Chromatography 
Ion exchange chromatography was used as a subsequent purification step to 
Ni-affinity chromatography. Isoelectric point (Pi) of the protein being purified 
was determined by submitting the protein sequence to the into the 
ProtParam program held on the Expert Protein Analysis Server ‘ExPASy’ 
(http://www.expasy.ch/tools/protparam.html).114 Choice of ion exchange 
column was determined by Pi of the protein being purified. Protein Pi values 
allowed 1ml or 5ml CaptoQ anion exchange columns (GE Healthcare) to be 
used exclusively. Buffers used throughout are described in table 2.11 The 
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column was washed for 5x column volumes with Anion Exchange Buffer A at a 
rate of 2ml/min before loading the protein sample. The sample was cycled 
through the column for 30mins to ensure maximum binding. The sample was 
kept on ice throughout. The column was then washed with 5x column 
volumes of Anion Buffer A to remove unbound proteins and transferred to an 
ÄKTAprime™ Plus (GE Healthcare) which was used to run an Anion Exchange 
Purification program (see Appendix A.5.3). The bound protein was eluted 
from the column using a linear gradient of Anion Exchange Buffer B (see table 
2.11). Fractions were collected and analysed by SDS-PAGE as described in 
2.10.1. 
 
Buffer Name Composition Comments 
   
Anion Exchange 
Buffer A 
20mM Tris HCl pH8 pH adjusted to 8.0 
with HCl, 
Filter sterilised with 
0.22µm filter 
 
Anion Exchange 
Buffer B 
20mM Tris HCl pH8 
1M NaCl 
pH adjusted to 8.0 
with HCl, 
Filter sterilised with 
0.22µm filter 
   
1 x Dulbecco’s 
Phosphate Buffered 
Saline (PBS). 
NaCl         10g 
KCl           250mg 
Na2HPO4   1.44g 
KH2PO4     410mg  
 
Make to 1L.  
pH adjusted to 7.12 – 
7.3.  
Filter sterilised 
through 0.22µm filter 
 
Table 2.11: Anion Exchange Buffers 
 
2.8.4 Size Exclusion Chromatography 
Size exclusion chromatography was performed on an S75 300ml size exclusion 
column (GE Healthcare) using an ÄktaPrime™ plus. Prior to loading, the 
protein was buffer exchanged into 20mM Tris HCl pH7.5, 200mM NaCl. The 
S75 column was washed with 2ml of the above buffer before sample 
application. The column was then run at a flow rate of 0.2ml per minute for 
1.5 column volumes. 5ml fractions were collected and analysed by SDS-PAGE. 
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2.9 Protein Manipulation 
2.9.1 Cleavage Of His6 Tag With C3-Protease. 
The His6 tag was removed from the recombinantly expressed protein during 
the purification process. 5µl C3-protease (see chapter 3.2 for generation of 
HRV C3-protease) was added per 10ml protein sample to be cleaved. This was 
supplemented with 10mM DTT, 1mM EDTA and incubated at 4oC while stirring 
with a magnetic stirring bar. Incubation was performed for at least 3hrs and 
preferably O/N. 
2.9.2 Buffer Exchange Of Protein Samples 
When required, protein samples were buffer exchanged using PD-10 Desalting 
Columns (GE Healthcare). Buffer exchange was performed according to the 
accompanying manufacturers protocol (see appendix A.5.1).128 
2.9.3 Concentration Of Protein 
In all cases, purified protein samples were concentrated by using Amicon 
Ultra-4 or -15 Centrifugal Concentrators (Millipore, Watford UK). Molecular 
Weight Cut-Off (MWCO) of concentrator membranes was varied according to 
molecular weight of purified protein. Samples were concentrated at 3000 x g, 
4oC in a Sigma 4K15 tabletop centrifuge (Sigma, Harz Germany) for 10mins. 
Samples were resuspended after each run to prevent aggregation or 
precipitation of the protein at the bottom of the concentrator during sample 
concentration. The process was repeated as necessary until the protein 
sample reached the desired concentration. Protein samples for immediate 
use were stored at 4oC, otherwise the purified, concentrated protein was 
aliquotted to avoid excessive freeze/thaw cycles and stored at -20oC for 
short-term storage or -80oC for long-term storage. 
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2.10 Protein Analysis 
2.10.1 SDS-PAGE 
SDS-PAGE analysis was carried out using the Invitrogen NuPAGE® Novex 
precast gel system which is based upon the Laemmli method.129 All analysis 
was carried out using 4-12% Bis-Tris gels in 1xNuPAGE MES buffer. Protein 
samples were mixed with NuPAGE loading dye supplemented with 10mM 
dithiothreitol (DTT) and denatured in a hot-block at 90oC for 5mins. 10µl of 
each prepared sample was run. 5µl of SeeBlue Plus 2 prestained molecular 
weight markers were included as standard. Electrophoresis was performed at 
200V for 35mins. SDS-PAGE gels were stained with coomassie R250 stain, 
destained with several changes of destain, then followed by several changes 
of dH2O. Coomassie stain and destain are detailed in table 2.12. 
Buffer Name Composition Comments 
   
1x NuPAGE MES 
running buffer 
Proprietary 
formulation 
Diluted from 25x 
concentrated stock 
with dH2O 
   
Coomassie R250 
stain 
1.25g/l Coomassie 
R250, 
40% EtOH, 10% 
glacial acetic acid 
Gravity-filtered 
through course 
filter paper before 
use 
   
Coomassie destain 40% EtOH, 10% 
glacial acetic acid 
N/A 
   
Table 2.12: Buffers used in SDS-PAGE 
 
2.10.2 Measurement Of Protein Concentration 
An absorbance reading at 280nm (A280) was taken for the protein sample using 
a NanoDrop ND-1000 (Fisher Scientific, Loughborough UK). The extinction co-
efficient of the protein sample was calculated by submitting the protein 
sequence into the ProtParam program held on the Expert Protein Analysis 
Server ‘ExPASy’ (http://www.expasy.ch/tools/protparam.html).114 Using this 
information, a derivation of the Beer-Lambert law was used to calculate 
protein concentration (illustrated in equation 2.1). 
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Equation 2.1: Equation for calculating protein concentration 
Where:  
 [Protein] = protein concentration 
 A280 = Absorbance value of sample taken at 280nm 
 
2.10.3 Western Blot 
Protein to be analysed by Western blotting was first subjected to SDS-PAGE as 
outlined in 2.10.1 Instead of staining the gel, the proteins were transferred 
to a Hybond™-P PolyVinylidene Fluoride (PVDF) membrane (Amersham 
Biosciences - GE Healthcare) using an Xcell II blotting module (Invitrogen)130 
according to the manufacturers instructions. Transfer was carried out at 30V 
for 1hr. Before assembly of the module, the Hybond-P membrane was 
activated by immersing in methanol for 1min. Probing of the membrane with 
relevant antibodies was carried out as described in the standard operating 
procedures devised by the Mitchell lab (see appendix A.3.2). 
2.10.4 Dynamic Light Scattering (DLS) 
DLS was employed to assess the molecular dispersal of the purified protein in 
solution. 5.5µl samples were analysed using an AvidNano W130i System at 
GlaxoSmithKline, Stevenage UK. 
2.10.5 Isothermal Titration Microcalorimetry (ITC) 
ITC was performed at the Biophysical Chemistry Group, University of Glasgow 
UK with the assistance of Margaret Nutley. 
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2.10.6 Mass Spectrometry 
MALDI–ToF mass spectrometry was performed in collaboration with both Dr. 
Richard Burchmore at the Sir Henry Wellcome Functional Genomics facility, 
University of Glasgow UK, and Satty Borman at GlaxoSmithKline, Stevenage 
UK. 
2.10.7 N-terminal Protein Sequencing 
N-terminal sequencing was performed using the Edman Degradation 
method131 in collaboration with Neil Freeman at GlaxoSmithKline, Stevenage 
UK. Samples were prepared for sequencing by SDS-PAGE analysis as described 
in 2.8.1. and transferred to a PVDF membrane (Invitrogen) as for transfer for 
Western blot (see 2.8.2). The PVDF membrane was stained with Coomassie 
R250 stain and destained. The membrane was washed extensively to remove 
residual acid from the membrane and allowed to air dry. Samples were 
analysed using a Procise® protein sequencer (Applied Biosystems). 
2.10.8 Nuclear Magnetic Resonance 
1-Dimensional NMR was performed in collaboration with Dr. Brian Smith at 
the Protein Science Group, University of Glasgow UK. Protein was supplied in 
1x Dulbecco’s PBS buffer (see table 2.11). Further details are given in the 
relevant chapters. 
2.10.9 Circular Dichroism (CD) 
Far-UV CD was carried out in collaboration with Dr. Sharon Kelly at the 
Protein Characterisation Facility, University of Glasgow UK. Far-UV CD 
experiments were also undertaken at GlaxoSmithKline, Stevenage UK. 
Experiments were carried out at ambient temperature in Tris buffer 
comprising 50mM Tris HCl pH7.5, 500mM NaCl. Further information is given in 
the relevant chapters. 
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2.10.10 Protein Melting Temperature (Tm) 
The effect of different protein buffers on the Tm of the protein samples was 
assessed by CD. Samples were measured at a fixed wavelength over 
increasing temperature at set time-intervals. Increase in the proportion of 
random coil in the sample was monitored as an indication of protein 
denaturation. Further details are given in the relevant chapter. 
2.10.11 Analytical Ultra-Centrifugation (AUC) 
AUC was carried out in collaboration with Dr. Olwyn Byron, Glasgow 
Biomedical Research Centre, University of Glasgow UK. Protein samples were 
provided at a concentration of 5mg/ml in 1x Dulbecco’s PBS buffer.  
2.10.12 Limited Proteolysis 
Limited proteolysis was performed at ambient temperature. Essentially, the 
experiment was a controlled time-course tryptic digest. Purified F/L PhtD 
protein was incubated with proteomics grade trypsin (Roche) and samples 
removed at set time-points. Samples were either denatured by mixing in a 
1:1 ratio with NuPAGE SDS loading-dye and analysed by SDS-PAGE as outlined 
in 2.10.1 or quenched by addition of Trichloroacetic acid (TCA) for intact-
mass spectrometry. Specific reaction details are given in the relevant 
chapters. 
2.11 Protein Crystallisation 
2.11.1 Crystal Screening 
Screening of proteins for protein crystallisation was carried out at the 
University of Glasgow using the sitting drop vapour diffusion method in 96 
well plate format. Crystal screens were dispensed using a Hamilton Liquid 
Handling Robot (Hamilton), crystal trials were performed using a HoneyBee 
8+1 robot (Cartesian), stored at 20oC and monitored of crystal growth.  
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Crystallisation screening was also performed at GlaxoSmithKline, Stevenage 
UK. Crystal screens were dispensed using a Hydra (Thermo Scientific). Crystal 
trials were performed using a Mosquito (Molecular Dimensions). Crystal trials 
were stored at 20oC and monitored for crystal growth. 
Latterly, crystallisation screening was performed in collaboration with Prof. 
Juan Hermoso at the Instituto de Quimica Fisica “Rocasolano”, Spanish 
National Research Council, Madrid Spain. 
2.11.2 Crystal Screens 
Many commercially available crystal screens were utilised throughout the 
screening process. A list of the crystal screens used and their manufacturers 
is given in table 2.13. 
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Crystal Screen  Manufacturer 
   
Crystal Screen 1  Hampton Research 
 
Crystal Screen 2  Hampton Research 
 
PEG/Ion Screen  Hampton Research 
 
CryoScreen 1  Emerald Biosystems 
 
CryoScreen 2  Emerald Biosystems 
 
Wizard 1  Emerald Biosystems 
 
Wizard 2  Emerald Biosystems 
 
Structure Screen 1  Molecular Dimensions 
 
Structure Screen 2  Molecular Dimensions 
 
Morpheus Screen  Molecular Dimensions 
 
Cations Screen  Qiagen 
 
PEGsII Screen  Qiagen 
 
PACT Screen  Qiagen 
 
Nextal Classics Screen  Qiagen 
 
JCSG+  Qiagen 
 
Ammonium Sulphate 
Screen 
 Qiagen 
   
Table 2.13: Commercial crystal screens 
 
2.12  Computational Software 
A variety of computer software was used throughout the duration of this 
project for data analysis and in presentation of data in this thesis. 
 Crystallographic computer work was performed using programs from the 
CCP4132 and PHENIX133 suites of crystallographic software. Processing of raw  
X-ray diffraction data was performed using MOSFILM134 or D*TREK.135 
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Visualisation of electron density maps and molecular models, and the manual 
manipulation of molecular models were performed using COOT.136 Diagrams 
of molecular models determined by macromolecular crystallography in this 
thesis were generated using PyMOL.137 
Pairwise sequence alignments of DNA and protein sequences for illustrative 
purposes in this thesis were performed using the program MULTALIN.138 
Physical and chemical parameters (e.g. predicted molecular weight iso-
electric point) for the proteins in this thesis were calculated from the 
respective protein sequence using the program PROTPARAM hosted at 
http://expasy.org/tools/protparam.html 
Sequence-based disorder prediction of the F/L PhtD protein and its truncated 
versions was carried out using the Random Order Neural Network (RONN)139 
hosted at http://www.strubi.ox.ac.uk/RONN 
Graphical illustrations for analysis of CD and Tm data and illustrative 
representation of the corresponding results in this thesis were generated 
using PRISM 4. 
Analysis of DNA sequencing data was performed using VectorNTI 11.5 
(Invitrogen)140 or CLC Genomics Workbench 4 (CLCbio, Aarhus Denmark. 
www.clcbio.com).120 Expression constructs were designed and plasmid maps 
generated using CLC Genomics workbench 4.
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Chapter 3 : Crystallographic Studies Of Proteins 
From Gram Positive Bacteria 
3.1 Overview 
The data presented in this chapter was generated through the process of 
learning the technique of X-ray crystallography, including crystal 
manipulation, handling X-ray diffraction data and structure determination, to 
provide experience of data processing prior to the event of successful 
crystallisation of PhtD. 
Both of the proteins described in this chapter were chosen for investigation 
for a number of reasons. Firstly, both could be purified in milligram 
quantities, a prerequisite for X-ray crystallographic studies due to the high 
concentrations normally used in crystallisation experiments. The expression 
plasmid for the transketolase (TktA) protein was provided through 
collaborative work; a search of the Protein Data Bank (PDB)141 revealed that 
transketolase protein structures had been successfully determined in the 
past, indicating that there was a possibility that we would succeed in 
obtaining crystals, and of determining the structure by the molecular 
replacement method using a structure present in the PDB. As the protein 
Putative Protease Maturation protein A (PpmA) from the pneumococcus had 
previously been investigated in our laboratory, PpmA was included in 
crystallographic studies in an attempt to further progress with this protein. 
As a novel protein, molecular replacement would not be possible in this case, 
requiring incorporation of heavy-metals for successful structural 
determination.  
As such, investigation into the determination of the crystal structure of the 
transketolase enzyme TktA from Lactobacillus salivarius would provide 
training for how to handle protein crystals, formulate planning of data-
collection for the TktA crystals, and to provide experience of processing the 
raw-data through various crystallographic computer programs, subsequently 
using the processed data to determine the 3D crystal structure of TktA by the 
increasingly common method of molecular replacement. In essence, TktA was 
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used as a positive control or exercise in the process of protein structure 
determination -from protein purification to final refinement of the 3D-crystal 
structure- in readiness for handling any PhtD protein crystals that were 
generated. 
In addition, the pneumococcal protein PpmA was investigated due to prior 
interest in our laboratory, where biochemical data for this protein has 
already been obtained. As a novel protein, PpmA was included in this study as 
an exercise in problem solving; the 3D crystal structure of PpmA is desired in 
order to further understand the protein function. Because it is a novel 
protein, crystallisation and structural determination of PpmA would provide 
experience of ways (other than molecular replacement) of solving the ‘phase-
problem’ in X-ray crystallography, such as selenomethionine (Se-Met) 
labelling of PpmA or incorporation of heavy-metals into native PpmA protein 
crystals, which were not required in the case of TktA but would be required 
in the structural determination of PhtD, as although a fragment of one of the 
other Pht proteins has been successfully determined,98 this fragment alone 
would be insufficient to determine the whole 3D crystal structure of PhtD 
through molecular replacement, therefore additional methods such as those 
described above would also need to be implemented. 
The transketolase TktA from the lactic acid bacterium Lactobacillus salivarius 
acts as a link between glycolysis and the pentose-phosphate pathway. The 
transketolase enzyme is able to mediate the reversible transfer of a two-
carbon ketol unit from a ketose to an aldose (specifically from D-xylulose 5-
phosphate to D-ribose 5-phosphate, generating D-sedulose 7-phosphate and 
D-glyceraldehyde 3-phosphate in the process).142, 143 A key enzyme in sugar 
synthesis, the transketolase is able to shift excess quantities of fructose-3-
phosphate and D-glyceraldehyde-3-phosphate from glycolysis to the pentose-
phosphate shunt, thus eliminating an excess of these harmful metabolites 
from the cytosol.144 
The pneumococcal protein PpmA has been predicted to be a member of the 
family of proteins classed peptidyl-proline isomerases (PPIases). Specific 
information on PpmA is outlined later in this chapter (see chapter 3.10). 
PPIases mediate the cis-trans isomerisation of peptide bonds in proline 
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residues. Unlike other amino acids, proline is unique in its structure; the 
tetrahedral CH3 groups of proline are similarly ‘crowded’ in either cis or trans 
state, and therefore a relatively small free energy difference exists between 
the cis and trans conformations. This means that unlike other amino acids -
which are present predominantly as trans isomers- proline residues are able 
to exist distinctly in either the cis or trans state.145 Proline will not 
spontaneously adopt the intended conformation; a PPIase is needed in order 
to effect the required isomerisation.146 PPIases therefore act like chaperones 
to protein folding, limiting the rate at which folding occurs and preventing 
the accumulation of reaction intermediates that are prone to form non-native 
protein conformations.147
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Expression, Purification, Crystallisation And Data 
Collection Of TktA from Lactobacillus salivarius 
3.2 Reference 
This chapter is a detailed explanation of the work published in Horsham, M., 
Saxby, H., Blake, J., Isaacs, N.W., Mitchell, T.J. and Riboldi-Tunnicliffe, A. 
“Expression, purification, crystallisation and preliminary X-ray 
crystallographic data from TktA, A transketolase from the lactic acid 
bacterium Lactobacillus salivarius” Acta cryst F, 66, 899-901 (2010).148 
3.3  Sequence Search Of The PDB With TktA 
The protein sequence for TktA (see Appendix A.1.10.2) was downloaded from 
the CMR database149 hosted by the JCVI institute at http://cmr.jcvi.org/tigr-
scripts/CMR/CmrHomePage.cgi  
A sequence search of the PDB141 was performed using default settings with 
the TktA amino acid sequence as the search query, which returned 45 
possible matches, including two structures determined by NMR. This showed 
that the structures of transketolase enzymes from other sources had been 
successfully determined, and that there was a possibility that crystallisation 
of TktA from L. salivarius would be successful. Furthermore, it revealed that 
the structure of TktA could be determined by molecular replacement if 
crystals were successfully grown. 
3.4 Overexpression Of TktA From L. salivarius 
3.4.1 TktA Clone 
An expression plasmid containing the full gene encoding the TktA protein 
(LSL1946) was kindly provided by Dr. Martin Walsh (ESRF BM-14, Grenoble 
France; Diamond Light Source, Oxford UK).150, 151 The TktA gene was inserted 
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in-frame into the vector pOPINF119 (see chapter 2.3.3), which encodes a His6 
tag at the N-terminus, separated by a HRV-C3 protease cleavage site 
(MAHHHHHHSSGLEVLFQ↓GP). The vector map and amino acid sequence is 
given in figure 3.1 The clone was transformed as described in 2.7.1 into 
Subcloning Efficiency™ DH5α™ competent cells and stored long term as a 
glycerol stock at -80oC. 
 
 
Figure 3.1: TktA expression construct 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The translated protein sequence is also illustrated. 
The plasmid map was generated using CLC Genomics Workbench 4.120 
 
3.4.2 Transformation And Expression of TktA 
The TktA expression construct was transformed into the E. coli expression 
strain 2(DE3)pLysS as described in 2.7.1. ~400ng expression plasmid was 
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incubated with 50µl 2(DE3)pLysS cells on ice for 30mins. The cells were heat-
shocked at 42oC for 30secs in a water-bath, thereafter the cells were allowed 
to recover on ice for 2mins. Cells were diluted with 450µl GS-96 growth 
media and incubated in a standing incubator at 37oC for 1hr. Cells were 
grown on LB agar supplemented with 54µg/ml carbenicillin and 34µg/ml 
chloramphenicol O/N at 37oC. 
 A small volume culture of 50ml sterile LB supplemented with the above 
antibiotics was inoculated with a single colony of transformed cells and 
incubated in a shaking incubator at 37oC, 170rpm O/N. The following day, 
2x500ml cultures of sterile LB medium supplemented with the above 
antibiotics were each inoculated with 5ml of the O/N starter culture. These 
expression cultures were incubated at 37oC, 170rpm until OD600 had reached 
0.6. Thereafter, 500µl 1M IPTG was added to each and the temperature was 
lowered to 22oC and incubated for the remainder of the 24hr period. The 
cultures were harvested at 4000rpm, 4oC for 30mins in a Beckman J-6B large 
volume centrifuge to pellet bacteria. 
3.5  Purification Of TktA 
3.5.1 IMAC Ni-Affinity Chromatography 
Cell pellets were divided in two and re-suspended in 50ml lysis buffer (See 
table 2.10) and each was supplemented with 2µl DNase1, a Complete EDTA-
free protease inhibitor tablet and 25µl 0.5M MgSO4 to aid in bacterial DNA 
breakdown and inhibition of undesired protease activity. Cells were lysed as 
described in 2.7.3 Lysed cells were centrifuged at 7500 x g, 4oC for 30mins 
and the pellet discarded. The supernatant was then further centrifuged at 
40,000 x g, 4oC for 30mins, the pellet discarded and the supernatant passed 
through a 0.22µm syringe filter. 
The cleared lysate was subjected to Ni-affinity IMAC purification as described 
in 2.8.2 The loaded column was transferred to an ÄKTAprime plus purification 
system, which was used to implement a linear gradient elution program from 
Ni-buffer A to B (for composition see table 2.10). A typical elution profile for 
purification of TktA is shown in figure 3.2 Eluted samples corresponding to 
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the A280 peak were analysed by SDS-PAGE as outlined in 2.10.1. The resulting 
gel is shown in figure 3.3 Selected fractions were pooled and dialysed back 
into Ni-buffer A to remove excess imidazole over-night at 4oC in 10 kDa 
MWCO dialysis tubing which had been pre-treated by boiling for 10mins in 
dH2O. 
 
Figure 3.2: Elution profile for Ni-affinity purification of TktA 
Purification was carried out an Äkta Prime Plus purification system, using a 1ml HisTrap HP 
column. Protein was eluted from the column at a flow rate of 2ml/min using a linear 
gradient elution starting at 0% and ending at 100% of nickel buffer B. (Refer to table 2.10). 
Fractions corresponding to the peak in the UV trace were collected for analysis by SDS-
PAGE. Fractions corresponding to the peak in the UV trace were collected for SDS-PAGE 
analysis. 
 
 
 
Figure 3.3: SDS-PAGE gel of selected fractions from Ni-affinity purification of TktA 
Lane 1: SeeBlue Plus 2 mol wt. marker, Lane 2 – 10: elution fractions. The arrow indicates 
the recombinantly expressed TktA. 
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3.5.2 Concentration Of Purified TktA 
Purified TktA was subjected to a rigorous routine of concentration by 
centrifugation as described in 2.9.3 Protein concentration was measured as 
described in 2.10.2 Concentration of TktA was halted at 13.2mg/ml as it was 
over the 10mg/ml threshold deemed acceptable for attempting 
crystallisation trials. Protein was stored at 4oC for immediate use. 
3.6 Crystallisation And Data Collection Of TktA 
Purified, concentrated TktA was subjected to crystal trials using the sitting-
drop vapour diffusion technique at the University Of Glasgow as outlined in 
2.11.1. Crystal screening was carried out using the commercial screens 
JCSG+, PEG/Ion, GridScreen, and Cryo1&2 screens (see table 2.13). Protein 
was dispensed at 13.2mg/ml and 9.1mg/ml. 
After 72hrs incubation at 20oC, crystals were observed in a number of the 
conditions at both protein concentrations from the JCSG+, PEG/Ion and 
Cryo1&2 screens, with the vast majority appearing in conditions from the 
PEG/Ion screen. As a general observation, it was noted that the crystals 
produced at the lower protein concentration were smaller and “uglier”. Two 
conditions- JCSG+ 22 (0.2M magnesium chloride, 0.1M sodium cocodylate, 
50% (v/v) PEG200) and PEG/Ion screen2 36 (0.07M citric acid, 0.03M Bis-Tris 
propane pH3.4, 16% (w/v) PEG3350) produced small rhombic plates.  All 
other crystallising conditions produced crystals that had the appearance of 
hexagonal rods. Typical crystals for the hexagonal form are shown in figure 
3.4 Rhombic crystals are shown in figure 3.5 A summary of the conditions that 
yielded crystals is given in table 3.1. 
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Screen & Condition Composition Protein Concentration 
(mg/ml) 
Crystal Morphology 
Cryo1&2 24 0.1M sodium-potassium 
phosphate pH6.2, 0.2M 
sodium chloride, 40% (v/v) 
PEG 400 
13.2 & 9.1 Hexagonal rods (edges not 
well defined) 
JCSG+ 8 0.2M ammonium formate, 
20% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
JCSG+ 10 0.2M potassium formate, 
20% (w/v) PEG 3350 
13.2 Single Rectangular crystal 
JCSG+ 22 0.2M magnesium chloride, 
0.1M sodium cocodylate, 
50% (v/v) PEG200 
13.2 Rhombic plates 
JCSG+ 37 24% (w/v) PEG 1500, 20% 
(w/v) glycerol 
13.2 & 9.1 Hexagonal rods 
PEG/Ion1 1 0.2M sodium fluoride   
pH7.3, 20% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion1 2 0.2M potassium fluoride 
pH7.3, 20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion1 3 0.2M ammonium fluoride 
pH6.2, 20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion1 5 0.2M magnesium chloride 
pH5.9, 20% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion1 6 0.2M sodium chloride   
pH6.9, 20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion1 9 0.2M ammonium chloride 
pH6.3, 20% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion1 15 0.2M lithium nitrate     
pH7.1, 20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion1 21 0.2M sodium formate   
pH7.2, 20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion1 22 0.2M potassium formate 
pH7.3, 20% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion1 23 0.2M ammonium formate 
pH6.6, 20% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion1 27 0.2M sodium acetate    
pH8.0, 20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion1 30 0.2M Ammonium acetate 
pH7.1, 20% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion2 26 0.2M sodium acetate    
pH7.0, 20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion2 27 0.1M sodium formate pH7.0, 
12% (w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion2 28 0.2M sodium formate pH7.0, 
20% (w/v) PEG 3350 
13.2 Hexagonal rods 
PEG/Ion2 34 2% (v/v) tacsimate pH7.0, 
0.1M HEPES pH7.5, 20% 
(w/v) PEG3350 
13.2 & 9.1 Hexagonal rods 
PEG/Ion2 36 0.07M citric acid, 0.03M Bit-
Tris propane/pH3.4, 16% 
(w/v) PEG 3350 
13.2 & 9.1 Rhombic plates 
PEG/Ion2 37 0.06M citric acid, 0.04M Bit-
Tris propane/pH4.1, 16% 
(w/v) PEG 3350 
13.2 & 9.1 Hexagonal rods 
Table 3.1: Crystal producing conditions from crystallisation screens 
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Figure 3.4: Typical hexagonal rod TktA crystals 
Protein = TktA incorporating His6 tag. Protein concentration = 13.2mg/ml. Drop vol = 1µl. 
Droplet volume = 1µl, comprising 1:1 ratio of protein : reservoir solution. 
 
 
 
Figure 3.5: Rhombic plate TktA crystals from PEG/Ion2 36 
Protein = TktA incorporating His6 tag. Protein concentration = 13.2mg/ml. 
Droplet volume = 1µl, comprising 1:1 ratio of protein : reservoir solution. 
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3.6.1 In-House Testing Of TktA Crystals 
In-house testing of the grown TktA crystals was performed on a Rigaku 
Micromax-007 HF X-Ray generator (Rigaku Europe, Kent UK). Data was 
collected on a Mar345 dtb detector. Crystals were flash-cooled in a stream of 
nitrogen gas maintained at 110K (-163oC). Attempts were made to 
cryoprotect the protein crystals utilising various cryoprotectants, with dried 
paraffin oil being most successful, producing fewest ice-rings and maintaining 
diffraction quality. Crystals were exposed to 2 x 30sec exposures separated 
by 90o to test for diffraction quality. Crystals grown in PEG/Ion 1 condition 6 
provided the best in-house diffraction, therefore replicate trays of this 
condition were set up. The resulting crystals were cryoprotected with dried 
paraffin oil and frozen in a stream of nitrogen gas at 110K (-163oC) as before. 
3.6.2 TktA Crystallographic Data Acquisition And Processing 
Frozen TktA crystals measuring approximately 200 x 40 x 40 µm in size from 
the replicate trays of PEG/Ion 1 condition 6 were taken to the European 
Synchrotron Radiation Facility (ESRF – Grenoble, France) and exposed to 
synchrotron X-rays on the beamline ID14-1.150 Diffraction data were collected 
on a single crystal using an ADSC Q210 CCD detector with a crystal rotation of 
1o per frame. An example plate of the collected diffraction data is given in 
figures 3.6 and 3.7. 
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Figure 3.6: Diffraction image for a single crystal of TktA 
Figure 3.7: Close-up diffraction image for a single crystal of TktA 
The arrow shows the limit of diffraction at 2.3Å resolution. Outer blue arc shows       
diffraction limit at 2.9Å 
 
The space group to which the crystal belonged was determined with the 
utilisation of the program POINTLESS,132, 152 which revealed that the crystal 
belonged to the space group P3221. The collected data were processed in 
P3221 with the crystallographic program MOSFILM.134 A summary of the data 
collection statistics is given in table 3.2. 
   
Source  ID14-1, ESRF, Grenoble150 
Wavelength (Å)  0.934 
Resolution (Å)  36.94-2.30 (2.42-2.30) 
Space group  P3221 
Unit-cell parameters (Å, o)  a = b =75.43, c = 184.11,        
α = β = 90.0, γ = 120.0 
   
Rmerge  0.126 (0.352) 
Total No. of reflections  55793 
No. of unique reflections  25397 
Average redundancy  2.2 
Completeness (%)  92.8 (93.6) 
   
Table 3.2: Data collection statistics for TktA 
(Values in parentheses are for the outer shell) 
 
   ↓ 
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Additionally, the crystallographic program MATTHEWS132 was utilised to 
estimate the solvent content of the crystal. Statistics are given in table 3.3. 
 
Nmol/asym Matthews Coeff 
(Å3Da-1) 
% Solvent Probability 
    
1 2.03 39.36 1.00 
    
Table 3.3: Statistics for calculated Matthews coefficient of TktA crystal 
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Structural Determination Of TktA 
3.7 Reference 
The work discussed in this section is a version of Horsham, M., Mitchell, T.J & 
Riboldi-Tunnicliffe, A. “2.3 Ångstroms Crystal Structure Of TktA, A 
transketolase from the lactic acid bacterium Lactobacillus salivarius” To be 
published. 
3.8  Molecular Replacement 
3.8.1 Solution To The Phase Problem 
In order to calculate the electron density ρ(xyz) from the measured 
intensities of indexed diffraction data for an unknown crystal structure, it is 
necessary to use the inverse Fourier transform of the structure factor vector 
F(hkl).153 The structure factor vector comprises two separate components; an 
amplitude, and a phase angle F(hkl) = |F(hkl)|eiα(hkl) (equation 6.1). 
€ 
ρ xyz( ) = 1V F(hkl) exp −2πi(hx + ky + lz) + iα(hkl)[ ]h,k,l
∑  
Where:  ρ(xyz) = electron density at point (xyz) in the unit cell 
  V = the volume of the unit cell 
  |F(hkl)| = structure factor amplitude for reflection (hkl) 
  iα(hkl) = phase angle for reflection (hkl) 
 
Equation 3.1: The electron density equation 
 
The X-ray diffraction experiment provides only the amplitude; the phase 
angle is lost. This gives rise to what is commonly known as the Phase 
Problem, as without the phase angle it is not possible to calculate the 
electron density in the unit cell. There are however, several ways to solve 
the phase problem, with one of the most popular being molecular 
replacement. 
 62 
Molecular replacement relies upon the provision of a suitably homologous 
model to that of the unknown crystal structure. If a suitable model is 
available, then it can be used as a template for the unknown crystal 
structure. Using the known model as a template, the phase angles of the 
known model are applied to the indexed diffraction data of the unknown 
crystal structure. Molecular replacement consists of two steps; a rotation 
process and a translation process, to estimate the location of the target 
model in the unit cell.154 With this initial template correctly in place, it is 
then possible to perform refinement of the model to give a final, chemically 
acceptable model of the target protein. It should be noted that with the 
exponential growth in the number of determined structures present in the 
Protein Data Bank (PDB),141 the method of molecular replacement has 
become exceedingly powerful, as the number of potential template models 
has increased drastically over the last few years, currently standing at 
greater than 65,000 entries with more than 85% of the deposited structures 
determined by X-ray crystallography. 
3.8.2 Choice Of Molecular Replacement Model 
A search of the PDB was preformed using the amino acid sequence of TktA as 
before in the preliminary stages of setting up crystallographic trials (see 
chapter 3.3). With a sequence identity of 51% (illustrated in figure 3.8), the 
PDB entry 1ITZ (maize transketolase in complex with TPP) was chosen as the 
template to be used for molecular replacement. The PDB file was edited to 
remove any additional data such as H20 molecules or ligands, leaving Chain A 
of the PDB file (the monomeric transketolase molecule) for use as a search 
model.
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Figure 3.8: Sequence alignment of TktA and 1ITZ 
Red = high consensus residues, Blue = low consensus residues, Black = neutral residues. 
There is 51% identity between the TktA sequence and the sequence of the 1ITZ model. 
Alignment was performed using MULTALIN.138 
 
3.8.3  Molecular Replacement Of TktA 
Molecular replacement of the TktA data was performed using PHENIX AutoMR 
from the PHENIX133 suite of crystallographic programs. The edited 1ITZ PDB 
file comprising of Chain A alone was used as the search model for the 
molecular replacement of the indexed TktA data over the resolution range 
36.94 – 2.30Å One copy of the molecule was successfully located per 
asymmetric unit; the biologically relevant dimer is formed through a 
symmetry operation. 
3.8.4  Model Building And Refinement 
The molecular replacement solution from AutoMR is output as two separate 
files; the .mtz file contains the electron density map, and the .pdb file 
contains the model of the protein molecule. Visualisation of the initial MR 
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model and the electron density map was performed using COOT.136 With the 
sequence alignment of TktA and 1ITZ as a reference, manual manipulation of 
the model was performed in COOT136 by mutation, deletion or insertion of 
residues so that the model sequence was identical that of TktA. Restrained 
refinement of the TktA model was performed using REFMAC5 from the CCP4 
suite of crystallographic programs.132 Iterative rounds of refinement were 
performed; in each case the resulting model was checked manually for any 
required alterations to the model. In order to prevent bias from occurring 
between the model and data, each round of refinement using REFMAC5 was 
performed by refining the latest post-refinement model with the initial .mtz 
file containing the electron density map from the AutoMR solution, with Rwork 
and Rfree values successfully decreasing after each round of refinement. 
Figure 3.9 illustrates the electron density map of TktA and the TktA model 
fitted to the same region of electron density. 
 
Figure 3.9: Modelling of TktA structure to electron density. 
The image on the left shows the electron density for a region of TktA. The image on the 
right shows how the corresponding refined region of the TktA model fits into the 
aforementioned region of electron density. Figure generated using COOT.136 
 
3.8.5  Final Model Refinement And Analysis 
Final model refinement is ongoing at present, with modelling of alternate 
conformations of residue side-chains and placement of H2O atoms underway. 
Current model statistics show that Rwork = 20% and Rfree = 26.8%. Validation of 
the structure (see figure 3.10) shows 4 outliers in the Ramachandran plot –
which calculates acceptable bond geometry of the amino acids in protein 
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structures- corresponding to 0.68% of the structure, 554 (94.2%) residues lie 
in preferred regions with the final 30 (5.1%) present in allowed regions.  
 
Figure 3.10: Ramachandran plot for refined TktA structure. 
Validation of refined TktA structure. Four plots are generated corresponding to residue-
class (indicated above each section). Light blue ringed areas encompass favoured regions, 
dark blue rings encompass allowed regions. Outliers are highlighted as individual named and 
numbered residues corresponding to protein sequence. The plot indicates that there are 4 
outliers, corresponding to 0.68% of all residues, 94.2% of all residues are in favoured 
regions, 5.1% are in allowed regions. Ramachandran plots were generated using the 
MolProbity server.155 
 
172 H2O molecules have been modelled into the structure to date; further 
modelling of waters (and additional unattributed density; possibly Chloride 
atoms, or PEG molecules) is ongoing. A molecular model of the TktA 
generated using the refined TktA monomer (figure 3.11) is shown in its 
biologically functional dimeric form in figure 3.12. 
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Figure 3.11: Monomeric molecular model of refined TktA structure 
The image was generated from the refined TktA structure using PyMol.137 
 
 
Figure 3.12: Molecular model of TktA 
Molecular model of TktA in its biologically functional dimeric form. The two TktA monomers 
are distinguished from each other using the separate colours purple and orange. The image 
was generated from the refined TktA structure using PyMol.137 
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The packing order of the TktA molecule in the crystal lattice is shown in 
figure 3.13 
 
Figure 3.13: Crystal packing in TktA 
Top: Crystal packing in TktA viewed along the X-axis. The TktA model is shown bottom-left, 
coloured by bonds. A two-fold axis of symmetry along the X-axis forms the biologically 
relevant dimer. The yellow cuboid denotes the unit cell. 
Bottom: Crystal packing for TktA viewed along the Z-axis. The TktA model is shown top-left, 
coloured by bonds. Symmetry related molecules in the crystal lattice are illustrated in 
matching colours. Images were generated using COOT.136 
 
The refined TktA model is illustrated using the “coloured by bonds” 
representation, showing all side-chains. Symmetry related molecules are 
shown in orange using the “C-alphas” representation where only the main-
chain carbon atoms are used to trace an outline of the model.  A two-fold 
axis of symmetry exists along the X-axis, which allows the formation of the 
biologically relevant dimer. This symmetry is shown clearly in figure 3.14. 
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Figure 3.14: Illustration of 2-fold symmetry for TktA 
Viewing the model along the X-axis. As a result of the 2-fold axis of symmetry along X, 
rotating the TktA monomer 180o around the X-axis reveals the dimeric form of TktA 
molecule responsible for its biological function. 
The refined TktA model is represented in purple. The dimer-forming symmetry related 
molecule is shown in orange. The image was generated from the refined TktA structure 
using PyMol.137 
 
The TktA molecule has been successfully cloned, expressed, purified and 
crystallised. Crystallisation was performed using the sitting-drop vapour 
diffusion technique. The structure has been determined using the molecular 
replacement method to solve the phase problem. Iterative rounds of 
restrained refinement have successfully improved the quality of the model as 
seen by acceptable Rwork and Rfree values for data of this resolution (2.3Å). 
Final refinement is ongoing in an attempt to bring outlying residues as 
calculated in the Ramachandran plot into acceptable geometric 
conformations; outliers currently comprise 0.68% of the structure with a final 
target value of 0.2%, as is completion of modelling solvent components (H2O 
molecules and other associated elements such as chloride atoms). 
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Expression, Purification, Crystallisation And Data 
Collection Of PpmA From S. pneumoniae 
3.9 Reference 
The data presented in this section (to be published) is a detailed account of 
that which has been drafted for submission to Acta Crystallographica Section 
F: Crystallisation Communications, with the proposed running title 
“Expression, Purification, Crystallisation And Preliminary Diffraction Data For 
PpmA, A Predicted Cis-Trans Isomerase From The Pathogenic Bacteria 
Streptococcus pneumoniae” Horsham, M., Isaacs, N.W., Mitchell, T.J. and 
Riboldi-Tunnicliffe, A. 
3.10  Introduction 
The protein named Putative Protease Maturation Protein A (PpmA) is one of 
two pneumococcal proteins that have been shown to have homology to a 
family of proteins known as the peptidyl-protease isomerases (PPIases).156 
These PPIases are responsible for the cis-trans isomerisation of proteins at 
proline residues and act as an aid to protein folding. However, to date PpmA 
has not been shown to have any PPIase activity, nor is it known which protein 
PpmA activates.156, 157  It has been shown in a murine model that the absence 
of PpmA results in decreased pneumococcal virulence and an increase in 
susceptibility to opsonophagocytosis in PpmA-deficient pneumococci,157 
making it a possible candidate for inclusion in a novel protein-based vaccine. 
It is hoped that structural determination of PpmA could aid the discovery of 
PpmA function and therefore allow development of inhibitors or mimics of 
the PpmA protein. 
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3.11  Overexpression Of PpmA From S. pneumoniae 
3.11.1 PpmA Clone 
The PpmA expression construct was kindly provided by Dr. Alan Riboldi-
Tunnicliffe. The F/L PpmA gene from the S. pneumoniae strain TIGR4 was 
inserted into the expression vector pOPINF119 in-frame with an N-terminal 
His6 tag separated by an HRV –C3 protease cleavage site using the In-Fusion125 
technique as detailed in chapter 2.6.2.4 The resulting construct illustrated in 
figure 3.15 enabled production of recombinantly expressed PpmA protein 
which could be purified with the aid of the cleavable His6 tag. 
 
 
Figure 3.15: PpmA expression construct and protein translation 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The translated protein sequence is also illustrated. 
The plasmid map was generated using CLC Genomics Workbench 4.120 
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3.11.2 Transformation And Expression Of PpmA 
The PpmA expression construct was transformed into the chemically 
competent E. coli expression cell-line Rosetta 2(DE3)pLysS as outlined in 
chapter 2.7.1 ~400ng of PpmA expression construct were incubated with 50µl 
competent cells for 30mins on ice. Plasmid uptake was induced by heat-
shocking the culture at 42oC for 30secs. The culture was allowed to recover 
on ice for 2mins before being diluted 10-fold with sterile GS96 growth media 
to a final volume of 500µl, and was then incubated at 37oC for 1hr. Post 
incubation, the culture was plated out onto 1ml LB agar supplemented with 
54µg/ml carbenicillin and 34µg/ml chloramphenicol at dilutions of 5, 10, 15, 
and 20µl, allowed to dry then inverted and incubated at 37oC O/N. 
Essentially, protein expression was performed as outlined in chapter 2.7.2. A 
single colony from the resulting transformed bacteria was used to inoculate a 
small-volume starter culture of 50ml LB supplemented with the above 
antibiotics and incubated at O/N at 37oC, 170rpm in a shaking incubator. The 
following day, 2x500ml large-volume cultures of sterile TB-Onyx auto-
induction expression media supplemented with 54µg/ml carbenicillin and 
3µg/ml chloramphenicol were inoculated with 5ml each of the O/N starter 
culture and incubated at 37oC, 170rpm in a shaking incubator until an O.D600 
of 0.6 was achieved; thereafter the temperature was lowered to 25oC and 
incubation was continued for the remainder of the 24hr period. Cells were 
then harvested as described in chapter 2.7.2. 
3.12  Purification Of Recombinant PpmA 
3.12.1 Cell Lysis 
PpmA was purified using the general purification protocol previously outlined 
in chapter 2.8 The cell pellets were split into two and each was resuspended 
in 50ml lysis buffer (see table 2.10). Each was supplemented with 2µl 
DNase1, a complete EDTA-free protease inhibitor tablet and 25µl 0.5M MgSO4 
to aid in breakdown of bacterial DNA and inhibit undesired protease activity. 
The cells were lysed in a French Press as described in chapter 2.7.3, and the 
cellular debris cleared from the cell lysate containing the soluble PpmA 
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protein by centrifugation at 7500 x g for 30mins at 4oC and then 
centrifugation of the resulting lysate at 40,000 x g for a further 30mins at 4oC 
before being filtered through a 0.22µm syringe filter to remove remaining 
particulate matter. 
3.12.2 Initial IMAC Ni-Affinity Purification 
Cleared cell lysate containing expressed PpmA was loaded onto a 1ml HisTrap 
HP column (GE Healthcare) and Ni-affinity purification was performed using a 
linear elution gradient as outlined in chapter 2.8.2 1ml fractions were 
collected and those corresponding to the A280 peak and presumed to contain 
the recombinantly expressed PpmA were analysed by SDS-PAGE as outlined in 
chapter 2.10.1 A typical trace for Ni-Affinity purification of PpmA is detailed 
in figure 3.16 and typical SDS-PAGE of analysed fractions is shown in figure 
3.17. 
 
Figure 3.16: Typical Ni-affinity trace for purification of PpmA 
Purification was carried out an Äkta Prime Plus purification system, using a 1ml HisTrap HP 
column. Protein was eluted from the column at a flow rate of 2ml/min using a linear 
gradient elution starting at 0% and ending at 100% of nickel buffer B. (Refer to table 2.10). 
Fractions corresponding to the peak in the UV trace were collected for analysis by SDS-
PAGE. Fractions corresponding to the peak in the UV trace were collected and analysed by 
SDS-PAGE. 
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Figure 3.17: Typical SDS-PAGE of PpmA after Ni-affinity purification 
Lane 1: SeeBlue Plus 2 mol wt. marker, Lanes 2 – 6: elution fractions 
PpmA is known to exist as a dimer when in an oxidised state. The lower band shows the 
monomer at ~38 kDa (predicted 34 kDa). The Larger band shows the dimer at ~62 kDa 
(predicted 68 kDa- predictions based on theoretical MW from ProtParam114) 
 
The fractions containing purified PpmA were buffer exchanged back into Ni-
buffer A (see table 2.10) as described in chapter 2.9.2 The His6 tag was then 
cleaved from the purified PpmA with C3-protease O/N as described in 2.9.1 
The Cleaved PpmA was subjected to additional Ni-affinity purification by 
means of reverse Ni-affinity chromatography. The sample containing the 
cleaved PpmA, C3-protease and cleaved His6 tags was cycled through a 1ml 
HisTrap HP column at a rate of 2ml/min on ice using a peristaltic pump. The 
cleaved PpmA passed through the column, whilst the His6 tags and any other 
remaining bacterial proteins including the non-cleavable His-tagged C3-
protease, were bound by the Ni-resin, separating them from the desired 
PpmA. The his6 tags and remaining bound proteins were eluted from the 
column with 10ml Ni-buffer B and discarded. Purified, cleaved PpmA was 
buffer exchanged into anion exchange buffer-A (see table 2.11) as outlined in 
2.9.2 in preparation for anion exchange chromatography. 
3.12.3 Ion Exchange Chromatography Of PpmA 
The cleaved, Ni-affinity purified PpmA was subjected to further purification 
by ion-exchange chromatography. In order to determine the type of ion 
exchanger suitable for PpmA, the PpmA amino acid sequence was 
  M  2  3   4  5   6   7  8  9 
 
 
188 kDa 
 
98 kDa 
 
62 kDa 
 
49 kDa 
 
38 kDa 
 
28 kDa 
 
17 kDa 
14 kDa 
 
6 kDa 
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downloaded from the CMR database149 and input into the ExPASy proteomics 
server114 to calculate the isoelectric point (PI) of PpmA. ExPASy114 calculated 
that the PI of PpmA was 5.04 and therefore an anion exchanger was chosen 
for ion exchange purification of PpmA. Anion-exchange chromatography was 
carried out on a 1ml CaptoQ anion exchange column (GE Healthcare) using a 
linear gradient elution as outlined in chapter 2.8.3 A typical trace for anion-
exchange chromatography of PpmA is shown in figure 3.18 1ml fractions were 
collected and those corresponding to the A280 peak were analysed by SDS-
PAGE as outlined in 2.10.1 Typical SDS-PAGE analysis of anion-exchange 
purified PpmA is illustrated in figure 3.19. 
 
Figure 3.18: Typical anion exchange trace for PpmA 
Purification was carried out an Äkta Prime Plus purification system, using a 1ml CaptoQ 
column. Protein was eluted from the column at a flow rate of 1ml/min using a linear 
gradient elution starting at 0% and ending at 100% of anion buffer B. (Refer to table 2.11). 
 
 
Figure 3.19: Typical SDS-PAGE of PpmA post-anion exchange 
       Lane 1: SeeBlue Plus 2 mol wt. marker, Lanes 2 -15: elution fractions 
 1  2  3   4   5   6  7   8  9  10 11 12 13 14 15 
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28 kDa 
 
 
17 kDa 
14 kDa 
 
6 kDa 
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3.12.4 Concentration And Storage Of Purified PpmA 
Purified PpmA was concentrated using 10 kDa MWCO centrifugal 
concentrators (Millipore) to a concentration greater than 10mg/ml, 
aliquotted and stored until required as previously described in 2.9.3 
3.13  Crystallisation And Data Collection Of PpmA 
Due to the high purity of the PpmA protein even after the initial Ni-affinity 
purification step, crystal trials were carried out using several purification 
states of PpmA protein. Four states of PpmA protein were produced and are 
outlined in table 3.4 
Protein Form Ni-Affinity purified C3-cleaved  
(His6 tag removed) 
AEC Purified 
    
I ✓ ✗ ✗ 
II ✓ ✓ ✗ 
III ✓ ✗ ✓ 
IV ✓ ✓ ✓ 
    
Table 3.4: Various forms of PpmA protein that were subjected to crystallisation trials 
Forms I and III incorporate the His6 tag used for purification; forms III and IV have been 
subjected to additional purification by anion exchange chromatography. These forms 
explore a wide range of variables that may either help or hinder the crystallisation process. 
The effects of these differences were fully explored experimentally. 
 
(i) Ni-affinity purified PpmA + His6 tag;  (ii) PpmA – His6 tag, (iii) PpmA + His6 
tag, LPS removed, (iv) PpmA – His6 tag, LPS removed. The LPS 
(lipopolysaccharide) removal is a by-product of the anion exchange 
chromatography purification process; since LPS has an overall negative 
charge, the LPS will also bind the anion exchange column, but binds very 
tightly being left behind when the protein is eluted from the column. An 
artefact arising from use of bacterial expression systems, most recombinant 
proteins expressed in this way are coated in LPS, which may be undesirable. 
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 PpmA protein was concentrated to 30mg/ml and subjected to crystal trials 
at this concentration and also at a diluted concentration of 16mg/ml using 
the sitting-drop vapour diffusion technique, by mixing protein and reservoir 
solution 1:1 (500µl:500µl) to form the drop using a Honeybee 8+1 robot 
(Digilab, Cambridgeshire UK). Crystal trials included a number of 
commercially available screens (see table 2.13) including CryoScreens 1&2, 
PEG/Ion screens 1&2 and Structure Screens 1&2. First crystals grew over a 
period of 48hrs at 20oC with crystals observed in many of the conditions for 
PEG/Ion screen 2 (Hampton Research) after 2 weeks. The higher 
concentration of PpmA produced showers of micro-crystals that formed a 
large crystalline mass. The lower protein concentration produced thin plate-
like crystals of varying size as seen in figure 3.20 Interestingly, PpmA protein 
crystals were only successfully grown after the bare minimum of purification, 
as the crystals grew from the PpmA form (i) or (ii). Conversely, no crystals 
were obtained at either of the two concentrations when using PpmA protein 
forms (iii) or (iv) where further purification had been performed, including 
the depletion of LPS levels. 
 
Figure 3.20: PpmA crystals from PEG/Ion 2 
Thin plates of PpmA Form I. Protein concentration = 16mg/ml. Total droplet volume = 1µl 
comprising a 1:1 ratio of protein : reservoir solution. 
 
3.13.1 In-House Testing Of PpmA Crystals 
Testing of the PpmA crystals was initially performed in-house on a Rigaku 
Micromax 007 HF x-ray generator (Rigaku). Data was collected on a Mar DTB 
detector. Crystals were tested with a variety of cryoprotectants the best 
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being 20% w/v PEG 400. The crystals were flash cooled in a stream of 
nitrogen gas maintained at 110K (-163oC) and subjected to 2x30sec exposures 
separated by 90o to test diffraction quality. Following optimisation the best 
crystal was obtained from a reservoir solution comprising 31% (w/v) PEG 
4000, 0.18M ammonium acetate and 0.1M sodium acetate and showed 
diffraction data to beyond 2.5Å. Replicates of this condition were set-up in 
96-well sitting-drop plates, and also set-up in larger volume 24 well sitting-
drop plates using a total drop size of 2µl in an attempt to obtain larger 
crystals. Resulting crystals were cryoprotected with 20% (w/v) PEG 400 and 
flash cooled as before. 
3.13.2 Data Collection And Processing of PpmA 
PpmA crystals were exposed to synchrotron X-rays at the ESRF (Grenoble, 
France) on beamline ID14-1. Diffraction data were collected on a single 
crystal using an ADSC Q210 CCD detector with a crystal rotation of 1o per 
frame. Diffraction quality was good in one plane, giving strong, clear spots to 
beyond 2.5Å resolution as shown in figure 3.21, however diffraction data 
quality decreased upon 90o rotation of the crystal with spots becoming 
streaky rather than the defined points observed before.  
 
Figure 3.21: In-House X-ray diffraction image for a single crystal of PpmA 
Diffraction data acquired at 0o rotation for a single PpmA crystal. Clean X-ray diffraction is 
evident to beyond 2.5Å resolution. Diffraction quality decreases at 90o rotation of the 
crystal. 
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Despite this it was possible to process the diffraction data obtained to gain an 
indication of space group and the volume of the unit cell for PpmA. Data 
were processed using the crystallographic program MOSFILM.134 As the 
diffraction pattern was very messy, spots were hand-picked over 10 images. 
Preliminary analysis of the diffraction data for PpmA is given in table 3.5 
   
Resolution (Å)  2.5Å 
Space group  P212121 
Unit cell parameters (Å, o)  a= 65.0, b=105.0, 
c=120.0, 
α=β=γ=90.0 
   
Table 3.5: Preliminary data statistics for a single PpmA crystal. 
 
To provide additional information, the program MATTHEWS132 was used to 
estimate the solvent content of the unit cell for PpmA. This data is given 
below in table 3.6 
Nmol/Asym Matthews Coeff 
(Å3Da-1) 
% Solvent Probability 
    
1 5.95 79.33 0.00 
2 2.97 58.65 0.48 
3 1.98 37.98 0.51 
4 1.49 17.31 0.00 
    
Table 3.6: Solvent content for single crystal of PpmA 
Predicted solvent content of the PpmA crystal was calculated using the crystallographic 
program MATTHEWS from the CCP4 suite of crystallographic programs.132 Values were 
calculated using the predicted MWT of the PpmA molecule and unit cell dimensions. 
 
MATTHEWS predicts either 2 or 3 molecules of PpmA per asymmetric unit; 
previous work in our lab using gel-filtration studies has shown that PpmA 
exists as a dimeric molecule under non-reduced conditions. 
Although PpmA has been successfully crystallised and rudimentary diffraction 
data obtained, there is insufficient data at present to determine the 
structure of PpmA. Work is ongoing at present in an attempt to grow crystals 
that yield better quality X-ray diffraction data. The decrease in X-ray 
diffraction quality may be due to poor crystal mosaicity caused either by 
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unsuitable cryo-conditions or possibly crystal bending. It is thought that the 
latter situation is more likely as the crystals appear as very thin plates and 
could therefore be susceptible to bending upon manipulation, affecting the 
mosaicity of the crystal lattice; diffraction quality is good along one plane 
and therefore cryo-conditions seem acceptable. In addition, since PpmA is 
predicted to be a novel type of cis-trans isomerase, conventional molecular 
replacement methods will be unsuitable for the determination of the 
structure of PpmA, with heavy atom soaks or SeMet protein derivatives 
potentially having to be generated in order to overcome the phase-problem153 
and successfully determine the structure of PpmA.
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Chapter 4 : Cloning, Expression And Purification 
Of Pneumococcal Histidine Triad D (PhtD) From 
Streptococcus pneumoniae 
4.1 Introduction 
Initially, purified PhtD protein was supplied by GlaxoSmithKline (GSK-
Rixensart, Belgium). To avoid potential problems with supply of PhtD protein, 
and to clone alternative fragments of the protein the decision was taken to 
clone the PhtD gene encoding the mature protein into an expression vector 
capable of expressing PhtD recombinantly in a bacterial expression system 
from which it could then be isolated and purified. This chapter details the 
production process, from initial isolation of genomic DNA from S.pneumoniae, 
through creation of the expression vector to expression and purification of 
the recombinantly expressed PhtD. 
4.2 Human Rhinovirus-C3 (HRV-C3) Protease 
4.2.1 General Notes 
All expression constructs used in this thesis were generated using the pOPINF 
expression vector119 which fuses an HRV-C3 protease cleavable His6-tag to the 
N-terminus of the recombinantly expressed protein of interest (POI). The 
His6-tag has been engineered specifically to aid during the protein 
purification process, and must be removed to achieve as close to the desired 
final protein sequence as possible. It was therefore required that a stock of 
HRV-C3 protease be generated for this purpose. Plasmid DNA expressing HRV-
C3 protease was kindly supplied by Dr. Alan Riboldi-Tunnicliffe, and has been 
engineered to include a non-cleavable His6-tag for the purpose of removing 
the C3 protease from the sample post-cleavage.  
HRV-C3 protease is a cysteine protease and is able to cleave proteins 
between the Q and G of the eight amino acid recognition sequence 
(LEVLFQ↓GP). A single glycine and proline residue remain at the N-terminus 
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of the recombinantly expressed protein as an artefact of the cleavage 
process. HRV-C3 protease is required to be maintained in a reduced 
environment in order to preserve its activity. This section describes the 
production of a stock of C3 protease for use in cleavage of His6 tags from 
recombinantly expressed proteins as an aid to protein purification. 
4.2.2 Bacterial Transformation 
A 50µl aliquot of Rosetta 2(DE3)pLysS chemically competent E. coli cells were 
incubated on ice with ~400ng of plasmid DNA encoding HRV-C3 protease for 
30mins. Cells were then heat-shocked in a water bath at 42oC for 30secs and 
allowed to recover on ice for 2mins. Cells were diluted 1:50 to a final volume 
of 500µl with GS96 growth media and incubated at 37oC for 1hr. Serial 
dilutions of this culture were plated out onto LB agar supplemented with 
50µg/ml ampicillin and 34µg/ml chloramphenicol and allowed to dry. Plates 
were inverted and incubated at 37oC O/N. 
4.2.3 Preparation Of Starter Culture 
A single colony of transformed Rosetta cells was picked into 50ml of LB 
supplemented with 50µg/ml ampicillin and 34µg/ml chloramphenicol. This 
small volume culture was incubated at 37oC, 170rpm in a shaking incubator 
and allowed to grow O/N. 
4.2.4 Large Scale Expression Of HRV-C3 Protease 
4l of LB was prepared as previously described in 4x 2l conical flasks, and 
supplemented with 54µg/ml carbenicillin and 34µg/ml chloramphenicol 
immediately before culture growth. 10ml of O/N starter culture was used to 
inoculate each 1l of prepared LB. Cultures were grown at 37oC, 170rpm in a 
shaking incubator until O.D600 = 0.6 was achieved. Protein production was 
then induced by addition of 1mM IPTG to each flask. The temperature was 
lowered to 22oC and allowed to grow for the remainder of the 24hr period 
post-inoculation. Cells were harvested as described in 2.7.2. 
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4.2.5 Purification of HRV-C3 Protease 
N.B. Due to the physiological nature of the C3 protease, all buffers used in 
the purification process were supplemented with 10mM β-mercaptoethanol 
to preserve the reduced state of the protein. Harvested cells were lysed as 
described in 2.7.3 Lysed cells were centrifuged at 6.5k x g at 277K for 30mins 
in a Sigma 4K15 tabletop centrifuge. The supernatant was then centrifuged 
for a further 30mins at 40 000 x g, 4oC in a Beckman Allegra™ 64R tabletop 
centrifuge (Beckman-Coulter, High Wycombe UK) to pellet any remaining cell 
debris. The resulting cleared lysate was syringe filtered through a 0.22µm 
syringe filter before being subjected to Ni-affinity chromatography as 
described in 2.8.2 10mM Dithiothreitol (DTT) was added to fraction collection 
tubes keep the protein in a reduced state after elution from the Ni-affinity 
column (DTT was used as a substitute reducing agent at this stage due to β-
mercaptoethanol toxicity). 
4.2.6 Size Exclusion Chromatography 
Size exclusion chromatography or gel filtration was performed as a final 
purification step, as described in 2.8.4 The final product, purified C3-
protease is illustrated in figure 4.1. 
 
 
Figure 4.1: SDS-PAGE of purified C3-protease 
Lane 1: SeeBlue Plus 2 mol wt. marker, Lanes 2 – 4: final, purified C3-protease 
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4.2.7 HRV-C3 Protease Storage 
The purified C3-protease was concentrated to 1ml volume, and diluted 1:1 
with sterile 100% glycerol, giving a final concentration of ~1.5mg/ml. The 
purified protein was divided into 100µl aliquots and stored at -80oC for long-
term storage. A single aliquot was stored at -20oC for use and replaced from 
the long-term stock when required. 
4.3 Construction Of PhtD Expression Plasmid 
4.3.1 Production Of S. pneumoniae gDNA 
Genomic DNA was prepared and extracted from the S. pneumoniae TIGR4 
strain as described in 2.5.1. 
4.3.2 PhtD Nucleotide Sequence 
SP_1003, the nucleotide sequence of the gene encoding PhtD was extracted 
from the Central Microbial Resources (CMR) database 
(http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi)149 hosted by the J. 
Craig Venter Institute (JCVI - http://www.jcvi.org/). The sequence was 
trimmed of the first 60 nucleotides -which encode the signal sequence of the 
protein- in order to replicate the composition of the PhtD previously supplied 
by GSK. Hereafter this protein shall be referred to as F/L PhtD, as it is 
essentially the mature protein. An annotated schematic of the PhtD protein 
sequence is illustrated in figure 4.2. 
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Figure 4.2: PhtD protein sequence (downloaded from CMR database) 
Annotated PhtD sequence. Residues highlighted in yellow indicate signal sequence to target 
the protein to the cell surface. Residues highlighted in pink indicate the histidine triad 
motifs. 
 
4.3.3 Primer Design And Amplification Of PhtD Gene 
Primers were ordered from Sigma-Aldrich. Due to the precise nature of the 
product required, there was no choice as to position of the primer-binding 
region; in order to gain favourable primer characteristics (~60% G+C content, 
melting temperature >68oC) the gene specific portion of the primer was 
lengthened or shortened accordingly. In order to make the primers 
compatible with the In-Fusion® cloning system,125 a vector-specific region was 
included in the primer corresponding to the end regions of the pOPINF 
expression plasmid. Proposed primers were entered into the Sigma-Aldrich 
oligonucleotides Design Tool158 in order to determine melting temperature, 2o 
structure and primer-dimer prediction 
(http://www.sigmaaldrich.com/configurator/servlet/DesignTool?prod_type=S
TANDARD). Resulting primers used in amplification of the PhtD gene are given 
in table 4.1. 
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Primer Name Sequence Melting 
Temperature (oC) 
   
PhtD F/L FWD AAGTTCTGTTTCAGGGCCCGTCCTA 
TGAACTTGGTCGTCACCAA 
85.2 
PhtD F/L REV ATGGTCTAGAAAGCTTTACTGTATA 
GGAGCCGGTTGACTTTC 
75.9 
   
Table 4.1: Primers for amplification of F/L PhtD. 
Underlined region of sequence denotes vector-specific primer region. 
 
PCR was carried out to amplify PhtD as outlined in 2.5.4 Table 4.2 gives the 
specific conditions under which the reaction was carried out. Primers 52Q 
and 52R (See table 2.6) that are known to amplify a fragment of the gene 
encoding the protein pneumolysin (Ply)122 were used as positive and negative 
controls. The positive control substituted PhtD primers with 52Q and 52R to 
verify that the gDNA was viable in the case that amplification of a PhtD 
product failed. The negative control omitted template gDNA from the 
reaction-mix in order to show that contamination of the reaction-mix with 
undesired DNA had not occurred. PCR results were only deemed viable if a 
product was obtained in the positive control and absent in the negative 
control reactions. 
Reaction Step Temperature (oC) Time 
 
Init. Denaturation 
 
98 
 
30 seconds 
Melting 98 10 seconds 
Annealing 54 30 seconds 
Extending 72 90 seconds 
Final extension 72 5 minutes 
   
Table 4.2: PCR conditions for amplification of F/L PhtD 
 
The products from the PCR experiment were analysed by agarose gel 
electrophoresis as previously outlined in 2.6.1 Results are shown in figure 
4.3.  
} x35 
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Figure 4.3: 0.8% Agarose gel showing successful amplification of F/L PhtD gene 
Lane 1: 1kb+ standards, Lane 2: F/L PhtD PCR product, Lane 3: Ply frag +ve control, Lane 4: 
Ply frag –ve control. Amplification of PhtD gene was successful. 
 
A clean single band corresponding to the expected product size of 2496bp 
was obtained. The positive control showed successful amplification of the Ply 
fragment, while the negative control yielded no product as expected. The 
successfully amplified PhtD was used to generate an expression plasmid for 
recombinant protein expression. 
4.3.4 Generation Of PhtD Expression Plasmid 
An expression plasmid for PhtD was constructed by inserting the amplified 
PhtD into the vector pOPINF119 using the In-Fusion® system (Clontech).125 
Linearised pOPINF119 plasmid at a concentration of 100ng/µl was kindly 
provided by Dr. A. Riboldi-Tunnicliffe. The In-Fusion system is a ligation 
independent cloning system which utilises a viral exonuclease to degrade the 
ends of the vector and insert and subsequently ‘knits’ them together, hence 
the need for the long 20bp and 18bp vector/insert overlaps generated during 
the PCR process. 150ng linear pOPINF119 and 138ng amplified PhtD insert were 
utilised in the In-Fusion reaction, which was carried out as detailed in 2.6.2.4 
Transformation of the resulting construct was carried out immediately into 
      M      F/L PhtD      +       - 
 
 
 
3000bp 
 
2000bp 
 
1000bp 
 
 
400bp 
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XL-10 GOLD chemically competent cells. 2µl of the ligation mix were 
incubated on ice for 30mins with 20µl XL-10 GOLD cells. DNA uptake was 
induced by heat-shocking at 42oC for 30secs in a water-bath. Cells were 
allowed to recover on ice for 2mins before being diluted to a final volume of 
200µl with GS96 growth media and then incubated at 37oC for 1hr. Cells were 
plated out on LB agar supplemented with 54µg/ml carbenicillin, allowed to 
dry, and incubated O/N at 37oC. 
A single colony from the successfully transformed bacteria was used to 
inoculate 50ml LB supplemented with 54µg/ml carbenicillin and incubated in 
a shaking incubator O/N at 37oC, 170rpm. The following day, plasmid DNA 
was extracted from this O/N culture using the QIAquick miniprep kit127 
according to manufacturers instructions, substituting DNase & RNase-free 
dH2O for the elution buffer. 2µl plasmid DNA was analysed by agarose gel 
electrophoresis as previously described to confirm successful plasmid 
generation. Quality control was carried out by having the plasmid sequenced 
using T7 promoter and terminal primers, the original insertion primers and 
internal PhtD primers in order to obtain full read-through of the gene (refer 
to table 2.6). Sequencing was carried out at DNA Sequencing & Services 
(University Of Dundee, Scotland UK).159 Sequencing results showed no errors 
in the plasmid sequence. The resulting expression plasmid was named pMRH1 
and is shown in figure 4.4 along with the translated protein sequence. For 
storage, pMRH1 was transformed into DH5α cells as described above, a 
glycerol stock prepared as outlined in 2.3.1 and stored at -80oC. 
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Figure 4.4: pMRH1 F/L PhtD expression construct 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The bottom panel shows the resulting translated 
protein sequence. Plasmid map was generated using CLC Genomics Workbench 4.120
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4.4 Expression Of F/L PhtD 
4.4.1 Transformation 
Essentially, transformation was carried out as previously described. A 50µl 
aliquot of Rosetta™ 2(DE3)pLysS chemically competent cells were incubated 
on ice with ~400ng of pMRH1 plasmid for 30mins. DNA uptake was induced by 
heat-shocking at 42oC for 30secs in a water-bath. Cells were allowed to 
recover on ice for 2mins, diluted to a final volume of 500µl with GS96 growth 
media and incubated at 37oC for 1hr. Cells were plated out on LB agar 
supplemented with 54µg/ml carbenicillin, allowed to dry, and incubated O/N 
at 37oC. 
4.4.2 Protein Expression 
A single transformant was used to inoculate 50ml LB supplemented with 
54µg/ml carbenicillin and 34µg/ml chloramphenicol in a 200ml conical flask 
and incubated at 37oC in a shaking incubator O/N at 170rpm. Large scale 
protein expression was carried out using 2 x 500ml volumes of TB-Onyx auto-
induction media supplemented with 54µg/ml carbenicillin and 34µg/ml 
chloramphenicol in 2L conical flasks as described in 2.7.2 
4.5 Purification Of Recombinant F/L PhtD 
4.5.1 Initial IMAC Ni-Affinity Chromatography 
Pelleted cells were lysed in a French pressure cell as outlined in 2.7.3 Lysed 
cells were centrifuged at 7500 x g, 4oC for 30mins and the pellet discarded. 
The supernatant was then further centrifuged at 40,000 x g, 4oC for 30mins, 
the pellet discarded and the supernatant passed through a 0.22µm syringe 
filter to remove as much particulate matter as possible before 
chromatography. The cleared lysate was subjected to Ni-affinity 
chromatography as outlined in 2.8.2 Eluted fractions corresponding to the 
A280 peak on the trace were collected and analysed by SDS-PAGE as outlined 
in 2.10.1 A trace typical of the initial Ni-affinity purification for F/L PhtD is 
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shown in figure 4.5 Figure 4.6 shows typical SDS-PAGE analysis of fractions 
eluted from the Ni-affinity column. 
 
Figure 4.5: Typical Ni-affinity trace for F/L PhtD 
Purification was carried out an Äkta Prime Plus purification system, using a 1ml HisTrap HP 
column. Protein was eluted from the column at a flow rate of 2ml/min using a linear 
gradient elution starting at 0% and ending at 100% of nickel buffer B. (Refer to table 2.10). 
Fractions corresponding to the peak in the UV trace were collected for analysis by SDS-PAGE 
 
 
 
 
Figure 4.6: SDS-PAGE of F/L PhtD from Ni-affinity purification 
Lane1: mol wt. marker; Lanes 2-13: elution fractions. Arrow indicates recombinantly 
expressed F/L PhtD protein. 
 
     1  2   3  4   5   6  7  8 9 10 11 12 13 
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4.5.2 C3-Cleavage Of His6 Tag & Reverse Ni-Affinity 
Chromatography 
Fractions containing the highest abundance of target protein were pooled for 
continuation of the purification process (e.g. fractions 2-9 in figure 4.6). F/L 
PhtD was buffer exchanged back into Ni-buffer A using a PD-10 desalting 
column128 as outlined in 2.9.2. 
As and added purification step before ion exchange chromatography, the N-
terminal His6 tag was cleaved from F/L PhtD present in the Ni-affinity elution 
fractions with C3-protease as outlined in 2.9.1 Cleavage was carried out O/N. 
The cleaved protein was then subjected to reverse Ni-affinity 
chromatography by cycling the sample through a 1ml HisTrap HP Ni-column 
using a peristaltic pump at a flow-rate of 2ml/min for 30mins on ice. Because 
the His6 tag has been removed from the protein it no longer binds to the resin 
in the column, instead passing straight through whilst the cleaved His6 tags 
and contaminant host-proteins which had previously shown an affinity for the 
column still bind. The HRV-C3 protease also contains a non-cleavable His-tag, 
which allows it to be isolated from the cleaved target-protein sample by 
binding to the Ni-affinity column. The tags, contaminant proteins and C3-
protease were eluted from the Ni-column with 10ml of Ni-buffer B and 
discarded. The cleaved F/L PhtD was carried forward for further purification 
by ion exchange chromatography. 
4.5.3 Ion Exchange Chromatography (Anion Exchange) 
Ion exchange chromatography was carried out using a 1ml CaptoQ anion 
exchange column as previously described in 2.8.3. A typical trace for anion 
exchange chromatography of F/L PhtD is illustrated in figure 4.7 and a typical 
SDS-PAGE analysis of the resulting fractions is illustrated in figure 4.8. 
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Figure 4.7: Typical anion exchange trace of F/L PhtD 
Purification was carried out an Äkta Prime Plus purification system, using a 1ml CaptoQ 
column. Protein was eluted from the column at a flow rate of 1ml/min using a linear 
gradient elution starting at 0% and ending at 100% of anion buffer B. (Refer to table 2.11). 
 
 
 
Figure 4.8: SDS-PAGE for anion exchange of F/L PhtD 
Lane 1: mol wt. marker; Lanes 2-14: elution fractions. Arrow indicates purified F/L PhtD. 
 
Following purification by anion exchange chromatography and analysis by 
SDS-PAGE, it was judged that the F/L PhtD was of pure enough quality to be 
used without any further purification. The purest fractions were pooled, 
concentrated and stored at -20oC for short-term storage or -80oC for long-
term storage until required. 
         1   2  3  4  5  6   7   8    9  10  11 12  13  14 
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4.5.4 Concentration Of Purified F/L PhtD 
The purified F/L PhtD was buffer exchanged from Anion-exchange buffer B 
into 50mM Tris HCl pH7.5, 500mM NaCl, 20mM imidazole using a PD-10 
desalting column128 as described in 2.9.2 The purified F/L PhtD was then 
concentrated as outlined in 2.9.3 until a concentration of ~10mg/ml had 
been obtained. F/L protein was then aliquotted and stored as previously 
described in 2.9.3. 
4.6 Construction Of Truncated Forms of PhtD 
4.6.1 Overview 
Structural predictions and protein analysis by 1D-NMR (detailed in chapter 4) 
indicated that crystallisation and structural determination of the F/L PhtD 
molecule would prove challenging, and that greater success might be 
obtained by attempting to crystallise separate fragments of the PhtD 
molecule. It was therefore decided to use a targeted approach to identify 
structured regions of the F/L protein and to construct and purify these 
regions as truncated forms or fragments of the F/L PhtD molecule. To this 
end, regions of interest were identified by limited proteolysis, mass-
spectrometry and N-terminal sequencing (details of these experiments and 
their findings are given in the relevant chapters) and a set of truncated 
proteins constructed. The following sections outline the generation of these 
fragments. 
4.6.2 Fragment Design 
In total, 7 constructs were planned of which 1 was the F/L protein described 
previously and another was to attempt insertion of a TEV cleavage site into 
the middle of the F/L PhtD construct, although this was ultimately 
abandoned. The other 5 constructs were all fragments of the N-terminal half 
of the protein as this was seen to be the more highly structured region of the 
protein. These expression constructs were named pMRH1 – 7 as detailed in 
table 4.3. 
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Plasmid Name  N- And C- Term 
Translated Amino Acids 
Protein Name 
   
pMRH1 SYEL - APIQ F/L 
pMRH2 SNHW - APIQ C-Term 
pMRH3 SNHW - LLEK  ΔC-Term 
pMRH4 VTDP - APIQ 5.3 kDa 
pMRH6 SNHW – HYHN 34 kDa 
pMRH7 IKFE - LLEK Epitope 
   
Table 4.3: PhtD plasmids and resulting protein products 
Start and end sequences of translated amino acids for the pMRH constructs are given above. 
Full protein sequences are given with relevant vector maps. 
**pMRH5: F/L with TEV insert excluded 
 
A schematic diagram for ease of visualising the different fragments is shown 
below in figure 4.9 
 
Figure 4.9: Schematic representation of PhtD proteins 
 
4.6.3 Primer Design And Amplification Of PhtD Fragments 
As before, primer design was limited because of the exact location that was 
required to generate each fragment. The gene-specific region of each primer 
was coupled with the pOPINF119-specific region for In-Fusion cloning.125 
Primers are given in table 4.4. 
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Primer Name Primer Sequence Comments 
   
PhtD F/L Fwd AAGTTCTGTTTCAGGGCCCGTCCTA 
TGAACTTGGTCGTCACCAA 
Fwd primer for pMRH1 
PhtD F/L Rev ATGGTCTAGAAAGCTTTACTGTATA 
GGAGCCGGTTGACTTTC 
Rev primer for pMRH1, 
pMRH2 & pMRH4 
PhtD C-Term Fwd AAGTTCTGTTTCAGGGCCCGCCCAG 
CGCAAATCACAAGTCGAAC 
Fwd primer for pMRH2, 
pMRH3 & pMRH6 
PhtD ΔC-Term Rev ATGGTCTAGAAAGCTTTATTTTTCTA 
GCAAGGCCTCCGCATC 
Rev primer for pMRH3 & 
pMRH7 
PhtD 5.3kDa Fwd AAGTTCTGTTTCAGGGCCCGGTAACA 
GATCCTAGTATTAGAC 
Fwd primer for pMRH4 
PhtD 34kDa Rev ATGGTCTAGAAAGCTTTAGTTATGGT 
AATGGTCATAATGAGG 
Rev primer for pMRH6 
PhtD Epitope Fwd AAGTTCTGTTTCAGGGCCCGATCAAA 
TTTGAGTGGTTTGAC 
Fwd primer for pMRH7 
   
Table 4.4: Primers used for amplification of PhtD fragments.  
Underlined sequence denotes vector-specific region. 
 
 
4.6.4 Amplification Of PhtD Fragments 
PCR was carried out to amplify the PhtD fragments as outlined in 2.6.4. Table 
4.5 gives the specific conditions under which the reaction was carried out. 
Primers 52Q and 52R (See table 2.6) for amplifying a fragment of the gene 
encoding the protein pneumolysin (Ply)122 were used as positive and negative 
controls as previously described in section 3.3.3 
Reaction Step Temperature Time 
 
Init. Denaturation 
 
98oC 
 
30secs 
Melting 98oC 10secs 
Annealing 60oC 30secs 
Extending 72oC 50secs 
Final extension 72oC 5mins 
   
Table 4.5: PCR conditions for PhtD fragments 
 
Products of the PCR experiment were analysed by agarose gel electrophoresis 
as outlined in 2.6.1 Results for PCR of fragments are shown below in figure 
4.10 
 
} x35 
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Figure 4.10: 0.8% agarose gel showing products from PCR amplification of PhtD gene and 
fragments 
PCR products corresponding to F/L PhtD and the fragments of the PhtD coding for the 
selected PhtD protein fragments were all successfully amplified. The positive control 
yielded the Ply fragment and the negative control contained no product, as expected. 
 
All fragments generated were of the expected size. Fragment sizes are given 
in table 4.6 PCR products were cleaned using a QIAquick PCR Purification 
kit127 as described in 2.6.2.1 before being inserted into the pOPINF119 
expression vector. 
PCR fragment  Product Size (bp) 
pMRH1  2496 
pMRH2  1527 
pMRH3  1174 
pMRH4  192 
pMRH6  960 
pMRH7  453 
Table 4.6: PCR fragment product sizes 
All product sizes include the additional 38bp generated for In-Fusion cloning 
 
4.6.5 Generation Of pMRH Expression Constructs 
The process for generating the expression constructs pMRH2, pMRH3, pMRH4, 
pMRH6 and pMRH7 was exactly the same as that used for generating the 
   M       pMRH1  pMRH2  pMRH3   pMRH4  pMRH6  pMRH7                  +       - 
3000bp 
2000bp 
 
1000bp 
 
400bp 
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pMRH1 F/L expression construct as detailed in 3.3.4 The cleaned PCR product 
comprising the relevant fragment was inserted into linearised pOPINF119 
vector using the In-Fusion method.125 Resulting expression constructs were 
verified by sequencing and stored as glycerol stocks (see 2.3.1). Vector maps 
for these constructs and the resulting translated sequences of the protein 
fragments are shown below in figures 4.11 to 4.15. 
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Figure 4.11: pMRH2 expression construct 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The bottom panel shows the resulting translated 
protein sequence. Plasmid map was generated using CLC Genomics Workbench 4.120
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Figure 4.12: pMRH3 expression construct 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The bottom panel shows the resulting translated 
protein sequence. Plasmid map was generated using CLC Genomics Workbench 4.120
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Figure 4.13: pMRH4 expression construct 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The bottom panel shows the resulting translated 
protein sequence. Plasmid map was generated using CLC Genomics Workbench 4.120
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Figure 4.14: pMRH6 expression construct 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The bottom panel shows the resulting translated 
protein sequence. Plasmid map was generated using CLC Genomics Workbench 4.120
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Figure 4.15: pMRH7 expression construct 
DNA was fused N-terminally to a His6-tag that incorporates an HRV-C3 protease site for 
cleavage of the His6-tag. Regulation of recombinant protein expression was placed under 
control of the upstream T7 promoter. The bottom panel shows the resulting translated 
protein sequence. Plasmid map was generated using CLC Genomics Workbench 4.120 
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4.7 Expression Of Truncated Forms Of PhtD 
Expression of all truncated forms of PhtD was carried out in exactly the same 
way as expression of the F/L PhtD protein as described in 4.4 Plasmids were 
transformed into Rosetta2(DE3)pLysS competent cells, a starter culture was 
grown in LB, which was then used to inoculate the expression cultures of TB-
Onyx. 
4.8 Purification Of Recombinant Truncated Forms Of 
PhtD 
The process for purification of the various PhtD protein fragments was carried 
out in exactly the same way as the purification of the F/l PhtD protein as 
described in 4.5 Pelleted cells were lysed using a French Pressure cell, 
centrifuged and filtered to remove particulate matter then subjected to a 
process of IMAC Ni-affinity chromatography, His6 tag cleavage accompanied 
by reverse Ni-affinity chromatography, and finally anion exchange 
chromatography. Samples were analysed between each stage of the 
purification process by SDS-PAGE as outlined in 2.10.1 Purified PhtD protein 
fragments were concentrated to a concentration >10mg/ml using Amicon 
Ultra centrifugal concentrators with a MWCO of 10 kDa as outlined in 2.9.3 
Samples of resulting purified, concentrated PhtD protein fragments are shown 
in figure 4.16. 
 104 
   M  F/L   C   ΔC  34  
 
 
Figure 4.16: Recombinantly expressed and purified PhtD proteins 
Lane 1: SeeBlue +2 Marker, Lane 2: F/L, Lane 3: C-Term, Lane 4: ΔC-term, 
Lane 5: 34 kDa fragment. Each lane was loaded with 1µg of purified protein. 
 
Although the expression constructs pMRH4 and pMRH7 which were designed 
to encode the 5.3 kDa extreme C-terminus of PhtD and a 15 kDa region of 
interest were successfully created (and verified through sequencing), and 
could be cultured in bacterial cell lines allowing recombinant protein 
expression, it was not possible to obtain any recombinant protein for these 
two fragments. Initial attempts at protein purification were unsuccessful, and 
subsequent Western blotting of cell lysates from the expression cultures with 
anti-PhtD showed that the protein fragments encoded by these constructs 
were not expressed using the devised expression protocol. It is possible that 
variation of expression culturing conditions for these constructs may have 
resulted in successful protein expression; however due to time constraints 
this was not attempted and these two constructs were not taken forward any 
further. 
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Chapter 5 : Biophysical Characterisation Of PhtD 
5.1 Limited Proteolysis Of F/L PhtD 
Data presented in this thesis provides an insight into the structure of the 
PhtD molecule. Initially, bioniformatic analysis of the PhtD protein sequence 
was performed using structural prediction tools (RONN disorder prediction 
server). Structural investigation was carried out utilising a variety of 
techniques including Nuclear Magnetic Resonance (NMR) spectroscopy and 
Circular Dichroism (CD) to experimentally test the bioinformatics structural 
prediction results. The resulting data from the NMR analysis of F/L PhtD 
compounded the RONN139 prediction that PhtD has structured regions, but 
that PhtD as a whole is largely mobile, with regions moving independently of 
each other resulting in an overall very flexible or mobile protein structure 
(outlined in chapter 6.3). In order to assess whether it was possible to isolate 
the more highly structured regions of the protein, F/L PhtD was subjected to 
limited proteolysis by performing a controlled time-course tryptic digest.160 In 
conjunction with structural predictions (see chapter 6.2) and the NMR data, 
the results in this chapter were used to identify structured regions of the 
PhtD molecule to be cloned and expressed that may be more conducive 
crystallisation than the F/L PhtD molecule. 
5.1.1 Preliminary Investigation 
Before any wet labwork was performed, the PhtD AA sequence was input into 
the program PeptideCutter (http://www.expasy.ch/tools/peptidecutter/) 
hosted at the ExPASy proteomics server114 to identify potential protease 
cleavage sites. Trypsin is a serine protease, which is able to cleave proteins 
C-terminally to lysine or arganine residues. PeptideCutter identified 85 
possible cleavage sites, which would reduce the PhtD protein to very small 
fragments if 100% cleavage occurred. It was hypothesised that if there were 
highly structured regions within the molecule, these would intrinsically be 
rigid, folded regions of the protein and so any trypsin cleavage sites present 
in these regions could be inaccessible to the protease, resulting in stable 
fragments of the protein which were resistant to proteolytic degradation. 
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5.1.2 Limited Proteolysis Of Apo- F/L PhtD 
Limited proteolysis experiments were designed based on previous research.160 
For the limited proteolysis experiment, 1mg of purified F/L PhtD protein was 
exposed to 25µg of proteomics grade trypsin in a total reaction volume of 
500µl as outlined in table 5.1 The reaction was carried out at ambient 
temperature. 40µl samples were removed at 1, 3, 5, 10, 15, 20, 30, 45 and 
60min time intervals. Before the reaction was begun, a sample of the 
undigested protein was taken in order to confirm that degradation of the 
protein had not occurred prior to addition of the protease.  
Reaction Component  Quantity 
   
Recombinant purified F/L PhtD  1mg 
Proteomics grade trypsin  25µg 
   
 Final Vol 500µl 
Table 5.1: Limited proteolysis reaction composition 
Components were made up to final volume of 500µl with protein buffer (50mM      
Tris HCl pH7.5, 500mM NaCl, 20mM imidazole.) 
 
As a negative control to show that the F/L PhtD was not undergoing self-
degradation, the exact same reaction was performed using F/L PhtD protein 
from the same stock, but the trypsin protease was excluded from the 
reaction mixture. The two experiments were performed at the same time to 
ensure consistency between reactions. All samples were mixed 1:1 with 
NuPAGE SDS loading buffer and denatured in a boiling water-bath as soon as 
the samples were removed from the reaction in order to gain as accurate a 
profile of protein digestion as possible for each time-point. Samples were 
subsequently analysed by SDS-PAGE as outlined in 2.10.1. The resulting 
profile of limited proteolysis for Apo- F/L PhtD is shown in figure 5.1 
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Figure 5.1: Limited proteolysis of Apo-F/L PhtD 
The limited proteolysis experiment was carried out at ambient temperature in Tris buffer 
(50mM Tris HCl pH7.5, 500mM NaCl, 20mM imidazole). 1mg of protein at a concentration of 
2mg/ml was utilised for the experiment. A 40µl sample was removed at each time-point 
with each lane of the SDS-PAGE gel therefore theoretically comprising 80µg total protein.  
Lanes 1, 13 & 14: SeeBlue Plus 2 Mol. Wt. markers; Lane 2: Undigested F/L PhtD;     
Lanes 3 – 11: Time-points for F/L PhtD digest with trypsin; Lanes 14 -22: Time-points for F/L 
PhtD without trypsin; Lane 25: Trypsin. Boxes on the left show the two stable fragments 
throughout the proteolysis experiment. 
 
The limited proteolysis profile showed that the F/L PhtD was degraded very 
rapidly; after 1 minute there is no evidence of any F/L protein intact, and 
that after 5 minutes, the most abundant fragment of the protein is around 
half the size of the F/L molecule, with the largest visible product only two-
thirds the size of the F/L molecule. However, it can be seen that after 5 
minutes two stable bands (indicated in figure 5.1) have been obtained and 
appear resistant to any further degradation. These bands are approximately 
49 and 34 kDa in size respectively by SDS-PAGE. The negative control has 
confirmed that the F/L molecule is relatively stable under the same 
conditions when trypsin is absent, and that the presence of trypsin is 
required for proteolysis to occur. The identification of these two stable, 
structured regions of PhtD was successfully performed by utilising a 
combination of mass-spectrometry and N-terminal protein sequencing 
(discussed in chapter 5.2, 5.3 and 5.4). This data was subsequently used to 
generate expression constructs which allowed expression and purification of 
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these fragments in order to attempt to determine their structure by 
macromolecular x-ray crystallography (detailed in chapter 3). 
5.1.3 Limited Proteolysis Of Zn-Bound F/L PhtD 
From work carried out previously at the University of Glasgow and data in this 
thesis, there is evidence that the Pneumococcal Histidine Triad family of 
proteins bind Zn2+ through the HxxHxH motifs for which the family is named. 
This was seen to be true in the crystal structure of a fragment of 
Pneumococcal Histidine Triad A (PhtA) which revealed a Zn2+ atom bound in 
the HxxHxH motif.98 It was hypothesised that the binding of Zn2+ atoms may 
induce some form of conformational change in the F/L PhtD molecule 
resulting in a more overall ordered protein and therefore more resistant to 
proteolytic activity. To investigate this, the limited proteolysis experiment 
outlined in 5.1.2 was repeated but this time a source of Zn2+ atoms was 
introduced to the F/L PhtD protein before exposure to trypsin. The reaction 
was set up and performed as described above, but before addition of the 
trypsin, ZnSO4 was added to the F/L PhtD to a final concentration of 10mM. 
Samples were again taken at set time-points and analysed by SDS-PAGE. The 
resulting SDS-PAGE is shown in figure 5.2. 
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Figure 5.2: Limited proteolysis of Zn2+-bound F/L PhtD 
The limited proteolysis experiment was carried out at ambient temperature in Tris buffer 
(50mM Tris HCl pH7.5, 500mM NaCl, 20mM imidazole). 1mg of protein at a concentration of 
2mg/ml was utilised for the experiment. A 40µl sample was removed at each time-point 
with each lane of the SDS-PAGE gel therefore theoretically comprising 80µg total protein. 
Lanes 1, 13 & 14: SeeBlue Plus 2 Mol. Wt. markers; Lane 2: Undigested Zn-bound F/L PhtD; 
Lanes 3 – 11: Time-points for Zn-bound F/L PhtD digest with trypsin; Lanes 14 -22: Time-
points for Zn-bound F/L PhtD without trypsin; Lane 25: Trypsin. 
Boxed areas show the two stable protein fragments in the presence of Zn2+ showing the 
increase in MWT of the two fragments when compared to the Apo-form. 
 
A side-by-side comparison of the two digests (Figure 5.3) shows that there is 
a marked difference in the limited proteolysis profile of F/L PhtD when 
comparing the Apo- and Zn2+-bound forms of the protein. 
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Figure 5.3: Comparison of Apo- and Zn2+-bound F/L PhtD limited proteolysis 
The limited proteolysis experiment was carried out at ambient temperature in Tris buffer 
(50mM Tris HCl pH7.5, 500mM NaCl, 20mM imidazole). 1mg of protein at a concentration of 
2mg/ml was utilised for the experiment. A 40µl sample was removed at each time-point 
with each lane of the SDS-PAGE gel therefore theoretically comprising 80µg total protein. 
Boxed out regions denote the stable fragments in the Apo-form on the left and in the Zn2+-
bound form on the right. 
 
The first major observation is that there are still two proteolytically resistant 
bands on the SDS-PAGE gel for the Zn2+-bound F/L PhtD, but that they have 
increased in size by approximately 25 kDa for the larger protein fragment 
from ~49 kDa to ~75 kDa, and by approximately 21 kDa for the smaller 
protein fragment from ~34 kDa to ~55 kDa. In relation to this stabilising 
effect on the fragments, it has been observed that whilst there is a complete 
absence of intact F/L PhtD after 1min under Apo- conditions, in contrast it is 
evident that under Zn2+-bound conditions intact F/L molecule is still present 
after 5mins in the presence of the protease. This reinforces the hypothesis 
that structural changes induced by the binding of Zn2+ atoms are conferring a 
more highly ordered proteolytically resistant structure on the F/L PhtD 
molecule. 
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5.1.4 Limited Proteolysis Of F/L PhtD In The Presence Of Selected 
Divalent-Cations 
Due to the ability of PhtD to bind Zn2+ atoms via its canonical HxxHxH motifs, 
the possibility that the protein would be able to bind other divalent cations 
was investigated.  
 
 
Figure 5.4: Limited proteolysis of F/L PhtD in the presence of selected divalent cations 
Two samples were analysed for each cation; an initial time-point and then 20mins post 
incubation with trypsin. These profiles were compared to the apo-form where no cation was 
present. Zn2+is the only cation which appears to have a visible effect on protein stability, 
with F/L PhtD still present after 20mins. All others show the same profile as the apo-digest 
suggesting they have no effect on protein structure. 
 
  
As before, purified F/L PhtD was subjected to limited proteolysis in the same 
way as outlined in 5.1.2 and 5.1.3 with the relevant metal being added to the 
F/L PhtD before incubation with the protease (trypsin). A selection of 
divalent-cations were used to test the hypothesis that PhtD was able to 
selectively bind divalent cations and thus had an exclusive affinity for Zn2+ 
atoms. Selected metals were as follows: CuSO4, CoCl2, FeSO4, and MnSO4 All 
solutions were made up as a 0.5M stock. To conserve protein stocks, all 
values were reduced by a factor of 10 from the original limited proteolysis 
 M     Cu2+       Co2+          Fe2+          Mn2+        Zn2+   
No 
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experiments and only 2 time-points were taken; one at 1 minute post-
incubation and one at 20 minutes post-incubation. These time-points were 
chosen as they were expected to show a clear difference between profiles. 
To provide comparable digest profiles, limited proteolysis digests were also 
performed with an equivalent concentration of ZnSO4 to act as a positive 
control, and without any divalent-cation present to act as a negative control. 
40µl samples were removed for each per time point, mixed 1:1 with NuPAGE 
SDS-loading dye and denatured immediately in a boiling water-bath for 
5mins. Samples were run on SDS-PAGE as before to visualise digest profiles. 
These results are illustrated in figure 5.4. 
Analysis of the digest profiles for the various selected divalent-cations shows 
that of the divalent-cations tested, all profiles were visually identical to the 
profile of the Apo- F/L PhtD limited proteolysis digest, with no F/L molecule 
evident in the second time-point sample for any of the tested Cu2+, Co2+, Fe2+ 
or Mn2+ divalent cations, and a large band present of ~55 kDa. In contrast 
there is an absence of this strong ~55 kDa band at the second time-point, and 
clearly a significant quantity of F/L PhtD molecule present in the second 
time-point sample for the PhtD digest in the presence of ZnSO4 supporting 
the hypothesis that PhtD may have a ability to bind Zn2+ atoms to the 
exclusion of other divalent-cations. It is possible however, that any of these 
metals tested my have an effect at a higher concentration, although it was 
expected that the concentrations used would be sufficient to saturate any 
binding sites and therefore that any effect would have been noticed at the 
concentration used.  
5.2 Mass-Spectrometry Analysis Of F/L PhtD Limited 
Proteolysis Profiles 
5.2.1 Overview 
The technique of mass spectrometry was used in two ways. Primarily, 
coupled with N-terminal protein sequencing, it was used as an aid to 
identification of the stable, structured regions of PhtD observed in the 
limited proteolysis experiments. Furthermore, once these regions had been 
identified and a cloning strategy designed and adopted, mass spectrometry 
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was again employed; this time, coupled with DNA sequencing of the 
expression constructs, the resulting expressed PhtD fragments were also 
analysed by mass spectrometry in a ‘belt and braces’ approach to make 
doubly sure that the correct product had been obtained from the protein 
expression process. Mass-spectrometry was carried out at the University of 
Glasgow with the kind assistance of Dr. Richard Burchmore, and at 
GlaxoSmithKline Biologicals with the assistance of Satty Borman. 
5.2.2 Intact-Mass MALDI-ToF Mass Spectrometry Of Limited 
Proteolysis Profiles (Peptide Mass Fingerprinting) 
An Apo- F/L PhtD limited proteolysis experiment was performed exactly as 
outlined in 5.1.2 Duplicate samples were removed at each time-point; one 
sample was mixed 1:1 with NuPAGE SDS loading dye and denatured as before 
for analysis by SDS-PAGE. With the second sample the reaction was quenched 
by addition of 2µl TCA, as the serine-protease trypsin is rendered inactive 
when under acidic conditions.161 The addition of 2µl neat TCA proved enough 
to lower the pH in the reaction below pH7 and into an acidic environment. 
This was required as intact-mass measurement requires that the protein/s to 
be analysed are in their native-state to obtain accurate mass measurements 
of the sample, hence the reaction could not be stopped in the usual way by 
denaturing with SDS. 
In contrast to traditional MALDI-ToF mass spectrometry for an in-gel sample, 
the samples were not subjected to further tryptic digestion before running 
through the mass spectrometer in an attempt to identify each fragment 
based on its accurate mass-fingerprint. The samples from three distinct time-
points were analysed in this way. Once the accurate masses had been 
obtained for the various fragments in each of the time-point samples, results 
were analysed using the MASCOT search engine 
(www.matrixscience.com/).162 The partner SDS-PAGE gel is shown in figure 
5.5 Samples taken at time-points 1, 3, and 60mins were subjected to PMF. 
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Figure 5.5: SDS-PAGE profile of F/L PhtD tryptic digest subjected to PMF 
Samples from the TCA quenched reaction corresponding to the 1, 3, and 60min time-points 
on the SDS-PAGE gel were analysed by PMF. 
 
Analysing the resultant mass spectrometry data with MASCOT162 successfully 
identified the protein from which the fragments were derived, giving the 
expected gene number SP_1003, which corresponds to PhtD in the 
pneumococcal strain TIGR4. Disappointingly, no accurate masses were 
obtained which corresponded to the 49 kDa or 34 kDa stable fragments. 
However, accurate masses were obtained for many much smaller protein 
fragments, with coverage of these smaller fragments increasing over time 
that could be mapped back to the N-terminal half of the protein and the 
extreme C-terminus of the protein, leaving a large area in the C-terminal half 
of estimated molecular weight 35.7 kDa, corresponding roughly to one of the 
stable fragments which appeared resistant to digestion. It was elucidated 
that either the samples had failed to ionise sufficiently to fly in the mass-
spectrometer, or that they were simply too large to fly without being further 
digested. The results of the MASCOT162 search comparing the 1 and 3min 
samples are illustrated in figures 5.6 and 5.7. 
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Figure 5.6: PMF analysis of 1min digest sample 
Identified peptides are shown in blue. 
 
 
Figure 5.7: PMF analysis of 3min digest sample 
Identified peptides are shown in blue. There is an increase in peptides from the N-terminal 
half of the protein, whilst the C-term half remains resistant to proteolytic digestion. 
 
The largely intact area starting at residue 472 Q (glutamine) where no 
peptides have been recovered is clearly visible for both datasets. 
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To reinforce these findings, a selection of bands including the 49 kDa and 34 
kDa stable bands were excised from the SDS-PAGE gel and subjected to PMF. 
As these samples were isolated from each other as a result of the SDS-PAGE 
process, each sample was further digested with trypsin prior to PMF analysis. 
In this instance, the problem initially observed with the larger fragments was 
overcome due to the fact that the protein had been denatured and so any 
previously protected trypsin cleavage sites should be easily accessible 
resulting in smaller, processible peptide fragments. As before, resulting data 
was processed using the MASCOT162 search engine, and protein identity was 
successfully confirmed as being derived from SP_1003. 
As postulated, when the PMF profiles for the 49 kDa and 34 kDa bands were 
mapped onto the PhtD protein sequence, they fell exactly into the region 
which was shown to be protected from proteolysis in the non-denatured 
samples. The MASCOT162 results for these two protein fragments are 
illustrated in figures 5.8 and 5.9.  
 
Figure 5.8: PMF analysis of 49 kDa fragment excised from SDS-PAGE gel 
Identified peptides are shown in blue. The identified peptides correspond to those absent 
from the matching region of sequence from analysis under non-denatured conditions. 
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Figure 5.9: PMF analysis of 34 kDa band excised from SDS-PAGE gel 
Identified peptides are shown in blue. The identified peptides correspond to those absent 
from the matching region of sequence from analysis under non-denatured conditions. 
 
It can clearly be seen that the peptides recovered from these two samples 
under denatured conditions corresponds to the region in the non-denatured 
samples that previously showed no mapped peptides. 
As a result of these experiments, it was possible to successfully identify the 
region of the protein that seemed the most proteolytically resistant and 
therefore hypothetically was highly structured; a physiological characteristic 
which would contribute to proteolytic resistance due to the highly folded 
nature of this region making cleavage sites inaccessible. 
In order to determine a definitive starting region for the 49 kDa and 34 kDa 
stable fragments, samples were subjected to Western transfer, prepared as 
outlined in 2.10.3 and sent for N-terminal sequencing at the University of 
Dundee. Analysis of the two fragments revealed that both fragments started 
at serine 344, with the leading sequence SNHWVPD. This corroborated the 
PMF data, as comparable peptides were recovered for both bands at the N-
terminus, however the 49 kDa fragment contained extra peptides not present 
in the 34 kDa fragment at the C-terminal end. Using the sum of all this data, 
these two fragments have been successfully identified, allowing for a 
targeted cloning approach to be used in generation of protein fragments, 
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which can be employed in attempts to determine protein structure by 
macromolecular X-ray crystallography. 
5.2.3 Western Blot Analysis Of PhtD 
In an attempt to uncover specific regions of interest in the PhtD protein, the 
limited proteolysis profile of Apo- F/L PhtD was subjected to Western 
blotting as described in 2.10.3 using a polyclonal antibody raised in rabbits 
against F/L PhtD. It was hypothesised that, as the protein was digested over 
time, it may have been possible to elucidate antibody-binding regions of the 
protein. 
Western blotting was carried out on Hybond-P PVDF membrane (Amersham 
Biosciences – GE Healthcare) according to the SOP optimised in the Mitchell 
Pneumococcal Lab (outlined in appendix A.3.2), using primary (1o) and 
secondary (2o) antibody dilutions of 1 in 2000. 1o polyclonal antibody 
(provided by GSK, Rixensart Belgium) was raised against F/L PhtD protein in 
rabbits. 2o antibody consisted of HRP-conjugated donkey anti-rabbit antibody 
(Amersham Biosciences – GE Healthcare). Reaction of the protein with the 
antibody was detected directly on the PVDF membrane by exposure to 4-
chloro-1-napthol, which visually reacts with HRP to produce a blue/purple 
colour. The developed membrane is shown in figure 5.10 and the 
corresponding coomassie stained SDS-PAGE gel is shown in figure 5.11. 
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Figure 5.10: Western blot of Apo- F/L PhtD 
Blotting with anti-PhtD polyclonal antibody reveals that the 34 kDa fragment does not react 
with the anti-body whereas the 49 kDa fragment is reactive. Using this information and 
prior mass-spectrometry data regarding the identity of the two stable fragments, it is 
elucidated that the additional 15 kDa of sequence present in the 49 kDa fragment contains 
the major antibody-binding site. 
Figure 5.11: Coomassie stained gel corresponding to western blot (Fig 5.10) 
This SDS-PAGE gel is a duplicate of the samples analysed by Western blot. The gel was 
stained with coomassie R250 visualising the range of fragments in the samples to allow 
direct comparison with the Western blot result. 
 
It is clear from the comparison of the developed membrane and the 
accompanying coomassie stained gel that the 34 kDa band is not recognised 
by the anti-PhtD antibody. 
Because the identity of these two protein fragments has been successfully 
identified using the mass-spectrometry PMF and N-terminal sequencing 
techniques, it is possible therefore to elucidate the dominant antibody 
binding epitope region. As the two fragments have the same starting 
sequence, it has been hypothesised that the 15 kDa region of the protein 
which differentiates the two fragments is contains this antibody binding 
domain. This region begins at iso-leucine 651 with the leading sequence 
IKFEW and ending at lysine 788 with the ending sequence DAEALLEK. The 
resulting protein sequence of the predicted antibody-binding domain is 
illustrated in figure 5.12. 
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Figure 5.12: Sequence of predicted dominant PhtD antibody-binding region 
 
 
As a result of these findings, it has been possible to locate pinpoint the 
dominant antibody-binding region for PhtD to within a 15 kDa fragment of the 
full 92 kDa protein. Utilising these findings, an expression construct for this 
fragment has been created (see chapter 3.6) so that structural determination 
of this small important fragment comprising the antibody-binding region may 
be possible if the full protein structure is not achieved. 
5.3 Analysis Of Purified PhtD Proteins By MALDI-ToF 
Mass-Spectrometry 
5.3.1 Overview 
The results obtained from the data described above allowed a targeted 
approach to generating a series of expression constructs encoding selected 
fragments of the F/L PhtD protein (previously described in chapter 3.6). 
Following their construction, all newly created expression constructs (pMRH1-
7) were sequenced in order to confirm that inserts had been successfully 
introduced into the pOPINF119 vector in-frame, without the presence of any 
mutations. Upon confirmation that the expression construct sequences were 
correct, expression and purification of the various fragments was carried out, 
detailed in chapter 3.8. As an additional precaution, samples of the various 
purified PhtD fragments were analysed by mass-spectrometry. This section 
details the results from the mass-spectrometry analysis of the various 
purified PhtD protein fragments. 
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5.3.2 Preparation Of PhtD Samples For Mass-Spectrometry 
Analysis 
The 4 successfully recombinantly expressed and purified proteins (F/L, C-
term, ΔC-term, and 34 kDa fragment) were each mixed 1:1 with NuPAGE SDS-
loading dye and denatured at 90oC for 5mins in a hot-block. Samples of each 
were run in triplicate by SDS-PAGE against SeeBlue Plus 2 mol wt. markers as 
outlined in 2.10.1, loading 5µg of purified protein per lane in order to provide 
the maximum possible quantity of protein for analysis. The SDS-PAGE gel was 
stained with coomassie-R250 and destained with extensive changes of 
destain, followed by copious washing with dH2O in order to remove residual 
destain. 
5.3.3 Analysis Of Purified PhtD Proteins 
Mass spectrometry of the purified F/L, C-term and ΔC-term proteins was 
performed with the kind assistance of Satty Borman at GlaxoSmithKline 
Biologicals, Stevenage, UK. Each of the bands corresponding to the purified 
proteins were excised from the gel with a scalpel. Three proteases were 
utilised in the analysis of the samples. Proteases used and their properties 
are given in table 5.2. 
 
 
Protease  Properties 
   
Trypsin   Cleaves C-terminally to K or R 
residues (unless downstream 
residue is P) 
 
Chymotrypsin  Cleaves C-terminally to Y, W, or 
F residues 
 
Asp-N  Cleaves N-terminally to D or E 
residues 
   
Table 5.2: Proteases used in mass-spectrometry analysis of purified PhtD proteins.114 
 
 
In order to gain the maximum possible coverage for each purified protein, the 
above three enzymes which all recognise different cleavage sites were 
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employed in order to digest the samples as much as possible. The SDS-PAGE 
gel corresponding to the samples analysed is shown in figure 5.13. 
 
 
Figure 5.13: SDS-PAGE of purified PhtD samples for mass-spectrometry 
Boxed samples indicate bands to be analysed. Each sample analysed in triplicate. Sample 1: 
F/L, Sample 2: C-term, Sample 3: ΔC-term. N.B. Samples are overloaded at 5µg per lane. 
Standard loading of 1µg per lane shows a clean, single band. 
 
In order to gain as much data as possible for each protein, two forms of mass-
spectrometry were employed; peptide mass fingerprinting (PMF) and tandem 
mass-spectrometry (MS-MS). The resulting mass-spec data was analysed using 
MASCOT.162 Figures 5.14, 5.15 and 5.16 show the combined coverage obtained 
from mass-spectrometry for F/L, C-term and ΔC-term PhtD respectively. 
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Figure 5.14: Complete mass-spectrometry results for purified F/L PhtD 
Identified peptides are highlighted in blue. Peptides identified by MS-MS are underlined. 
N.B. MS-MS identified peptides may duplicate PMF recovered peptides for some regions of 
sequence. 
 
 
Figure 5.15: Complete mass-spectrometry results for PhtD C-term fragment 
Identified peptides are highlighted in blue. Peptides identified by MS-MS are underlined.   
N.B. MS-MS identified peptides may duplicate PMF recovered peptides. (Italicised residues 
show start and end of fragment). 
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Figure 5.16: Complete mass-spectrometry results for ΔC-term PhtD fragment 
Identified peptides are highlighted in blue. Peptides identified by MS-MS are underlined.    
N.B. MS-MS identified peptides may duplicate PMF recovered peptides. (Italicised residues 
show start and end of fragment). 
 
As a result of the extensive analysis through the use of 3 different proteases, 
coupled with the two mass-spectrometry techniques, it was possible to 
recover ~90% of the peptides present in each of the purified PhtD proteins, 
and showed definitively that the proteins had been correctly expressed 
without any mutations or unexpected alterations. 
Mass-spectrometry analysis of the 34 kDa PhtD fragment was kindly 
performed with the assistance of Dr. Richard Burchmore at the University of 
Glasgow, as there was no stock of this protein fragment available during the 
time at GlaxoSmithKline when the previous proteins were analysed. 5µg of 
the 34 kDa PhtD protein fragment was run on an SDS-PAGE gel, stained and 
the band excised as before. The excised sample was digested with trypsin 
and analysed by PMF. The resulting mass-spectrometry data was analysed 
using MASCOT.162 The interpreted data of recovered peptides mapped onto 
the PhtD sequence is shown in figure 5.17.  
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Figure 5.17: Mass-spectrometry results for 34 kDa PhtD protein fragment 
Identified peptides are highlighted in blue. (Italicised residues show start and end of 
fragment).  
N.B. Sequence coverage is lower due to the use of 1 enzyme (trypsin) compared to 3 for the 
other samples (trypsin, chymotrypsin, Asp-N). 
 
Due to the use of only one enzyme rather than three, coverage of recovered 
peptides was less than before, but still gave enough evidence that this 
protein fragment had also been correctly expressed without any unexpected 
alterations. 
5.4 Analysis Of PhtD Limited Proteolysis Profiles By N-
Terminal Sequencing 
5.4.1 Overview 
N-terminal protein sequencing was kindly performed with the assistance of 
Neil Freeman at GlaxoSmithKline Biologicals, UK. As a complimentary 
approach to the mass-spectrometry analysis for the limited proteolysis 
profiles of the F/L PhtD protein, N-terminal sequencing was employed to 
identify the starting sequence of each of the bands produced by the Apo- 
proteolysis experiment. Additionally, the N-terminal sequencing technique 
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was also used to identify the starting sequence of bands from the Zn2+-bound 
samples to allow comparison between the Apo- and Zn2+-bound datasets.  
5.4.2 Sample Preparation 
Using the SDS-PAGE samples generated from the F/L PhtD Apo- and Zn2+-
bound limited proteolysis experiments, samples were prepared for N-terminal 
sequencing as outlined in 2.10.7 N-terminal sequencing was performed on a 
Procise® protein sequencing system (Applied Biosystems) utilising the Edman 
degradation method.131 The protein on the PVDF membrane is washed with 
Edman reagent (phenolisothiocyanate); using anhydrous acid the terminal 
amino residue is cleaved as an unstable t-amino acid. The t-amino acid form 
is treated with aqueous acid to form a stable p-amino acid form. This single 
stable peptide is then analysed by High Performance Liquid Chromatography 
(HPLC) and the process repeated cyclically. N-terminal sequencing was set up 
to read 7 amino acids for each sample. A total of 11 bands were sequenced; 7 
from the blot of the apo-digest and 4 from the blot of the Zn2+-bound digest. 
The stained membranes of the two blotted digests are illustrated in figures 
5.18 and 5.19 Samples used for analysis are indicated on the relevant 
membranes. 
 
Figure 5.18: Western transfer for Apo- F/L PhtD digest 
Bands analysed by N-terminal sequencing are highlighted in boxes. 
Figure 5.19: Western transfer for Zn2+-bound F/L PhtD digest 
Bands analysed by N-terminal sequencing are highlighted in boxes. 
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5.4.3  N-terminal sequencing Analysis Of Apo- F/L PhtD And Zn2+-
bound F/L PhtD 
Table 5.3 presents the sequence identification of the bands selected for N-
terminal sequencing of Apo- F/L PhtD. The identified sequences are mapped 
onto the amino acid sequence for F/L PhtD in figure 5.20 
Band Identity Sequence Observed pmol 
   
1a LSENHNL 3.90 
3a SNHWVPD 1.40 
5a LSENHNL 2.60 
10a SNHWVPD 9.90 
45a LAKQESL 
SNHWVPD 
2.10 
1.70 
10b VSYIDGD 
KNKVDQ 
NKVDQD 
7.60 
6.60 
6.00 
15a LSENHNL 
AQGRYTT 
EGINAEQ 
13.80 
5.00 
0.70 
   
Table 5.3: N-terminal sequencing results of Apo- F/L PhtD 
Sequence identities of bands N-terminally sequenced from Apo- F/L PhtD limited proteolysis 
experiment. Band identities correspond to those given in figure 5.18. Larger molecular 
weight fragments show either LSENHNL or SNHWVPD as starting sequences for stable 
regions. Smaller molecular weight bands show a variety of sequences indicating that the 
band consists of a variety of breakdown products from the digestion process. 
 
 
Figure 5.20: Apo-F/L PhtD N-term sequencing results mapped onto F/L PhtD sequence 
Identified N-terminal protein sequences are highlighted in blue. Underlined residues 
illustrate sequences corresponding to larger molecular weight bands. Dominant stable band 
10a begins with the sequence SNHWVPD. Smaller molecular weight bands consist of a 
mixture of the remaining sequences, indicating their presence as smaller breakdown 
products as a result of proteolysis. 
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It is apparent that the stable bands from the Apo-limited proteolysis 
experiment begin with the sequence SNHWVPD. The smaller molecular weight 
bands comprise a mixture of fragments with various N-terminal sequences, 
which identify them as proteolytic breakdown products of the unstructured 
N-terminal half of the F/L PhtD molecule. 
The identities of the bands N-terminally sequenced from the limited 
proteolysis of F/L PhtD in the presence of Zn2+ are given in table 5.4. The 
identified N-terminal sequences are mapped onto the F/L PhtD amino acid 
sequence in figure 5.21. 
Band Identity Sequence Observed pmol 
   
1a LSENHNL 5.80 
15a LSENHNL 8.30 
45a SNHWVPD 6.10 
45b LAKQESL 4.40 
   
Table 5.4: N-terminal sequencing results for Zn2+-bound F/L PhtD 
Sequence identities of bands N-terminally sequenced from Zn2+-bound F/L PhtD limited 
proteolysis experiment. Band identities correspond to those given in figure 5.19. 
Products of the proteolysis experiment are much more resistant to degradation in Zn2+-
bound form, with the majority of the proteins stabilising at a higher molecular weight than 
in the Apo- proteolysis experiment. The dominant stable band 15a begins with sequence 
LSENHNL and is of a higher molecular weight than the dominant stable band in the Apo-
experiment.  
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Figure 5.21: Zn2+-bound F/L PhtD N-term sequencing results mapped onto F/L PhtD 
sequence 
Identified N-terminal protein sequences are highlighted in blue. Underlined residues 
illustrate sequences corresponding to larger molecular weight bands. Dominant stable band 
15a begins with the sequence LSENHNL. 
 
Direct comparison between the Apo- and Zn2+-bound N-terminal sequencing 
experiments shows that upon addition of Zn2+ proteolysis profile changes, 
with a much lower abundance of smaller molecular weight products present 
in the Zn2+-bound experiment. Additionally, there is a change in the 
proportion of the stable bands seen in the two experiments; the two stable 
bands from the Apo- experiment had a molecular weight of 49 kDa and 34 kDa 
(10a and 45a). The dominant band 10a had the N-terminal sequence 
SNHWVPD. In contrast in the Zn2+-bound experiment, the two stable bands 
are 55 kDa and 49 kDa (15a and 45a). The dominant band 15a is of a larger 
molecular weight than in the Apo- experiment and has the N-terminal 
sequence LSENHNL, which is closer to the N-terminus of the F/L molecule 
than SNHWVPD. This concurs with the limited proteolysis and mass-spec 
results that the binding of Zn2+ in F/L PhtD is having a stabilising effect on 
the protein, protecting the protein from the action of proteolysis. Its is 
thought that this protection is a result of the change in structure induced by 
the addition of Zn2+, as observed in the CD experiments (detailed in chapter 
4.4). 
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5.5 ITC Analysis Of Zn2+ Binding With PhtD 
ITC was performed at the department of physical chemistry, University of 
Glasgow with the kind assistance of Mrs. Margaret Nutley. 
As previous investigation at the University of Glasgow had revealed through 
macromolecular X-ray crystallography that PhtA is able to bind Zn2+ atoms via 
the HxxHxH motifs which give the Pht protein family their name, and 
experiments discussed elsewhere in this thesis show that PhtD is also able to 
bind Zn2+ atoms resulting in extensive structural reorganisation,98 Isothermal 
Titration micro-Calorimetry (ITC) was employed in an attempt to reveal the 
stoichiometric relationship between PhtD and the Zn2+ atoms. It was 
hypothesised based on the evidence from the partial PhtA crystal structure 
that each HxxHxH motif would be able to bind 1 Zn2+ atom, and that the 
number of binding sites would correlate to the number of HxxHxH motifs 
present in the protein sequence. As PhtD contains 5 HxxHxH motifs, it was 
therefore postulated that ITC would return a stoichiometry value of 5 Zn2+ 
per PhtD molecule. 
2mg of purified F/L PhtD protein was used for analysis in 1ml of 20mM Tris 
HCl pH7.5, 200mM NaCl, which equated to a concentration of ~20µM. This 
was diluted 1:1 with the same buffer to give a final volume of 2ml (required 
to fill the sample-cell of the calorimeter) with a concentration of ~10µM 
(when measured, protein concentration was found to be 9µM). 0.5M ZnSO4 
was prepared from the same buffer stock as the protein in order to minimise 
differences between solutions when titration was performed. 
ITC was performed using a VP-ITC Isothermal Titration Calorimeter (MicroCal, 
GE Healthcare, Buckinghamshire UK). The instrument was cleaned by purging 
multiple times with buffer from the same stock used to prepare the protein 
(F/L PhtD) and ligand (ZnSO4). A blank titration was carried out by injecting 
the ligand into buffer without any protein in order to obtain a background 
reading, which could then be subtracted from the experimental titration 
during analysis to factor in contributions from the background signal. 
Titration was carried out at 25oC. 10µl of ZnSO4 solution at a concentration of 
1.16mM (dilution was carried out with the same stock of protein buffer) was 
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injected into the 2ml solution of F/L PhtD at a concentration of 9µM every 
3mins for an experimental duration of 90mins and each exothermic heat-
pulse recorded. Data were analysed and integrated with a one-sites model 
and are illustrated in figure 5.22. 
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Figure 5.22: ITC analysis of PhtD Zn2+ binding 
Upper-panel: Exothermic heat-pulse raw data.                 
Lower panel: Integrated heat data. Background has been accounted for. 
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From the raw data, it is evident that binding is occurring, as an increased 
exothermic heat pulse was observed compared to the blank reading. As 
expected, a gradual decrease in exothermic heat pulse was observed, due to 
decreasing free binding sites in the protein over time due to Zn2+ uptake. The 
values recorded for the exothermic heat pulse readings are relatively small at 
a maximum of ~0.4µcal/sec (compared to Hen Egg White Lysozyme binding 
tri-N-acetyl-glycosamine with a reading of ~1.5µcal/sec).163 Due to the fact 
that a small value such as this was observed with a 100-fold increase of ligand 
to protein (1.16mM ZnSO4 : 9µM F/L PhtD) coupled with the observation in 
the raw data that there was no definitive sharp decrease in heat-pulse 
recorded, it was postulated that the interaction between PhtD and Zn2+ was 
through weak binding. This was confirmed upon integration of the raw heat-
data (figure 5.22, lower panel). Analysis of the integrated data with a one-
sites standard model resulted in a binding affinity Kass = 7.3 x 104 M-1 ± 1.9 x 
104 with the dissociation value Kdiss (=) 1/Kass = 14µM confirming as 
hypothesised that the binding between PhtD and Zn2+ was weak. The 
stoichiometry value N = 6.3 ± 0.50 confirms the presence of multiple binding 
sites, and suggests that there may be 6 Zn2+ binding sites per PhtD molecule. 
However, as the association between protein and ligand is through weak 
binding, no definitive point of saturation can be seen leading to decreased 
accuracy when N is calculated, and it is therefore quite possible that the 
original hypothesis of 5 Zn2+ binding sites per PhtD molecule is correct. 
It is interesting to compare this occurrence of zinc-binding in PhtD with other 
known zinc-binding proteins. The binding of zinc atoms by PhtD is somewhat 
unusual, as a weak interaction is observed between the protein and ligand; in 
contrast, other known zinc-binding proteins illicit a strong interaction 
between protein and ligand (ie tight binding) such as the ABC transporters 
ZnuA and TroA.164 In instances such as these, the binding of zinc atoms may 
be required to ‘lock’ a protein into a specific conformation in order to allow 
transport of substances across the cell membrane. Similarly, zinc-dependant 
metalloproteases may require a high affinity to Zn-atoms in order to remain 
active when performing proteolytic activity. The binding of zinc atoms may 
also act as a stimulus or regulator of a biological process and therefore high-
affinity binding may be advantageous in order for the organism to keep the 
relevant pathway active or inactive (depending on whether the zinc atom 
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acts as a promoter or repressor). In contrast, the incidence of weak binding 
observed by PhtD fits well with the hypothesis of the protein acting as a 
siderophore (metal scavenger – for use by the bacterium under stress 
environments), as the bacterium would be required expend less energy in 
order to free the scavenged zinc atoms when required, a clear advantage for 
the hypothetical function of PhtD as a siderophore, compared to the large 
amount of energy that would need to be expended in order to free a tightly 
bound zinc atom in an instance where the bacterium is already disadvantaged 
by its environment.
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Chapter 6 : Structural Analysis Of PhtD 
6.1 Overview 
This chapter details an attempt to uncover the biological function of PhtD 
using a structural approach. The primary method employed for this 
investigation was macromolecular x-ray crystallography, due to previous 
success in determining the structure for a section of Pneumococcal Histidine 
Triad A (PhtA) from the same protein family.98 Additionally the techniques of 
Nuclear Magnetic resonance (NMR), Circular Dichroism (CD) and Analytical 
Ultra-Centrifugation (AUC) were also utilised to gain as much of an insight 
into the structure of PhtD as possible, and are also described in this chapter. 
6.2 Preliminary Investigation 
Before any experiments were performed, the F/L PhtD protein sequence was 
input into the disorder prediction tool Regional Order Neural Network (RONN  
- http://www.strubi.ox.ac.uk/RONN )139 hosted at the Division of Structural 
Biology (STRUBI) at the University of Oxford. 
Where two proteins have a similar biological function, then the primary 
sequences of the two molecules usually elicit a significant similarity, which 
can be detected by sequence alignment programs such as BLAST.165 Based on 
this observation, RONN utilises a ‘bio-basis neural network pattern 
recognition’ algorithm166 in order to predict the probability of order or 
disorder for regions of an input protein sequence. This ‘neural network’ is 
trained using an extensive dataset (in the case of RONN, generated from a 
full annotation of entries in the Molecular Structure Database hosted at the 
European Bioinformatics Institute).167 It is expected that the biological 
function of the query sequence will be the same as that of a protein 
sequence of known function if the alignment score is high enough. RONN 
implements this to predict order or disorder in a query protein sequence by 
performing alignments of the query sequence with those of known folding 
states; the resulting alignment homology scores are used for statistical 
pattern recognition to classify the query sequence as ordered or disordered 
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using the trained ‘neural network’, which are then averaged to give disorder 
probability scores for each individual residue in the query sequence.139 The 
RONN program outputs the results of protein disorder prediction in graphical 
format. 
The resulting disorder prediction graph for F/L PhtD is shown in figure 6.1 
The fragments C-term PhtD, ΔC-term PhtD and the 34 kDa fragment were also 
subjected to disorder prediction analysis using RONN; the resulting disorder 
prediction graphs are illustrated in figures 6.2, 6.3 and 6.4. 
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Figure 6.1: F/L PhtD disorder prediction 
Disorder prediction generated using the RONN server.139 Probability of disorder increases as 
value approaches 1.0. The location of each HxxHxH motif is boxed out in yellow. The 
location of the corresponding known crystal structure from PhtA is boxed out in pink. 
 
 
Figure 6.2: C-term PhtD disorder prediction 
Disorder prediction generated using the RONN server.139 Probability of disorder increases as 
value approaches 1.0. HxxHxH motifs are boxed out in yellow. 
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Figure 6.3: ΔC-term PhtD disorder prediction 
Disorder prediction generated using the RONN server.139 Probability of disorder increases as 
value approaches 1.0. HxxHxH motifs are boxed out in yellow. 
 
 
Figure 6.4: 34 kDa PhtD fragment disorder prediction 
Disorder prediction generated using the RONN server.139 Probability of disorder increases as 
value approaches 1.0. HxxHxH motifs are boxed out in yellow. 
 
Residue number is shown along the X-axis, with probability of disorder shown 
along the Y-axis. Probability is measured on a scale of 0.0 to 1.0 where 0.0 
indicates a probability that the analysed residue is highly ordered and 1.0 
indicates a probability of the analysed residue being natively unordered. A 
threshold of 0.5 is imposed by the program, with anything <0.5 classed 
natively structured, and anything >0.5 classed natively unordered. Looking at 
the results of the RONN prediction for PhtD, it can be seen that a large 
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proportion of the protein (~60%) falls above the set 0.5 threshold and is 
predicted unstructured by the RONN program. It is apparent from the data 
that the protein appears to contain extensive regions of natively unordered 
protein interspersed with short regions of structured protein. However, as 
the program only uses sequence data applied to an algorithm, it should be 
noted that the results of the RONN analysis can only give an indication of how 
the protein may behave. It is unable to take into account other factors such 
as the incorporation of ligand-binding –in the case of PhtD, Zn2+ atoms- and 
the change in structure which the binding process may induce. As a starting 
point however, it indicated that determining the structure of the F/L PhtD 
protein may be difficult due to the large flexible regions apparently present, 
thus preventing the generation of an ordered protein lattice, which is 
required for crystal formation. 
6.3 One-Dimensional Nuclear Magnetic Resonance (1D-
NMR) Spectroscopy Of PhtD 
6.3.1 Initial 1D-NMR Analysis Of Apo- F/L PhtD 
NMR spectroscopy was done in collaboration with Dr. Brian Smith at the 
Protein Science Group, University of Glasgow. 
In an attempt to obtain some physical evidence to relate to the preliminary 
indication by sequence analysis with RONN that PhtD may be relatively 
unordered in its apo- form, 1D-NMR was utilised in order to ascertain the 
nature of Apo- F/L PhtD in solution. 1mg of F/L PhtD was used at a 
concentration of 1mg/ml. 1D-NMR was carried out on this sample in 
1xDulbecco’s PBS buffer. The resulting spectrum is shown in figure 6.5. 
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Figure 6.5: 1D-NMR Spectrum of Apo- F/L PhtD 
 
There are two easily discernible discrete regions in the spectrum; the first 
region from 0 – 5ppm is defined the aliphatic region and corresponds to 
signals generated by CH3 groups. The second region, which is present in the 
spectrum between 6 – 9ppm is classed as the amide region, and as such 
corresponds to signals generated by NH2 groups. As 1D-NMR does not require 
the protein to be labelled in any way (unlike 2D-NMR which requires the 
protein of interest to be 15N and 13C labelled) it is a very quick way of 
determining rudimentary information about a protein. However, the NMR 
spectrometer does require a ‘lock on’ signal during experimental setup and 
therefore a small quantity of D2O (deuterium) is added to the sample to be 
analysed. The D2O appears as a very strong peak at ~4.75ppm and is evident 
in the spectrum for the Apo- F/L PhtD sample analysed above. 
In a highly structured protein, the extreme ends of the aliphatic and amide 
regions show discrete, sharp peaks due to the restricted movement of the 
residues resulting from intra-molecular bonding. Conversely, in a natively 
unstructured protein, these regions broaden out showing no peaks, as the 
residues in the protein are able to move about and so give a less well-defined 
spectrum. The differences in spectra generated from varying grades of 
protein are illustrated in the reference spectra shown in figure 6.6. 
PPM 
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Figure 6.6: Reference 1D NMR spectra 
Reference spectra for various grades of protein classed “A” to “D”. (a) High quality “A”-
grade proteins were candidates for structure determination by NMR or X-ray 
crystallography, (b) “B”-grade proteins were earmarked for X-ray crystallography, (c) “C”-
grade indicated folded globular proteins and (d) “D”-grade are nonglobular, unfolded 
polypeptides. Figure reproduced from Page et al (2005).168 
 
In the spectrum generated for the Apo- F/L PhtD protein, the edges of the 
aliphatic and amide regions of the spectrum show small peaks to be present, 
reminiscent of the spectrum for “B” or “C”-grade protein suggesting that 
although the Apo- PhtD protein appears largely unstructured, it should be a 
globular protein, and have small regions which are highly structured. These 
results concur with the RONN139 sequence analysis data, giving rise to the 
analogy that PhtD may be thought of as having a ‘beads on a string’ 
appearance, where localised, highly structured regions of the protein are 
connected by regions of random coil, allowing a structured region to act 
independently of the others or flex around and interact with one or more of 
the other structured regions. The presence of structured regions within the 
protein has been shown through the use of limited proteolysis experiments, 
and that the addition of Zn2+ causes a stabilising effect thought to be brought 
about by a change in protein structure upon ligand-binding (Limited 
proteolysis results are discussed in chapter 5). 
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6.3.2  1D-NMR Analysis Of Zn2+ Binding 
In order to investigate the effect that the binding of Zn2+ conferred on PhtD, 
1D-NMR was performed on purified F/l PhtD protein, and also the purified C-
terminal and ΔC-terminal fragments. In each case NMR was carried out as 
before in 4.3.1 to give an apo- spectrum. A source of Zn2+ in the form of 
ZnSO4 was titrated in, the sample was re-examined in the NMR spectrometer 
and spectra were generated after each titration. Comparison of the 
sequential spectra allowed any changes in protein structure to be observed. 
The two PhtD fragments above were analysed to provide a comparison with 
the F/L to see if changes were as evident in the C-terminal half of PhtD 
compared to the F/L molecule. 
In all experiments, a spectrum of the Apo-protein was generated, the sample 
was recovered from the NMR tube and the required quantity of Zn2+ 
introduced, and a subsequent Zn2+-bound spectrum was generated. This 
procedure was repeated for all titrations of each protein. In all cases, the 
same ZnSO4 solution was used for titration of Zn2+ atoms into each sample. 
PhtD has 5 HxxHxH Zn2+ binding motifs, and it is thought that each motif 
binds 1 Zn2+ atom as seen in the PhtA crystal structure98, giving a ratio of 5 
Zn2+ atoms per 1 copy of the PhtD protein. To this end, an initial addition of 
ZnSO4 at 5x the concentration of PhtD sample was used in order to provide 
the required 5:1 molar ratio, giving the required 1 Zn2+ atom per HxxHxH 
binding motif. A subsequent addition of an equivalent concentration of ZnSO4 
was performed in order to double the molar ratio, resulting in 2 Zn2+ atoms 
per HxxHxH motif and any further effects noted. 
6.3.2.1  Zn2+ Binding in Purified F/L PhtD 
Initially, a 1D-NMR spectrum was generated for the Apo protein using 0.3mM 
F/L PhtD. A spectrum was then generated for 0.3mM F/L PhtD with 1.5mM 
ZnSO4. Finally, a further 1.5mM ZnSO4 was added, giving a 3mM ZnSO4 
concentration and doubling the molar ration of Zn2+ : F/L PhtD. The 3 
resulting spectra were overlaid for analysis as seen in figure 6.7. 
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Figure 6.7: F/L PhtD Zn2+ titration 
The image above shows the amide region for the 1D-NMR spectra. 
Green: Apo- F/L PhtD Red: F/L PhtD + 1.5mM ZnSO4 Blue: F/L PhtD + 3mM ZnSO4 
The green spectrum corresponds to a close-up view of the amide region from figure 6.5 
Upon initial addition of Zn2+ (red spectrum) a significant decrease in signal is observed, 
suggesting the presence of a much larger structure. 
 
Looking at the spectra above in figure 6.7, the signal generated by the F/L 
PhtD sample drops drastically upon addition of the 1st titration of Zn2+ atoms 
(red spectrum) when compared to the Apo-form (green spectrum). This would 
suggest that a much larger molecule –at the upper measurable limit by NMR- 
is tumbling in the NMR spectrometer, resulting in the production of the 
reduced signal seen in the Zn2+-bound form. Since PhtD is a large protein of 
92 kDa, it is possible that the addition of the Zn2+ atoms and subsequent 
binding, have caused a large change in structure of the protein, altering it 
from a flexible molecule with structured regions to a molecule comprising of 
 144 
a more singular, ordered structure. The presence of this larger single 
molecule would be enough to cause the difference seen between the spectra. 
When the data for the three spectra (apo-, 1.5mM Zn2+, 3mM Zn2+) are 
normalised as shown in figure 6.8 and the close-up in figure 6.9, additional 
changes can be seen.  
 
Figure 6.8: Scaled data for F/L PhtD Zn2+ titration 
The above images show normalised spectra for the amide and aliphatic regions region for 
the 1D-NMR spectra of F/L PhtD. 
Green: Apo- F/L PhtD  Red: F/L PhtD + 5:1 Zn2+  Blue: F/L PhtD + 10:1 Zn2+ 
Specific chemical shifts can be observed between 7 and 8 ppm (indicated by box). These 
changes are illustrated in greater detail in figure 6.9. 
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Figure 6.9: Close-up of scaled data for F/L PhtD Zn2+ titration 
The above image shows a close-up of the normalised amide region for the 1D-NMR spectra 
from 6.5 – 8.5ppm. 
Green: Apo- F/L PhtD  Red: F/L PhtD + 5:1 Zn2+    Blue: F/L PhtD + 10:1 Zn2+ 
The arrows indicate the regions that undergo a chemical shift when Zn2+ is added to the 
protein. Peaks present in the Apo-form (green spectrum) corresponding to His-sidechains, 
are observed to disappear in the Zn2+-bound forms (red and blue spectra). 
  
Comparing the Apo- F/L PhtD spectrum with the two spectra for Zn2+-bound 
F/L PhtD in figure 6.9, there are two main observations. The first is that 
there are a series of peaks present in the apo- spectrum (green) that have 
completely disappeared in the Zn2+-bound spectra (red and blue), indicated 
by the arrows in figure 6.9. These peaks correspond to those typically seen to 
be generated by histidine residues, and their complete absence in the other 
Zn2+-bound spectra is indicative of a complete chemical shift resulting from 
major structural re-arrangement of the histidine residues. Additionally, it is 
apparent that the remainder of the spectra in this region appears sharper and 
more defined in the Zn-bound spectra than in that generated by the Apo- F/L 
PhtD, suggesting a change to a more highly ordered structure. This is 
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evidence that in F/L PhtD, interaction with Zn2+ atoms is occurring, and that 
a substantial structural change has occurred as a result of this interaction 
with Zn2+. It is interesting to note however that though a major difference 
can be seen when comparing the two Zn2+-bound spectra with that for the 
apo- F/L PhtD, the differences between the 1.5mM and 3mM titration are 
minimal, implying that a molar ratio of 5:1 Zn2+ atoms per molecule may be 
enough to saturate the Zn2+-binding sites of PhtD, and that subsequent Zn2+ 
addition will have little further effect on the protein. 
6.3.2.2  Zn2+ Binding In Purified C-term PhtD Protein Fragment 
Spectra for the purified C-term fragment of PhtD were generated exactly the 
same way as previously described in 6.3.2.1 and overlaid for comparison as 
seen in figures 6.10 and 6.11 As there was little difference between addition 
of a 5:1 and 10:1 molar ratio of Zn2+ atoms : PhtD molecules in the 
experiments using F/L PhtD, it was deemed that the binding had reached 
saturation after Zn2+ addition at a 5:1 molar ratio, therefore only addition of 
a 5:1 molar ratio was performed for both the purified C-term and ΔC-term 
PhtD protein fragments. 
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Figure 6.10: C-term PhtD Zn2+ titration 
Red: Apo- C-term PhtD  Blue: C-term PhtD + 5:1 Zn2+ 
General observation of the spectra for C-term PhtD (either in apo- or Zn2+-bound form) 
shows it to be much closer in appearance to the reference spectrum for “A”-grade protein in 
figure 6.6, with much more defined peaks at the ends of the amide and aliphatic regions of 
the spectra (indicated by arrows). This is in contrast with the spectrum for the Apo-form 
F/L PhtD molecule, suggesting that the C-terminal half of PhtD has an intrinsically more 
defined structure than the N-terminal half of the F/L molecule. Chemical shifts caused by 
the addition of Zn2+ are illustrated in greater detail in the corresponding close-up image in 
figure 6.11. 
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Figure 6.11: Close-up of C-term PhtD Zn2+ titration 
The above image shows the amide region of the 1D-NMR spectra for C-term PhtD protein  
Red: Apo- C-term PhtD  Blue: C-term PhtD + 5:1 Zn2+ 
The two spectra show a much larger number of discrete peaks throughout the entire amide 
region when compared to the F/L molecule suggesting that it has a more intrinsically 
ordered structure than the F/L molecule. 
The boxed out region in the top left illustrates a close-up of the region showing the 
chemical shifts induced by the introduction of Zn2. As this fragment of the protein contains 
only 2 of the 5 HxxHxH motifs, the effect of the addition of Zn2+ is not as significant as 
when Zn2+ is introduced to F/L PhtD (see figure 6.9 in comparison). 
 
In contrast with the differences seen in the NMR experiments using F/L PhtD, 
there is no large change in signal upon addition of Zn2+. However, the 
abundance of discrete, sharp peaks in the sample even before the 
introduction of Zn2+ to the sample suggest that the C-terminal half of the 
protein is much more highly structured and therefore that much of the N-
terminal half of the protein is present as flexible loops or random coiled in 
structure. This concurs with the observations noted from the limited 
proteolysis and mass-spectrometry results discussed in chapter 5. It is still 
possible to see that the peaks in the amide region corresponding to histidine 
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residues (indicated in figure 6.11 by arrows in the detailed boxed out region) 
undergo a chemical shift, but as only two HxxHxH motifs are present (3 
HxxHxH motifs are present in the N-terminal half of the protein and therefore 
not present in this protein fragment) this shift is much less notable than that 
observed with the F/L protein. 
6.3.2.3  Zn2+ Binding In Purified ΔC-term PhtD Protein Fragment 
As for the previous two proteins, spectra for the purified ΔC-term fragment 
of PhtD were generated exactly the same way as previously described in 
6.3.2.1. The two spectra (apo- and Zn2+-bound) were overlaid for comparison 
as shown in figures 6.12 and 6.13. 
 
Figure 6.12: ΔC-term PhtD Zn2+ titration 
Red: Apo- ΔC-term PhtD Blue: ΔC-term PhtD + 5:1 Zn2+ 
There are minimal differences between the Apo-and Zn2+-bound spectra for the ΔC-term 
PhtD fragment. Additionally, it can be observed that much of the definition observed for 
the C-term PhtD spectra (figures 6.10 & 6.11) has been lost, suggesting that the 5 kDa of 
protein sequence that is included in the C-term PhtD fragment either plays a role in 
maintaining the overall protein structure of the molecule, or is highly structured in itself. 
 150 
 
Figure 6.13: Close-up of ΔC-term Zn2+ titration 
The above image shows the amide region of the 1D-NMR spectra 
Red: Apo- ΔC-term PhtD Blue: ΔC-term PhtD + 5:1 Zn2 
There are no obvious chemical shifts to be observed between the Apo- and Zn2+-bound forms 
of ΔC-term PhtD. The boxed out region illustrates the loss of peak definition in the ΔC-term 
PhtD fragment. 
 
As expected, the differences between the two spectra before and after 
addition of Zn2+ are minimal, since the only difference between the two PhtD 
fragments is that the ΔC-term excludes the last 5.3 kDa of the protein.  
Interestingly, the ΔC-term fragment appears to be less highly ordered than 
the C-term fragment as the edges of the amide and aliphatic regions show 
fewer, much broader and less defined peaks (example boxed out in figure 
6.13; figure 6.14 illustrates a comparison of the same region with the 
corresponding regions from F/L PhtD and C-term PhtD). 
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Figure 6.14: comparison of amide shoulder-region for F/L, C-term and ΔC-term PhtD 
The above figure shows the boxed out region in figure 6.13 for ΔC-term PhtD and the 
corresponding regions in the F/L and C-term PhtD spectra. 
It can clearly be seen that the C-term fragment has the most discrete peaks, suggesting that 
it is the most highly structured of the three proteins investigated. 
 
 It is possible therefore that the terminal 5.3 kDa of the protein is responsible 
for some important intramolecular interactions, which aid in keeping the C-
terminal half of the protein in a rigid conformation, and that if this region is 
removed, structural integrity is compromised, or that the 5 kDa of protein 
sequence by which C-term and ΔC-term fragments differ is in itself 
intrinsically structured. 
These preliminary NMR experiments confirm that the PhtD molecule is 
relatively flexible and it is likely that it has structured regions interspersed 
with flexible regions. Comparison between Apo- and Zn2+ bound forms of the 
protein reveals that the C-terminal half of the protein is more structured, 
and therefore Zn-binding brings the N-terminal region of the molecule into a 
more ordered conformation, either by itself or with some interaction with 
the C-terminal half of the molecule. Additionally, it would appear that the 
very end of the molecule has some role to play in providing the structural 
integrity of the C-terminal half of the molecule. 
With 1D-NMR analysis of the C-term fragment of PhtD revealing that it is 
relatively highly structured, easily expresses in milligram quantities and the 
fact that at 55 kDa it is within manageable size, it is possible that this 
fragment of the molecule could lend itself to structural determination by 
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NMR, if 15N and 13C labelled forms of the protein fragment could be 
successfully generated. 
6.4  Analysis Of PhtD By Circular Dichroism (CD) 
Circular Dichroism (CD) was used for further investigation into the structural 
changes to the PhtD molecule as seen in the limited proteolysis (see chapter 
5) and NMR experiments. Initial CD experiments were performed in 
collaboration with Dr. Sharon Kelly at the University of Glasgow. Subsequent 
CD experiments were performed at GSK, Stevenage UK. 
 It is possible to perform CD at two different ranges in the spectrum of light, 
both of which are in the Ultra-Violet (UV) region. Near-UV ranges from 260 – 
320nm and can be used to determine tertiary structure of a protein molecule 
based on signals emitted by aromatic residues such as Phe, Tyr and Trp, 
whilst secondary structure composition can be estimated by CD analysis in 
the far-UV region (170 – 260nm).169 By examining the resulting CD traces it is 
possible to determine the overall dominant secondary structure of the 
protein of interest. Further estimation of the ratios of the various secondary 
structural elements (α-helix, β-sheet and random coil) can be calculated 
using analysis software. Secondary structure ratios presented in this thesis 
were calculated using the Dichroweb structural prediction server.170 Figure 
6.15 illustrates the typical CD traces observed for the various protein forms. 
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Figure 6.15: Example far-UV CD spectra 
Far-UV CD spectra associated with various types of secondary structure. Solid line = α-helix; 
long dashed line = anti-parallel β-sheet; dotted line = type-I β-turn; cross-dashed line = 
extended 31-helix or poly (Pro) II helix; short dashed line = irregular structure. Figure 
reproduced from Kelly et al (2005).169 
 
As analysis was being performed to observe changes in the secondary 
structure of PhtD, CD experiments were carried out in the far-UV range, using 
a wavelength range (λ) from 185-260nm. Initial experiments were carried out 
on purified F/L PhtD to investigate the changes induced by the binding of Zn2+ 
Subsequent experiments were performed at GSK Stevenage UK, and included 
repetition of the original F/L PhtD experiments. In addition to repetition of 
the F/L CD, experiments investigating the effect of Zn2+ binding on the two 
PhtD fragments named ‘C-term’ and ‘ΔC-term’ were performed in order to 
compare the differences between the F/L molecule and these truncated 
forms. 
6.4.1  CD Analysis of F/L PhtD 
Initial CD analysis was performed at the University of Glasgow. 2 aliquots 
each comprising 1mg of purified F/L PhtD were supplied in 50mM Tris HCl 
pH7.5. The presence of chloride ions can cause signal-noise during CD 
experiments, however it was noted that protein stability could be 
compromised in the absence of NaCl. To this end, the above buffer was 
supplemented with 500mM NaCl for one of the aliquots.  
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In order to test the requirement of NaCl in the buffer, far-UV CD was carried 
out on the protein sample minus NaCl. The same sample was re-tested after 
incubation at 4oC for 2 weeks. These were then compared with data from 
protein sample in the presence of NaCl, as seen in figure 6.16.  
 
Figure 6.16: F/L PhtD Far UV CD spectra NaCl vs. No- NaCl 
(i) Green: F/L PhtD + buffer + 500mM NaCl (ii) Blue: F/L PhtD + buffer, no NaCl 
(iii) Red: F/L PhtD + buffer, no NaCl. Re-analyses of sample (ii) after incubation for 2 weeks 
at 4oC. 
Experiments were carried out at 20oC in 50mM Tris HCl pH7.5 (supplemented with 500mM 
NaCl where indicated), using a protein concentration of 0.5mg/ml. 
The top spectra show the CD signal of the three samples. Due to the presence of the 
chloride ions, data are unreliable below 200nm, due to excessive noise generated by the 
chloride ions. Comparing the three spectra from the region 240 -200nm it can be seen that 
the initial data for F/L PhtD + NaCl, and F/L PhtD – NaCl are comparable. However, Re-
analysis of the F/L PhtD – NaCl sample after incubation at 4oC for 2 weeks showed a 
decrease in CD signal, suggesting a degree of degradation had occurred. 
 
Between the range 240 – 200nm, the CD spectrum for F/L PhtD + NaCl and 
the initial spectrum for F/L PhtD - NaCl are comparable, as evidenced by 
their superimposible CD spectra between these wavelengths as seen in figure 
6.16. Below 200nm the CD data for the F/L PhtD + NaCl sample is 
compromised by signal-noise generated by the presence of the chloride ions 
in the buffer and thus the three spectra cannot be reliably compared below 
this wavelength. Subsequent CD experiments stopped data acquisition at 195 
or 200nm. Re-analysis of the F/L PhtD – NaCl sample after incubation at 4oC 
for a period of 2 weeks showed that the stability of the F/L PhtD – NaCl 
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sample has been compromised, with the new spectrum no longer matching 
that generated by the PhtD + NaCl sample over the same wavelength range of 
240 – 200nm. Furthermore, prior to sample re-testing it was noted that after 
the 2-week incubation period at 4oC the F/L PhtD - NaCl sample was lightly 
turbid, suggesting a degree of localised precipitation. In contrast to this, the 
F/L PhtD + NaCl sample had remained clear. It was therefore decided that 
NaCl should be included in the buffer for subsequent CD experiments. 
In order to assess the effect of Zn2+ binding on the F/L PhtD molecule, far-UV 
CD was performed on the sample in order to gain an initial spectrum. The 
sample was then removed and ZnSO4 added. The sample was then re-analysed 
in the CD spectrometer under the same conditions as before to generate a 
spectrum for the Zn2+ bound form of PhtD and the spectra overlaid for 
analysis. The results of this experiment are shown in figure 6.17. 
 
Figure 6.17: Far UV CD spectra of F/L Apo-PhtD vs. F/L PhtD + Zn2+ 
Blue: F/L Apo-PhtD Red: F/L PhtD + 0.8mM ZnSO4 Green: F/L PhtD + 10mM ZnSO4 
Experiments were carried out at 20oC in 50mM Tris HCl pH7.5, 500mM NaCl (supplemented 
with 0.8mM or 10mM ZnSO4 where indicated), using a protein concentration of 0.5mg/ml. 
Initial CD analysis of Apo- F/L PhtD (blue) showed that the molecule was predominantly α-
helical in structure (spectrum compared with example spectrum in figure 6.15). Addition of 
0.8mM ZnSO4 (red) showed little evidence of change in the secondary structure of the 
protein, with the resulting spectrum comparable to that of the Apo- sample. However, 
addition of an excess of ZnSO4 (green) induced a major change in protein structure, to a 
predominantly β-sheet conformation. 
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The spectrum generated by the apo-PhtD sample is typical for a protein that 
is predominantly α-helical in structure. It is apparent from the above spectra 
that the addition of 0.8mM Zn2+ has had no noticeable effect on the protein 
structure, with the spectrum almost identical to that of the Apo- F/L PhtD 
sample. In contrast, a significant change is observed in the spectrum 
generated with the addition of 10mM Zn2+ where the spectrum generated is 
much more typical of a β-sheet like structure. Comparing these two spectra, 
it would appear that upon binding Zn2+ PhtD changes from an α-helical to a β-
sheet like structure. In order to try and quantify this change the CD data 
were submitted to the Dichroweb structural prediction server 
(http://dichroweb.cryst.bbk.ac.uk/).170 Data returned from Dichroweb 
showing the proportion of structural changes is given in table 6.1. 
Protein Sample α-helix(%) β-sheet(%) Turns (%) Random Coil (%) 
     
Apo- F/L PhtD 49 13 15 23 
     
F/L PhtD + 10mM 
Zn2+ 
9 40 21 30 
     
Table 6.1: Dichroweb170 calculation of 2o structure elements 
Secondary structure estimates predict a change from 13% β-sheet in the Apo- form to 40% in 
the Zn2+-bound form of the protein. 
  
From the analysis, it would appear that although the proportion of random 
coil increases slightly in the Zn2+-bound sample, the most noticeable changes 
are how the proportions of α-helix and β-sheet almost completely switch 
between the apo- and Zn2+-bound samples. Furthermore, after analysis it was 
observed that the Zn2+-bound sample remained clear, indicating that the 
protein had not precipitated and that therefore these results were viable. In 
order to assess whether the binding process was reversible, EDTA was added 
to the Zn2+-bound sample in an attempt to chelate the metal ion from the 
protein, and the sample re-analysed which resulted in the original trace 
being reproduced, suggesting that Zn2+-binding was a reversible process. A 
significant change in the CD spectrum indicating conformational change was 
observed during repetition of these experiments during a placement of work 
carried out at GSK, Stevenage UK (figure 6.18). The CD experiments in the 
following sections were also carried out at GSK, however secondary structure 
proportions were unable to be calculated, due to analysis software requiring 
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data down to a wavelength of 190nm (previously excluded due to signal-noise 
from chloride ions). Repetition of these experiments to include readings at 
190nm should allow these ratios to be calculated. 
 
Figure 6.18: Far-UV CD spectra for F/L PhtD 
Experiments were carried out in Tris buffer (50mM Tris HCl pH7.5, 500mM NaCl) at 20oC. 
Protein concentration = 0.5mg/ml 
Black: Apo- F/L PhtD Blue: Zn2+-bound F/L PhtD (Zn2+-bound sample supplemented with 
ZnSO4 to a final concentration of 10mM before measuring). 
 
6.4.2 CD Analysis Of C-term and ΔC-term PhtD Fragments 
To try to determine the extent of the structural change induced by Zn2+-
binding, the same far-UV CD analysis was carried out on the two PhtD 
fragments ‘C-term’ and ‘ΔC-term’ respectively. In each experiment far-UV CD 
was performed using a Chirascan™ Circular Dichroism spectrometer (Applied 
Photophysics, Surrey UK) between 200 – 260nm at 20oC, with a measurement 
increment of 1nm/s. Multiple datasets were collected for each sample and 
the average for each of these was calculated for use in analysis. Far-UV CD 
was performed on the apo-samples. The sample was then removed from the 
cell, ZnSO4 was added at to a final concentration of 10mM and the sample 
was re-analysed using the same parameters as for the apo-sample. Multiple 
datasets were again collected for each sample, and the average used in 
analysis. Spectra were produced for visualisation of data using Prism 4. Figure 
6.19 shows a comparison of apo- C-term PhtD fragment and Zn2+-bound C-
term PhtD fragment. 
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Figure 6.19: Far-UV CD spectra of C-term PhtD fragment 
Experiments were carried out in Tris buffer (50mM Tris HCl pH7.5, 500mM NaCl) at 20oC. 
Protein concentration = 0.5mg/ml 
Black: Apo- C-term PhtD fragment Blue: Zn2+-bound C-term PhtD fragment (Zn2+-bound 
sample supplemented with ZnSO4 to a final concentration of 10mM before measuring). 
 
Although a change is still noticeable between the spectra generated by the 
apo- and Zn2+-bound C-term PhtD fragment, the difference is much less 
pronounced than when compared to the same conditions for the F/L PhtD 
molecule. 
When the same experiment is performed using the smaller ΔC-term fragment 
the results (shown in figure 6.20) are similar to those arising from the C-term 
fragment. 
 159 
 
 
Figure 6.20: Far-UV CD spectra for ΔC-term PhtD fragment 
Experiments were carried out in Tris buffer (50mM Tris HCl pH7.5, 500mM NaCl) at 20oC. 
Protein concentration = 0.5mg/ml 
Black: Apo- ΔC-term PhtD fragment Blue: Zn2+-bound ΔC-term PhtD fragment (Zn2+-bound 
sample supplemented with ZnSO4 to a final concentration of 10mM before measuring). 
 
The close similarity between the spectra generated by the two different 
fragments is unsurprising, as they both comprise largely the same part of the 
F/L molecule, and as a result both have the same two remaining HxxHxH 
motifs and so each should be able to perform the same binding as the other. 
The F/L PhtD molecule may undergo such a dramatic conformational change 
as a result of the three remaining HxxHxH motifs, which are present in the N-
terminal half of the molecule. As the N-terminal half of the PhtD molecule 
appears to be much less natively structured than the C-terminal half, it could 
be hypothesised that the binding of Zn2+ at the N-terminal sites may cause 
much more extensive structural re-organisation. It would also possibly be of 
merit to systematically remove each of the HxxHxH motifs independently and 
assess the effect on Zn2+ binding, and whether there is a dose-dependant 
relationship between these motifs and the Zn2+ atoms, or whether there is a 
key interaction between one or more of the motifs in the N-terminal half 
with those in the C-terminal half of the protein. 
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6.5 Crystallisation Of PhtD 
In an attempt to derive function from structure, the technique of 
macromolecular crystallography was utilised. Initial attempts were made to 
crystallise the F/L PhtD protein, followed by attempted crystallisation of 
truncated forms of PhtD, comprising various portions of the C-terminal half of 
the molecule. Crystal trials were carried out at three locations; the majority 
of work was performed at the University of Glasgow, with additional 
crystallisation attempts carried out during industrial placement at GSK, 
Stevenage. Finally, crystal trials were also carried out in collaboration with 
Prof. Juan Hermoso at the Spanish National Research Council, Madrid Spain. 
6.5.1  Crystallisation Of F/L PhtD 
All crystal trials were carried out using the sitting-drop vapour diffusion 
method171 in 96-well plate format with each well containing a different 
crystallisation condition effectively resulting in 96 separate experiments in 
one plate. This method, combined with the use of several commercially 
available crystallisation-screening kits allows a large number of crystallisation 
conditions to be tested. The protein of interest is mixed 1:1 with reservoir 
solution to form the droplet; the plate is sealed with a plastic film and stored 
at constant temperature whilst being monitored for crystal growth. If 
successful, crystals should begin to grow as the protein concentration in the 
droplet changes over time due to the equilibrium relationship between 
droplet and reservoir. The majority of crystal trials in this work were carried 
out at 20oC. Initially the possibility of crystallisation at 4oC was also explored, 
but yielded no positive results and was subsequently excluded. 
Initial screening of F/L PhtD was carried out using the original stock of 
purified F/L PhtD provided in PBS by GSK. Crystal trials were performed using 
a variety of commercially available screens (see table 2.13) and observed 
daily for the first week then periodically thereafter. Initial screening at 
10mg/ml in PBS yielded a few large crystals in various different 
crystallisation conditions after a short period of a few days. Testing on an In-
house X-ray source (Rigaku 007 X-ray generator) resulted in few large dark 
spots on the diffraction image indicating that crystals were salt, probably as 
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an artefact arising from the interaction of the phosphate buffer with 
components of the relevant crystallisation screen. Crystallisation screening 
was therefore carried out using a Tris buffer comprising 50mM Tris-HCl pH7.5, 
20mM Imidazole, and concentrations of NaCl varying from 500 - 200mM. 
Additional variations included increasing protein concentrations along a range 
from 10 – 25mg/ml, presence or absence of His6 tag, presence or absence of 
Zn2+. 
After several months, a few very small crystals were observed in a couple of 
conditions using F/L PhtD in Tris buffer with 500mM NaCl, – His6 tag, at a 
concentration of 10mg/ml (shown in figure 6.21 and 6.22).  
  
Figure 6.21: Crystal from screening with F/L PhtD 
Crystallisation conditions: 0.1M ammonium citrate. Protein concentration: 10mg/ml 
 
Figure 6.22: Crystal from screening with F/L PhtD 
Crystallisation conditions: 0.1M potassium citrate. Protein concentration: 10mg/ml 
 
Crystals were tested with X-rays in-house, however no diffraction was 
obtained at all. There could several possible reasons for this; it may be that 
the protein forming the crystals is too randomly ordered, or that the crystals 
are too small to produce a diffraction pattern. Although no protein 
diffraction was obtained for these crystals, no salt diffraction was obtained 
either. These findings, coupled with the observation that the crystals were 
very fragile, with several disintegrating upon attempted manipulation 
suggested that they were protein crystals. Attempts were made to reproduce 
or improve upon these crystals by screening around the initial hit conditions, 
but were unsuccessful. 
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As it had been observed that exposing F/L PhtD to trypsin resulted in the 
generation of stable portions of the molecule, this technique was applied to 
the crystallisation trial process, with the intention to observe whether 
gradual induced-degradation of the protein during the crystallisation process 
resulted in crystal formation of a fragment of the protein where a suitable 
quantity of random coil had been digested away allowing the more structured 
regions to pack into a crystal lattice more readily. To this end, proteomics 
grade trypsin (Roche) was added to an 8.5mg/ml F/L PhtD protein solution at 
a final concentration of 0.21mg/ml immediately prior to setting up crystal 
trials. This technique had previously been seen to yield success for 
challenging crystallography targets.172, 173 
After a period of 14 months, a single small crystal measuring approximately 
20 x 20 x 20µm was observed in one of the trypsin-supplemented 
crystallisation conditions resulting from screening of F/L PhtD in Tris buffer 
with 500mM NaCl as seen in figure 6.23.  
 
Figure 6.23: Crystal from screening F/L PhtD with trypsin 
Crystallisation conditions: 2.4M ammonium sulphate, 0.1M HEPES pH7.0  
Protein concentration: 8.5mg/ml (supplemented with 0.34mg/ml trypsin) 
 
In parallel with the crystal trials that yielded the above crystal, a duplicate 
set of trays were produced without the presence of the PhtD protein in order 
to provide negative controls. No crystals were observed in any of the 
conditions from the set of negative control trays. 
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The crystal was exposed to X-rays in-house. The crystal was flash cooled in a 
stream of nitrogen gas maintained at 110K (-163oC). Due to the small size of 
the crystal, no cryoprotectant was used. A single exposure of 1hr was 
acquired, as the crystal was of such small dimensions. The resulting 
diffraction image illustrated in figure 6.24 showed very weak spots diffracting 
to beyond 3Å resolution, with the spots clearly forming lattice lines, 
confirming that the crystal was protein, and not salt.  
 
Figure 6.24: Diffraction image for F/L PhtD crystal 
 
As the diffraction image was very weak, the crystal was stored under lN2 until 
the next available beam-time at a synchrotron radiation facility, which is 
capable of producing a much stronger, highly focused X-ray beam than an in-
house source and which should enable more extensive acquisition of data. 
As it required over one year to obtain the original crystal, 192 replicates of 
this condition were made, along with 192 replicates of the condition 
supplemented with double the trypsin concentration in an attempt to 
accelerate the crystallisation process. Unfortunately, it was not possible to 
reproduce the original crystal in the replicate conditions. It is possible that 
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due to the uncontrolled nature of the in-drop proteolysis process where it is 
unlikely that the same sequence happens in every drop, that the specific 
conditions were not achieved and therefore crystallisation did not occur in 
these cases. Other attributing factors may result in using subsequent protein 
batches or crystallisation screening kits, although precaution was taken to 
ensure minimal variation between preparation of protein batches, and 
commercial kits are quality controlled during factory preparation.  
Using the initial diffraction data acquired from the single in-house exposure, 
it was possible to gain some rudimentary information; namely indexing of the 
crystallographic data to obtain the unit cell parameters and a prediction of 
the space-group to which the protein belonged. Indexing was performed with 
the crystallographic program MOSFILM.134 The resulting data are illustrated in 
table 6.2. 
   
Source  Rigaku micromax 007 
Space group  C222 
Unit-cell parameters (Å, o)  a=142.19, b=207.05, 
c=209.31, α=β=γ=90.0 
Mosaic spread ( o)  0.77 
   
Table 6.2: Indexing statistics for single F/L PhtD crystal 
 
This rudimentary data, specifically the unit-cell parameters can give an 
indication about how the protein is appearing when packed into the crystal. 
Using the unit-cell parameters above and the molecular weight of the protein 
(purified F/L PhtD –His6 tag molecular weight = 91.735 kDa), the program 
MATTHEWS132 was run in order to obtain a Matthews co-efficient value, 
estimate number of protein molecules per asymmetric unit and corresponding 
solvent content174 for the PhtD crystal. These results are illustrated in table 
6.3. 
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Nmol/asym Matthews Coeff 
(Å3 Da-1) 
%solvent Prob 
    
1 8.40 85.36 0.00 
2 4.20 70.72 0.02 
3 2.80 56.08 0.41 
4 2.10 41.44 0.56 
5 1.68 26.80 0.00 
6 1.40 12.16 0.00 
    
Table 6.3: Results of MATTHEWS132 for F/L PhtD crystal 
 
The results of running MATTHEWS132 suggest that there are 3 or 4 protein 
molecules per asymmetric unit based on the probability (41% and 56%), 
suggesting that PhtD in this case has crystallised as a trimer or an oligomer 
consisting of 4 copies of the individual molecule. This seems plausible as it is 
generally observed that in most cases, protein crystals are ~50% solvent,174 
which concurs with the results obtained from MATTHEWS.132 The crystal was 
taken to the Diamond Light Source synchrotron (Didcot, Oxfordshire UK)151 for 
further data acquisition. Unfortunately the low-temperature transportation 
unit containing all the samples for the trip was damaged in transport to the 
facility resulting in the samples being destroyed; no more data was therefore 
able to be gathered for the PhtD crystal. 
F/L crystal trials at GSK continued the work performed at the University of 
Glasgow, in parallel with crystallisation trials of C-term and ΔC-term PhtD 
fragments (see sections 6.5.2. and 6.5.3). All crystallisation trials of F/L PhtD 
at GSK were performed with purified PhtD protein minus His6-tag, 
investigating a range of different protein concentrations, from 7.7 – 24.96 
mg/ml and lowering NaCl concentration to 200mM as standard. 
Before setting up crystal trials, samples were analysed by Dynamic Light 
Scattering (DLS) in order to determine whether the proteins were present as 
a monodisperse solution. Of the three proteins, F/L and ΔC-term were 
present as monodisperse solutions, whilst the C-term PhtD sample appeared 
to contain a large aggregate. The protein sample was filtered in order to try 
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and remove the aggregation and achieve a monodisperse solution for the C-
term PhtD protein before using for subsequent crystallisation trials.  
Crystal trials were performed using a number of commercially available 
screens (see table 2.13) including Morpheus and PACT and the Nextal Classics 
sparse matrix screen. Crystal trials were performed by the sitting-drop 
vapour diffusion method, and set up using a Mosquito® nanolitre liquid 
handling robot (TTP Labtech, Herts UK) to create 200nl droplets comprising 
of a 1:1 mixture of protein : reservoir solution. Initial one-off testing with the 
‘PCT’ pre-crystallisation test (Hampton Research) indicated that 
concentrations 10-12mg/ml should be the optimal range.  In addition each 
crystallisation trial had two available drop sites; apo-protein was used for the 
droplet in site 1, Zn2+-bound protein (ZnSO4 added to apo-protein at a final 
concentration of 1mM) was used for the droplet in site 2. Although lowering 
the NaCl concentration appeared to have an effect, with a larger proportion 
of crystallisation trial droplets showing variation from their initially clear 
appearance, no crystals were evident during the duration of the placement 
and there has been no evidence of crystal formation in the time since. 
Following protein-buffer screening experiments (see 6.5.1.1), crystallisation 
trials were performed on F/L PhtD using 50mM MES pH7.0, 200mM NaCl as the 
protein buffer. Crystal trials were set-up with a protein concentration of 
12.06mg/ml supplemented with ZnSO4 to a final concentration of 1mM in site 
1, and 10mM in site 2. These trials were initiated shortly before the end of 
the placement, at the end of which no crystals had been observed. 
Crystallisation trials continued to be monitored with updates provided; 
however to date no crystals have be obtained from any of the above 
conditions. 
6.5.1.1  Crystallisation Buffer Screening Of F/L PhtD 
As little success was being obtained using the Tris buffer for crystallisation, 
investigation was made into the possibility of finding a more suitable buffer 
that might better promote crystallisation of PhtD. Crystallisation buffer 
screening was performed by measuring protein melting-temperature (Tm) by 
circular dichroism. By repeatedly measuring the CD signal at a constant 
wavelength over time, whilst performing a linear gradient temperature 
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increase, it is possible to measure the increase in random coil present in the 
protein as it denatures due to the influence of increasing temperature. The 
stability of the protein of interest may vary under different buffer conditions, 
and by screening a number of different conditions, it may be possible to find 
the most thermostablising buffer that could then be used as the protein 
solution buffer in crystallisation attempts. It has been previously observed 
increasing protein thermostability has resulted in greater crystallisation 
success.175 
For performing the Tm experiment, 325µl of F/L apo-PhtD protein or Zn2+-
bound F/L PhtD (2mM ZnSO4 final concentration) at a concentration of 
0.1mg/ml was measured at a constant λ=222nm over a temperature range 
from 20 – 90oC. Temperature was increased at a linear rate of 1oC min-1 with 
data acquisition for 20secs after every incremental increase. Due to time 
constraints only two separate buffers were tested both with the apo-form of 
F/L PhtD and also with the Zn2+-bound form. Because of previous experience 
with the formation of phosphate crystals, PBS was excluded. Additionally, 
due to the phenomenon of the temperature-dependant pH of Tris, which 
makes measuring by this method difficult, and previous limited success in 
crystallisation using this buffer it was also excluded. The two buffers tested 
by Tm were 50mM HEPES pH6.5, and 50mM MES pH7.0. 
Screening of apo-protein by this method failed to produce the expected 
sigmoidal curve normally seen with this method, instead showing a gradual 
increase throughout the experiment as illustrated in figure 6.25. 
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Figure 6.25: Tm results for apo- F/L PhtD. 
Protein concentration = 0.1mg/ml 
Tm data were not interpretable for Apo- F/L PhtD as no melting curve was obtained. It is 
possible that due to the largely unstructured, flexible nature of the Apo- form there is no 
definitive point at which structure is lost, as a large proportion is natively present as 
random coil. 
 
Previous experiments using NMR and Far-UV CD methods showed the apo-form 
of the F/L PhtD molecule to be largely unordered in structure. Since a large 
portion of the F/L PhtD molecule exists naturally as random coil, it is 
understandable that there is no definitive point at which the protein becomes 
disordered; the localised sections of the molecule which possess a defined 
structure gradually denature leading to an increase in the proportion of 
random coil as seen in the results without a definitive structured-protein to 
unstructured-protein change observed. 
In contrast, the results from experiments performed with the same 
parameters on the Zn2+-bound form of F/L PhtD exhibit the normally observed 
trend, resulting in the typical melting-curve as seen in figure 6.26. 
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Figure 6.26: Tm results for Zn2+-bound F/L PhtD 
Protein concentration = 0.1mg/ml, sample was supplemented with ZnSO4 to a final 
concentration of 2mM before beginning experiment. 
Tm of the Zn
2+-bound form of F/L PhtD results in the typical melting-curve. Results show 
that F/L PhtD in HEPES buffer (black) has a Tm around 38
oC, contrasting with F/L PhtD in 
MES buffer which has a Tm around 48
oC and is therefore more thermostable in MES. 
 
The expected sigmoidal melting-curve was observed in the Zn2+-bound F/L 
PhtD samples. This could be because as other experiments have indicated, a 
large change in the structural organisation of the F/L PhtD molecule is 
induced upon Zn2+-binding. If the Zn2+ has resulted in the F/L PhtD protein 
becoming a more structured molecule than the apo-form, then this structure 
could be denatured with increasing temperature, leading to the more 
conventional results seen above, rather than those previously illustrated for 
the apo-form where the protein existed naturally in a largely unstructured 
conformation.  
In the above graph, it can be seen that with both buffers, the protein remains 
stable up to ~30oC. Above this temperature, there begins a rapid increase in 
the proportion of random coil for the samples, which decreases in rate at 
higher temperatures, presumably because the proportion remaining, 
structured protein is greatly decreased. The melting temperature Tm was 
attributed to the mid-point of the curve, which corresponded to ~38oC in the 
HEPES buffer and ~48oC in the MES buffer. It was observed therefore, that the 
same protein in MES buffer was 10oC more thermically stable than when in 
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HEPES buffer. As a result of these experiments, protein crystallisation was 
attempted using 50mM HEPES pH7.0, 200mM NaCl as the protein buffer 
solution. 
6.5.2  Crystallisation Of C-term And ΔC-term PhtD Fragments 
Crystallisation of the two fragments of PhtD which encode the structured N-
terminal half of the PhtD molecule were subjected to crystallisation trials at 
GSK during industrial placement. Attempted crystallisation of these 
fragments was performed in parallel with crystal trials of the F/L PhtD 
molecule. As such, the same selection of crystallisation screens were utilised, 
with the two protein fragments being screened over a range of different 
concentrations varying from 10.01 – 20.02mg/ml for the C-term fragment and 
12.15 – 24.3mg/ml for the ΔC-term fragment. Similarly to the approach used 
with the F/L PhtD protein initial crystallisation trials were performed using 
Tris buffer with either 500mM or 200mM NaCl. Each crystallisation 
experiment utilised both available droplet sites, with site one containing the 
apo- and site 2 the Zn2+-bound forms of the proteins respectively. As before, 
crystallisation trials were set up using the Mosquito® robot to give a 200nl 
droplet comprising 1:1 ratio of protein : reservoir solution, stored at 20oC and 
monitored for crystal growth. 
After a period of 4 days, a small crystal from the ΔC-term PhtD fragment trial 
at 12.34mg/ml with 1mM ZnSO4 (i.e. Zn2+ bound form) was observed 
beginning to grow in a single condition from the PACT screen which 
comprised 20%(w/v) PEG 3350, 0.2M sodium potassium phosphate, 0.1M Bis-
Tris propane pH8.5. Over the following 48hrs this crystal was observed to 
have grown in size, and is illustrated in figure 6.27 Preliminary testing was 
carried out using a PX-Scanner (Oxford Diffraction, Abingdon UK). An initial, 
short 20sec exposure yielded no diffraction, however a longer exposure of 6 
frames at 0.5o increments with a 100sec exposure per frame showed the 
presence of few, large dark spots in the diffraction image as seen in figure 
6.28 indicating that the crystal was a salt and not protein. 
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Figure 6.27: C-term PhtD crystal 
Crystal circled.  
Figure 6.28: Diffraction image for ΔC-term crystal test 
Large black spots identify crystal as salt. 
 
As a result of performing buffer screening experiments on F/L PhtD which 
identified MES buffer as a potentially good thermostabilising buffer for PhtD 
(see section 4.5.1.1.) Replication of the F/L PhtD crystal trials in the new 
MES buffer was performed for the C-term and ΔC-term fragments. Proteins 
were buffer exchanged into the 50mM MES pH 7.0 buffer with 200mM NaCl, 
concentrated to 17.6 and 20.1mg/ml respectively. Crystallisation trials were 
set up as previously outlined. Proteins were supplemented with 1mM and 
10mM final concentration ZnSO4 for sites 1 and 2 respectively, stored at 20oC 
and monitored for crystal growth. As these crystallisation trials were set up 
at the same time as those for the F/L PhtD protein, observation time was 
limited due to conclusion of the placement, however no crystals had been 
observed at the end of the placement, and continued observation reported 
that no crystals have been observed to this date. 
6.5.3  PhtD Crystallisation In Collaboration With CSIC Madrid 
Ongoing partnerships between the Mitchell Pneumococcal Group and other 
European laboratories through the Seventh Framework Program176 instigated 
by the European Commission (http://cordis.europa.eu/fp7/home_en.html) 
provided the opportunity for collaboration with Prof. J. Hermoso of the 
Spanish National Research Council on the crystallisation of PhtD. The 
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Hermoso Group177 has extensive experience of determining the structure of 
pneumococcal proteins by macromolecular X-ray crystallography.177-181 By 
providing purified protein and additional experimental data outlined in this 
thesis, it was hoped that this collaboration would yield diffraction quality 
protein crystals which could either be used to determine the structure, or 
perhaps obtain initial crystals which could provide a starting point for PhtD 
crystallisation, allowing crystal optimisation in order to provide crystals 
which could subsequently be used to determine the protein structure. 
Crystallisation trials were performed using the sitting-drop vapour diffusion 
method. Trials were set up using a Nanodrop™ liquid handling robot (Santa 
Rosa, California US) mixing a 1:1 ratio of protein : reservoir solution, to give 
a final drop volume of 500nl. Crystallisation trials were stored at 25oC and 
monitored for crystal growth. 
6.5.3.1  F/L PhtD 
F/L PhtD protein was buffer exchanged into 10mM HEPES pH7.5 using Amicon 
10K MWCO centrifugal concentrators (Millipore) and concentrated to 
16mg/ml. Crystallisation trials were performed as outlined above using a 
variety of commercially available crystallisation screens (See table 2.13) 
including Crystal Screen 1& 2. 7 months after initial setup, evidence of phase 
separation was observed in several conditions, illustrated in table 6.4 Phase 
separation may give an indication as to preferred crystallisation conditions 
where the protein and precipitant are reacting favourably and therefore 
provide a platform for further condition screening utilising components of 
these conditions. 
 173 
 
Buffer (0.1M) Precipitant Additive 
   
SPG pH7.0 25% PEG 1500 N/A 
SPG pH8.0 25% PEG 1500 N/A 
SPG pH9.0 25% PEG 1500 N/A 
HEPES pH7.0 20% PEG 6000 0.2M (NH4)2Cl2, 0.2M 
MgCl2, 0.2M LiCl2 
Tris pH8.0 20% PEG 6000 0.2M (NH4)2Cl2, 0.2M 
MgCl2, 0.2M LiCl2 
Bis-Tris pH8.5 20% PEG 3350 0.2M Na-malonate 
HEPES pH7.5 10% PEG 8000 8% Ethylene glycol 
Bicine pH9.0 50% PEG 200 2% Dioxane 
HEPES pH7.0 10% PEG 6000 N/A 
Tris pH8.0 40% MPD N/A 
Na CaCo pH6.5 30% PEG 8000 0.2M Ammonium sulphate 
N/A 30% MPD 0.2M Mg-acetate 
Tris pH8.0 30% PEG 4000 0.2M Na-acetate 
MES pH6.5 1.6M MgSO4, 30% 
Jeffamine M-600 
0.05M Caesium chloride 
   
Table 6.4: Selected crystallisation conditions from F/L PhtD trials 
Crystallisation conditions that gave phase separation after 7 months for F/L PhtD 
 
Although initial screening provided some interesting observations as noted 
above, no further change in these conditions was observed and no crystals 
have been obtained to date, although trials are continuing. 
6.5.3.2  C-term PhtD 
For the C-term PhtD protein fragment, buffer exchange was carried out as 
described in 6.5.3.1 buffer exchanging into 10mM Tris pH7.5, 20mM 
imidazole, and concentrated to 12.2mg/ml. Crystallisation trials were 
performed as before using a variety of commercial crystallisation screens (see 
table 2.13) and additionally, SaltRx screen (Hampton Research). Trials were 
stored at 25oC and monitored for crystal growth. 3 months after initial setup, 
18 trials showed evidence of changes in the droplet, outlined in table 6.5 
with condition 19 (highlighted) producing a visually poor quality crystal. 
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Buffer (0.1M) Precipitant Additive 
   
Na-cacodylate pH6.5 30% MPD Mg-acetate 
MES pH6.5 12% PEG 20000 1.6M Ammonium sulphate 
MES pH6.5 25% PEG 550 0.01M ZnSO4 
HEPES pH7.5 10% PEG 6000 0.5M Ammonium sulphate 
HEPES pH7.5 10% PEG 8000 N/A 
Tris pH8.5 1M LiSO4 0.01M NiCl2 
Na/K phosphate pH6.2 25% 1-2-propanediol 10% Glycerol 
Phosphate citrate pH4.5 20% PEG 8000 0.2M NaCl 
Citric acid pH4.0 20% PEG 6000 1M LiSO4 
Bis-Tris pH7.0 2.2M DL-malic acid N/A 
Tris pH8.5 2.5M Ammonium sulphate N/A 
SPG pH4.0 25% PEG 1500 N/A 
Na-acetate pH5.0 20% PEG 6000 0.2M LiCl2 
PCB pH4.0 25% PEG 1500 N/A 
PCB pH5.0 25% PEG 1500 N/A 
MNT pH4.0 25% PEG 1500 N/A 
Tris pH8.0 20% PEG 6000 0.01M ZnCl2 
Bis-Tris pH7.5 20% PEG 3350 0.2M potassium 
thiocyanate 
Tris pH8.5 20% PEG 2000 0.01M NiCl2 
   
Table 6.5: Selected conditions from C-term PhtD trials 
Crystallisation conditions which showed evidence of changes in droplet morphology after 3 
months. The condition that produced the crystal is highlighted in yellow. 
 
In preparation for testing the crystal in-house by exposure to X-rays, a cryo-
protecting solution (to protect the crystal during the flash-cooling process) 
was prepared by mixing the reservoir solution with glycerol to a final glycerol 
concentration of 20%. The crystal immediately cracked upon contact with the 
cryo-solution and partial melting of the crystal was also observed. It was 
therefore not possible to measure and acquire X-ray data, however the 
fragility of the crystal is a good indication of the crystal being a protein 
crystal. Unfortunately, to date reproducibility of the crystal obtained from 
this condition has not been achieved, although trials are continuing. 
6.5.3.3  ΔC-term PhtD 
The purified ΔC-term PhtD protein fragment was buffer exchanged into 10mM 
Tris pH7.0 using a PD10-desalting column (Amersham, GE Healthcare) and 
concentrated to 16mg/ml with amicon 10K centrifugal concentrators. Despite 
the absence of NaCl, the protein was judged to be stable in this buffer as no 
precipitation was observed. Crystal trials were performed as for the F/L PhtD 
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and C-term PhtD proteins by the sitting-drop vapour diffusion method, using a 
variety of commercial crystallisation screens (see table 2.13) with a total 
drop volume of 500nl. Among the conditions tested, two different conditions 
- 0.05M citrate pH5.0, 15% PEG 600 and 0.05M MES pH6.0, 2.5% PEG 600 – 
show evidence of crystal formation. Small crystals appear after 1 week of 
incubation at 20oC as illustrated in figures 6.29 and 6.30. 
   
Figure 6.29: Small ΔC-term PhtD crystals 
Crystals appear as very small, thin rods. 
Crystallisation conditions: 0.05M citrate pH5.0, 15% PEG 600. Protein concentration: 
16mg/ml. 
Figure 6.30: Small ΔC-term PhtD crystals 
Crystals appear as very small, thin rods. 
Crystallisation conditions: 0.05M MES pH6.0, 2.5% PEG 600. Protein concentration: 16mg/ml.  
 
Due to their extremely small size and morphology these crystals are too small 
and fragile to be useful for X-ray diffraction experiments as it would not be 
possible to manipulate the crystals without destroying them. Several trials to 
scale-up or optimise these conditions are ongoing in an attempt to grow 
bigger more robust crystals from which X-ray protein diffraction data could 
be acquired. Additionally, crystallisation trials have recently begun to be 
performed with the purified 34 kDa PhtD fragment and are being monitored 
for crystal growth. 
It is evident from the wide range of different crystallisation attempts carried 
out at the University of Glasgow, during placement at GlaxoSmithKline, and 
in collaboration with the CSIC in Madrid, Spain that crystallisation of the F/L 
PhtD protein molecule has been challenging. However, a rational approach to 
 176 
evaluating the protein structure, uncovering and generating isolated more 
highly structured fragments of the F/L PhtD protein has lead to greater 
success with the crystallisation process, with in-situ proteolysis during the 
crystallisation trials and crystallisation of recombinantly expressed PhtD 
fragments both showing promising results which are continuing to be 
investigated and built upon. 
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Chapter 7 : Final Discussion 
7.1  Structural Studies Of PhtD 
7.1.1 Crystallisation Of F/L PhtD 
The gene encoding the F/L PhtD protein was successfully isolated from the 
TIGR4 strain of S. pneumoniae, cloned into the expression vector pOPINF119 
and subsequently successfully purified to a quality such that analysis of 1µg 
of purified F/L PhtD by SDS-PAGE showed a single band on the SDS-PAGE gel 
when stained with coomassie R-250, and used in crystallisation trials. 
Structural prediction software, coupled with 1D-NMR data suggested that the 
F/L PhtD molecule comprised many flexible regions interspersed with 
structured sections of protein. Although a large number of crystallisation 
formulations were investigated under a varied range of protein conditions 
such as inclusion of the PhtD binding-partner Zn2+ and substitution of 
different protein buffers, crystallisation of the F/L molecule remained 
challenging, resulting in the limited success of growing a few poor quality 
protein crystals which were unsuitable for X-ray diffraction experiments due 
to their fragility, as they could not be manipulated without being destroyed. 
The addition of the protease trypsin to the crystallisation experiments in an 
attempt to crystallise the PhtD protein as unstructured loops were digested, 
providing more regimented crystal-contacts and therefore a higher likelihood 
of crystal formation proved more successful. This process resulted in 
obtaining a protein crystal that yielded rudimentary crystallographic data for 
PhtD, including a predicted space-group. This approach could be used more 
extensively, but would first need a degree of optimisation due to the long 
time-frame between the start of the experiment and crystal formation. 
7.1.2  Crystallisation Of PhtD Protein Fragments 
A rational approach to selecting fragments of the PhtD molecule, which 
included limited proteolysis and mass-spectrometry to identify structured 
regions of interest within the F/L molecule was used to generate a set of 
PhtD protein fragments. By removing much of the unstructured protein in the 
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F/L molecule and expressing the regions which were observed to have a more 
ordered structure it was postulated that these fragments would prove more 
conducive to the crystallisation process, by providing more regular crystal-
contacts and promoting crystal lattice formation. These fragments were 
successfully purified and subjected to crystallisation trials which resulted in 
successful crystallisation of two of these fragments (named C-term and ΔC-
term) where very small crystals were obtained over a relatively short time-
period –weeks compared to months for any F/L PhtD crystals. Although too 
small for X-ray diffraction experiments, this initial success is encouraging and 
has given an indication of the crystallisation conditions that should be 
explored in order to produce larger diffraction-quality crystals, which could 
then be used to determine the protein structure of a fragment of the PhtD 
molecule. The successful crystallisation of these fragments also validates the 
method devised here of targeting specific regions of the protein molecule 
through computational and biological techniques to generate suitable 
candidates for structural analysis. 
Generation of the protein fragments has also opened up new possibilities into 
investigating the structure of PhtD, as even the largest of these fragments at 
55 kDa in size falls inside the limits of determining the protein structure using 
NMR. 
7.1.3  Interaction Of Zn2+ With PhtD 
Data in this thesis has shown that PhtD is able to bind Zn2+ as previously seen 
in the crystal structure of a fragment of the related protein PhtA from work 
previously performed in our laboratory.98 Limited proteolysis experiments 
investigating the interaction of a variety of divalent-cations with PhtD lead us 
to believe that PhtD is capable of binding Zn2+ atoms exclusively. CD analysis 
has shown that upon binding Zn2+, the protein undergoes a large 
conformational change from a primarily α-helical structure to a 
predominantly β-sheet structure. Further CD experiments have shown that 
this binding process is reversible, with the protein returning to its original 
structure. Repetition of these CD experiments using the purified PhtD 
fragments, which exclude a number of the HxxHxH motifs shows a reduction 
in the magnitude of structural change which occurs upon Zn2+-binding, and is 
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backed-up by a similar observation in the NMR experiments. Further 
investigation would be needed in order to ascertain whether Zn2+-binding 
induces a “dose-dependant” conformational change in the protein structure, 
or if it promotes the formation of intra-molecular interactions by bringing key 
residues into proximity with each other. Crystal structures of the F/L PhtD 
protein in both apo- and Zn2+-bound forms would be the definitive way to 
reveal this mechanism as the two protein models could be visually compared. 
Analysis of the interaction of PhtD with Zn2+ by ITC reveals that weak binding 
occurs at multiple sites in the protein, reinforcing the theory that each 
HxxHxH motif is responsible for binding a Zn2+ atom. Recently published work 
has suggested that PhtD may perform a role as a zinc-scavenger, acting as a 
Zn2+-reservoir for the pneumococcus to survive in a zinc-depleted 
environment.102 The work presented in this thesis where we observe evidence 
of weak Zn2+-binding, which induces a reversible change in protein structure 
appears to corroborate this theory. 
7.1.4  Hypothetical Structure of PhtD 
A schematic representation of the hypothesised structure of PhtD, resulting 
from the findings presented in this thesis is outlined in figure 7.1. The full 
PhtD molecule has been represented in linear format. The locations of key 
structural components have been colour-coded on the molecule as indicated; 
the signal sequence responsible for targeting PhtD to the cell-surface is 
illustrated in yellow, HxxHxH motifs are illustrated in pink, the region 
thought to contain the dominant epitope is illustrated in green, the stable 
region of PhtD identified from limited proteolysis experiments and 
subsequently cloned as pMRH2 – 7 is illustrated in purple. Predicted 
disordered regions (e.g. flexible loops) are illustrated in red; one disordered 
region (res 550 – 610) contains one of the HxxHxH motifs, whilst another (res 
683 – 773) is present in the hypothesised epitope region. 
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Figure 7.1: Theoretical model of PhtD 
Key structural components are colour-coded as outlined above. Residue ranges for these 
components are provided in parenthesis. The region of deletion studies comprises those 
identified by limited proteolysis and subsequently generated as constructs pMRH2 – 7. 
 
7.1.5  PhtD Hypothesised Mode Of Action 
The data presented in this thesis has shown through NMR and CD studies that 
in the apo-form, PhtD appears to be a largely flexible protein, with localised 
regions that are highly structured. These regions appear to be in the C-
terminal half of the protein through mass-spectrometry analysis, with the N-
terminal half of the molecule present as flexible loops that are highly 
susceptible to proteolytic degradation. Upon addition of Zn2+ a significant 
change in protein structure occurs, as observed by NMR and CD. It is possible 
that the Zn2+ may bring key residues in the C-terminal half of the molecule 
together with the N-terminal half of the molecule, promoting intramolecular 
interactions which aid in “folding-up” the previously flexible structure and 
docking the Zn2+ atoms with the protein, resulting in a stable, more globular 
protein structure. The Zn2+-binding ability of PhtD appears reversible; with 
the metal ion chelated out the PhtD returns to its original flexible 
conformation, reinforced with ITC showing Zn2+-binding with PhtD to be a 
weak interaction, which could be released with minimal effort. This potential 
mode of action would concur with the postulated function of the Pht proteins 
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as metal scavengers that store metal-ions for use by the organism in metal 
depleted environments. 
7.1.6  PhtD As A Vaccine Candidate 
Previously published work has shown that immunisation with PhtD provides 
protection against pneumococcal invasion in a murine model, and that 
antibodies generated are cross-reactive with the other Pht family members.92 
The work presented in this thesis has uncovered the major PhtD epitope, 
which is localised to a 15 kDa region of the F/L molecule. It could therefore 
be advantageous to modify the vaccine strategy such that immunisation need 
only be carried out using this small 15 kDa fragment PhtD, cutting out the 
remaining 77kDa to produce a much more streamlined vaccine component. 
7.1.7  Further Work 
The data generated during this project and presented in this thesis has laid a 
solid foundation into the structural analysis of the protein PhtD from the Pht 
family of proteins, and has opened up new avenues of investigation which 
should eventually lead to the determination of part of the PhtD molecule; 
specifically an important section of the protein which encompasses the major 
PhtD epitope. Further experiments leading towards this goal should include: 
• Continued crystallisation trials of PhtD protein fragments, using the 
initial crystallisation conditions which produced the small crystals as a 
starting point for condition screening in order to obtain better quality 
protein crystals. 
• NMR spectroscopy of the PhtD protein fragments, especially the 55 kDa 
C-term and 15 kDa Epitope PhtD fragments in an attempt to uncover 
the structure of this important region of the protein, in parallel with 
the continued crystallisation experiments. 
• Further extensive screening of PhtD interaction with divalent-cations 
(supplementary to those investigated in this thesis) by ITC to uncover 
whether PhtD has affinity for any divalent-cations other than zinc. 
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• Investigation into whether PhtD : Zn2+ binding is “dose-dependant” 
through manipulation at the genetic level by mutagenesis techniques 
to systematically remove the HxxHxH motifs and test their ability to 
bind Zn2+ compared to the native form of F/L PhtD. 
 
7.2 Towards The Structure Of PpmA 
7.2.1  Summary Of Results Obtained 
PpmA protein was successfully expressed and purified for crystallisation 
trials. Crystals were successfully grown which showed X-ray diffraction to 
~2.5Å resolution. However, although diffraction quality was good along one 
plane of the crystal, rotation through 90o reduced diffraction quality. 
Indexing of the X-ray diffraction acquired to date has made it possible to 
reveal rudimentary crystallographic data, however a large body of work 
remains in order to determine the 3D crystal structure of PpmA. 
7.2.2 Future Work 
Future work in an attempt to determine the structure of PpmA should 
definitely focus on attempting to obtain better crystals, which would yield 
higher quality X-ray diffraction data. Screening around the current 
crystallising conditions in order to try improve crystal quality, or slowing 
down protein nucleation by varying incubation temperature in order to try 
and control crystal growth-rate may yield the desired results. It is thought 
that as current crystals appear as thin plates, improvement of crystal 
morphology to give a more 3-dimensional profile would result in a the 
presence of a more substantial lattice in all dimensions, reducing crystal 
mosaicity, thereby hopefully improving diffraction quality. In order to 
determine the protein structure, a method of obtaining the phases for the 
crystal, either by soaking in heavy-metals or producing selenomethionine 
derivatives of PpmA will then have to be investigated, as molecular 
replacement is not possible in this instance due to the fact that PpmA has 
been predicted to be a novel protein. 
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Appendices 
 
A.1  DNA And Protein Sequences 
 
A.1.1  PhtD (SP_1003) TIGR4 Natural Sequences 
 PhtD Nucleotide Sequence 
ATGAAAATTAATAAAAAATATCTAGCAGGTTCAGTGGCAGTCCTTGCCCTAAGTGTTTGTTCCTATGAA
CTTGGTCGTCACCAAGCTGGTCAGGTTAAGAAAGAGTCTAATCGAGTTTCTTATATAGATGGTGATCAG
GCTGGTCAAAAGGCAGAAAACTTGACACCAGATGAAGTCAGTAAGAGGGAGGGGATCAACGCCGAACA
AATCGTCATCAAGATTACGGATCAAGGTTATGTGACCTCTCATGGAGACCATTATCATTACTATAATGG
CAAGGTCCCTTATGATGCCATCATCAGTGAAGAGCTCCTCATGAAAGATCCGAATTATCAGTTGAAGGA
TTCAGACATTGTCAATGAAATCAAGGGTGGTTATGTTATCAAGGTAGATGGAAAATACTATGTTTACCT
TAAGGATGCAGCTCATGCGGATAATATTCGGACAAAAGAAGAGATTAAACGTCAGAAGCAGGAACACA
GTCATAATCACGGGGGTGGTTCTAACGATCAAGCAGTAGTTGCAGCCAGAGCCCAAGGACGCTATACA
ACGGATGATGGTTATATCTTCAATGCATCTGATATCATTGAGGACACGGGTGATGCTTATATCGTTCCT
CACGGCGACCATTACCATTACATTCCTAAGAATGAGTTATCAGCTAGCGAGTTAGCTGCTGCAGAAGCC
TATTGGAATGGGAAGCAGGGATCTCGTCCTTCTTCAAGTTCTAGTTATAATGCAAATCCAGCTCAACCA
AGATTGTCAGAGAACCACAATCTGACTGTCACTCCAACTTATCATCAAAATCAAGGGGAAAACATTTCAA
GCCTTTTACGTGAATTGTATGCTAAACCCTTATCAGAACGCCATGTGGAATCTGATGGCCTTATTTTCG
ACCCAGCGCAAATCACAAGTCGAACCGCCAGAGGTGTAGCTGTCCCTCATGGTAACCATTACCACTTTA
TCCCTTATGAACAAATGTCTGAATTGGAAAAACGAATTGCTCGTATTATTCCCCTTCGTTATCGTTCAAA
CCATTGGGTACCAGATTCAAGACCAGAACAACCAAGTCCACAATCGACTCCGGAACCTAGTCCAAGTCC
GCAACCTGCACCAAATCCTCAACCAGCTCCAAGCAATCCAATTGATGAGAAATTGGTCAAAGAAGCTGT
TCGAAAAGTAGGCGATGGTTATGTCTTTGAGGAGAATGGAGTTTCTCGTTATATCCCAGCCAAGGATC
TTTCAGCAGAAACAGCAGCAGGCATTGATAGCAAACTGGCCAAGCAGGAAAGTTTATCTCATAAGCTAG
GAGCTAAGAAAACTGACCTCCCATCTAGTGATCGAGAATTTTACAATAAGGCTTATGACTTACTAGCAA
GAATTCACCAAGATTTACTTGATAATAAAGGTCGACAAGTTGATTTTGAGGCTTTGGATAACCTGTTGG
AACGACTCAAGGATGTCCCAAGTGATAAAGTCAAGTTAGTGGATGATATTCTTGCCTTCTTAGCTCCGA
TTCGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGATGATGAGATTCAAGTAG
CCAAGTTGGCAGGCAAGTACACAACAGAAGACGGTTATATCTTTGATCCTCGTGATATAACCAGTGATG
AGGGGGATGCCTATGTAACTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTCTGAAG
CTGAGAGAGCGGCAGCCCAGGCTTATGCTAAAGAGAAAGGTTTGACCCCTCCTTCGACAGACCATCAG
GATTCAGGAAATACTGAGGCAAAAGGAGCAGAAGCTATCTACAACCGCGTGAAAGCAGCTAAGAAGGT
GCCACTTGATCGTATGCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTTTAATCATACCT
CATTATGACCATTACCATAACATCAAATTTGAGTGGTTTGACGAAGGCCTTTATGAGGCACCTAAGGGG
TATACTCTTGAGGATCTTTTGGCGACTGTCAAGTACTATGTCGAACATCCAAACGAACGTCCGCATTCA
GATAATGGTTTTGGTAACGCTAGCGACCATGTTCGTAAAAATAAGGTAGACCAAGACAGTAAACCTGAT
GAAGATAAGGAACATGATGAAGTAAGTGAGCCAACTCACCCTGAATCTGATGAAAAAGAGAATCACGCT
GGTTTAAATCCTTCAGCAGATAATCTTTATAAACCAAGCACTGATACGGAAGAGACAGAGGAAGAAGCT
GAAGATACCACAGATGAGGCTGAAATTCCTCAAGTAGAGAATTCTGTTATTAACGCTAAGATAGCAGAT
GCGGAGGCCTTGCTAGAAAAAGTAACAGATCCTAGTATTAGACAAAATGCTATGGAGACATTGACTGGT
CTAAAAAGTAGTCTTCTTCTCGGAACGAAAGATAATAACACTATTTCAGCAGAAGTAGATAGTCTCTTG
GCTTTGTTAAAAGAAAGTCAACCGGCTCCTATACAGTAG 
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 PhtD Protein Sequence 
MKINKKYLAGSVAVLALSVCSYELGRHQAGQVKKESNRVSYIDGDQAGQKAENLTPDEVSKREGINAEQIVIKIT
DQGYVTSHGDHYHYYNGKVPYDAIISEELLMKDPNYQLKDSDIVNEIKGGYVIKVDGKYYVYLKDAAHADNIRT
KEEIKRQKQEHSHNHGGGSNDQAVVAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSASE
LAAAEAYWNGKQGSRPSSSSSYNANPAQPRLSENHNLTVTPTYHQNQGENISSLLRELYAKPLSERHVESDGLI
FDPAQITSRTARGVAVPHGNHYHFIPYEQMSELEKRIARIIPLRYRSNHWVPDSRPEQPSPQSTPEPSPSPQPAP
NPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLSAETAAGIDSKLAKQESLSHKLGAKKTDLPSSD
REFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVPSDKVKLVDDILAFLAPIRHPERLGKPNAQITYT
DDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAQAYAKEKGLTPPSTD
HQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVKNGSLIIPHYDHYHNIKFEWFDEGLYEAPKGYT
LEDLLATVKYYVEHPNERPHSDNGFGNASDHVRKNKVDQDSKPDEDKEHDEVSEPTHPESDEKENHAGLNPS
ADNLYKPSTDTEETEEEAEDTTDEAEIPQVENSVINAKIADAEALLEKVTDPSIRQNAMETLTGLKSSLLLGTKD
NNTISAEVDSLLALLKESQPAPIQ 
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A.1.2  pMRH1 PhtD F/L Sequences 
 pMRH1 Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGTCCT
ATGAACTTGGTCGTCACCAAGCTGGTCAGGTTAAGAAAGAGTCTAATCGAGTTTCTTATATAGATGGTG
ATCAGGCTGGTCAAAAGGCAGAAAACTTGACACCAGATGAAGTCAGTAAGAGGGAGGGGATCAACGCC
GAACAAATCGTCATCAAGATTACGGATCAAGGTTATGTGACCTCTCATGGAGACCATTATCATTACTAT
AATGGCAAGGTCCCTTATGATGCCATCATCAGTGAAGAGCTCCTCATGAAAGATCCGAATTATCAGTTG
AAGGATTCAGACATTGTCAATGAAATCAAGGGTGGTTATGTTATCAAGGTAGATGGAAAATACTATGTT
TACCTTAAGGATGCAGCTCATGCGGATAATATTCGGACAAAAGAAGAGATTAAACGTCAGAAGCAGGAA
CACAGTCATAATCACGGGGGTGGTTCTAACGATCAAGCAGTAGTTGCAGCCAGAGCCCAAGGACGCTA
TACAACGGATGATGGTTATATCTTCAATGCATCTGATATCATTGAGGACACGGGTGATGCTTATATCGT
TCCTCACGGCGACCATTACCATTACATTCCTAAGAATGAGTTATCAGCTAGCGAGTTAGCTGCTGCAGA
AGCCTATTGGAATGGGAAGCAGGGATCTCGTCCTTCTTCAAGTTCTAGTTATAATGCAAATCCAGCTCA
ACCAAGATTGTCAGAGAACCACAATCTGACTGTCACTCCAACTTATCATCAAAATCAAGGGGAAAACATT
TCAAGCCTTTTACGTGAATTGTATGCTAAACCCTTATCAGAACGCCATGTGGAATCTGATGGCCTTATT
TTCGACCCAGCGCAAATCACAAGTCGAACCGCCAGAGGTGTAGCTGTCCCTCATGGTAACCATTACCAC
TTTATCCCTTATGAACAAATGTCTGAATTGGAAAAACGAATTGCTCGTATTATTCCCCTTCGTTATCGTT
CAAACCATTGGGTACCAGATTCAAGACCAGAACAACCAAGTCCACAATCGACTCCGGAACCTAGTCCAA
GTCCGCAACCTGCACCAAATCCTCAACCAGCTCCAAGCAATCCAATTGATGAGAAATTGGTCAAAGAAG
CTGTTCGAAAAGTAGGCGATGGTTATGTCTTTGAGGAGAATGGAGTTTCTCGTTATATCCCAGCCAAG
GATCTTTCAGCAGAAACAGCAGCAGGCATTGATAGCAAACTGGCCAAGCAGGAAAGTTTATCTCATAAG
CTAGGAGCTAAGAAAACTGACCTCCCATCTAGTGATCGAGAATTTTACAATAAGGCTTATGACTTACTA
GCAAGAATTCACCAAGATTTACTTGATAATAAAGGTCGACAAGTTGATTTTGAGGCTTTGGATAACCTG
TTGGAACGACTCAAGGATGTCCCAAGTGATAAAGTCAAGTTAGTGGATGATATTCTTGCCTTCTTAGCT
CCGATTCGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGATGATGAGATTCAA
GTAGCCAAGTTGGCAGGCAAGTACACAACAGAAGACGGTTATATCTTTGATCCTCGTGATATAACCAGT
GATGAGGGGGATGCCTATGTAACTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTCT
GAAGCTGAGAGAGCGGCAGCCCAGGCTTATGCTAAAGAGAAAGGTTTGACCCCTCCTTCGACAGACCA
TCAGGATTCAGGAAATACTGAGGCAAAAGGAGCAGAAGCTATCTACAACCGCGTGAAAGCAGCTAAGA
AGGTGCCACTTGATCGTATGCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTTTAATCA
TACCTCATTATGACCATTACCATAACATCAAATTTGAGTGGTTTGACGAAGGCCTTTATGAGGCACCTA
AGGGGTATACTCTTGAGGATCTTTTGGCGACTGTCAAGTACTATGTCGAACATCCAAACGAACGTCCGC
ATTCAGATAATGGTTTTGGTAACGCTAGCGACCATGTTCGTAAAAATAAGGTAGACCAAGACAGTAAAC
CTGATGAAGATAAGGAACATGATGAAGTAAGTGAGCCAACTCACCCTGAATCTGATGAAAAAGAGAATC
ACGCTGGTTTAAATCCTTCAGCAGATAATCTTTATAAACCAAGCACTGATACGGAAGAGACAGAGGAAG
AAGCTGAAGATACCACAGATGAGGCTGAAATTCCTCAAGTAGAGAATTCTGTTATTAACGCTAAGATAG
CAGATGCGGAGGCCTTGCTAGAAAAAGTAACAGATCCTAGTATTAGACAAAATGCTATGGAGACATTGA
CTGGTCTAAAAAGTAGTCTTCTTCTCGGAACGAAAGATAATAACACTATTTCAGCAGAAGTAGATAGTC
TCTTGGCTTTGTTAAAAGAAAGTCAACCGGCTCCTATACAGTAG 
 pMRH1 F/L PhtD Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPSYELGRHQAGQVKKESNRVSYIDGDQAGQKAENLTPDEVSKREGINAEQIVIKI
TDQGYVTSHGDHYHYYNGKVPYDAIISEELLMKDPNYQLKDSDIVNEIKGGYVIKVDGKYYVYLKDAAHADNIR
TKEEIKRQKQEHSHNHGGGSNDQAVVAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSA
SELAAAEAYWNGKQGSRPSSSSSYNANPAQPRLSENHNLTVTPTYHQNQGENISSLLRELYAKPLSERHVESD
GLIFDPAQITSRTARGVAVPHGNHYHFIPYEQMSELEKRIARIIPLRYRSNHWVPDSRPEQPSPQSTPEPSPSPQ
PAPNPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLSAETAAGIDSKLAKQESLSHKLGAKKTDL
PSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVPSDKVKLVDDILAFLAPIRHPERLGKPNA
QITYTDDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAQAYAKEKGLTP
PSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVKNGSLIIPHYDHYHNIKFEWFDEGLYEAP
KGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVRKNKVDQDSKPDEDKEHDEVSEPTHPESDEKENHAG
LNPSADNLYKPSTDTEETEEEAEDTTDEAEIPQVENSVINAKIADAEALLEKVTDPSIRQNAMETLTGLKSSLLLG
TKDNNTISAEVDSLLALLKESQPAPIQ 
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 pMRH1 F/L PhtD Protein Sequence Minus His6 Tag 
GPSYELGRHQAGQVKKESNRVSYIDGDQAGQKAENLTPDEVSKREGINAEQIVIKITDQGYVTSHGDHYHYYN
GKVPYDAIISEELLMKDPNYQLKDSDIVNEIKGGYVIKVDGKYYVYLKDAAHADNIRTKEEIKRQKQEHSHNHG
GGSNDQAVVAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSASELAAAEAYWNGKQGSR
PSSSSSYNANPAQPRLSENHNLTVTPTYHQNQGENISSLLRELYAKPLSERHVESDGLIFDPAQITSRTARGVAV
PHGNHYHFIPYEQMSELEKRIARIIPLRYRSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVK
EAVRKVGDGYVFEENGVSRYIPAKDLSAETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQ
DLLDNKGRQVDFEALDNLLERLKDVPSDKVKLVDDILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTE
DGYIFDPRDITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIY
NRVKAAKKVPLDRMPYNLQYTVEVKNGSLIIPHYDHYHNIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPN
ERPHSDNGFGNASDHVRKNKVDQDSKPDEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKPSTDTEETEEE
AEDTTDEAEIPQVENSVINAKIADAEALLEKVTDPSIRQNAMETLTGLKSSLLLGTKDNNTISAEVDSLLALLKES
QPAPIQ 
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A.1.3  pMRH2 C-term PhtD Truncate Sequences 
 pMRH2 C-term PhtD Truncate Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGTCAA
ACCATTGGGTACCAGATTCAAGACCAGAACAACCAAGTCCACAATCGACTCCGGAACCTAGTCCAAGTC
CGCAACCTGCACCAAATCCTCAACCAGCTCCAAGCAATCCAATTGATGAGAAATTGGTCAAAGAAGCTG
TTCGAAAAGTAGGCGATGGTTATGTCTTTGAGGAGAATGGAGTTTCTCGTTATATCCCAGCCAAGGAT
CTTTCAGCAGAAACAGCAGCAGGCATTGATAGCAAACTGGCCAAGCAGGAAAGTTTATCTCATAAGCTA
GGAGCTAAGAAAACTGACCTCCCATCTAGTGATCGAGAATTTTACAATAAGGCTTATGACTTACTAGCA
AGAATTCACCAAGATTTACTTGATAATAAAGGTCGACAAGTTGATTTTGAGGCTTTGGATAACCTGTTG
GAACGACTCAAGGATGTCCCAAGTGATAAAGTCAAGTTAGTGGATGATATTCTTGCCTTCTTAGCTCCG
ATTCGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGATGATGAGATTCAAGTA
GCCAAGTTGGCAGGCAAGTACACAACAGAAGACGGTTATATCTTTGATCCTCGTGATATAACCAGTGAT
GAGGGGGATGCCTATGTAACTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTCTGAA
GCTGAGAGAGCGGCAGCCCAGGCTTATGCTAAAGAGAAAGGTTTGACCCCTCCTTCGACAGACCATCA
GGATTCAGGAAATACTGAGGCAAAAGGAGCAGAAGCTATCTACAACCGCGTGAAAGCAGCTAAGAAGG
TGCCACTTGATCGTATGCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTTTAATCATACC
TCATTATGACCATTACCATAACATCAAATTTGAGTGGTTTGACGAAGGCCTTTATGAGGCACCTAAGGG
GTATACTCTTGAGGATCTTTTGGCGACTGTCAAGTACTATGTCGAACATCCAAACGAACGTCCGCATTC
AGATAATGGTTTTGGTAACGCTAGCGACCATGTTCGTAAAAATAAGGTAGACCAAGACAGTAAACCTGA
TGAAGATAAGGAACATGATGAAGTAAGTGAGCCAACTCACCCTGAATCTGATGAAAAAGAGAATCACGC
TGGTTTAAATCCTTCAGCAGATAATCTTTATAAACCAAGCACTGATACGGAAGAGACAGAGGAAGAAGC
TGAAGATACCACAGATGAGGCTGAAATTCCTCAAGTAGAGAATTCTGTTATTAACGCTAAGATAGCAGA
TGCGGAGGCCTTGCTAGAAAAAGTAACAGATCCTAGTATTAGACAAAATGCTATGGAGACATTGACTGG
TCTAAAAAGTAGTCTTCTTCTCGGAACGAAAGATAATAACACTATTTCAGCAGAAGTAGATAGTCTCTT
GGCTTTGTTAAAAGAAAGTCAACCGGCTCCTATACAG 
 pMRH2 C-term PhtD Truncate Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVKEAVRKVGD
GYVFEENGVSRYIPAKDLSAETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGR
QVDFEALDNLLERLKDVPSDKVKLVDDILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPR
DITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKK
VPLDRMPYNLQYTVEVKNGSLIIPHYDHYHNIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNG
FGNASDHVRKNKVDQDSKPDEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKPSTDTEETEEEAEDTTDEA
EIPQVENSVINAKIADAEALLEKVTDPSIRQNAMETLTGLKSSLLLGTKDNNTISAEVDSLLALLKESQPAPIQ 
 pMRH2 C-term PhtD Truncate Protein Sequence Minus His6 Tag 
GPSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLS
AETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVP
SDKVKLVDDILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHS
HWIKKDSLSEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVK
NGSLIIPHYDHYHNIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVRKNKVDQDS
KPDEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKPSTDTEETEEEAEDTTDEAEIPQVENSVINAKIADAEA
LLEKVTDPSIRQNAMETLTGLKSSLLLGTKDNNTISAEVDSLLALLKESQPAPIQ 
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A.1.4  pMRH3 ΔC-term PhtD Truncate Sequences 
 pMRH3 ΔC-term PhtD Truncate Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGTCAA
ACCATTGGGTACCAGATTCAAGACCAGAACAACCAAGTCCACAATCGACTCCGGAACCTAGTCCAAGTC
CGCAACCTGCACCAAATCCTCAACCAGCTCCAAGCAATCCAATTGATGAGAAATTGGTCAAAGAAGCTG
TTCGAAAAGTAGGCGATGGTTATGTCTTTGAGGAGAATGGAGTTTCTCGTTATATCCCAGCCAAGGAT
CTTTCAGCAGAAACAGCAGCAGGCATTGATAGCAAACTGGCCAAGCAGGAAAGTTTATCTCATAAGCTA
GGAGCTAAGAAAACTGACCTCCCATCTAGTGATCGAGAATTTTACAATAAGGCTTATGACTTACTAGCA
AGAATTCACCAAGATTTACTTGATAATAAAGGTCGACAAGTTGATTTTGAGGCTTTGGATAACCTGTTG
GAACGACTCAAGGATGTCCCAAGTGATAAAGTCAAGTTAGTGGATGATATTCTTGCCTTCTTAGCTCCG
ATTCGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGATGATGAGATTCAAGTA
GCCAAGTTGGCAGGCAAGTACACAACAGAAGACGGTTATATCTTTGATCCTCGTGATATAACCAGTGAT
GAGGGGGATGCCTATGTAACTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTCTGAA
GCTGAGAGAGCGGCAGCCCAGGCTTATGCTAAAGAGAAAGGTTTGACCCCTCCTTCGACAGACCATCA
GGATTCAGGAAATACTGAGGCAAAAGGAGCAGAAGCTATCTACAACCGCGTGAAAGCAGCTAAGAAGG
TGCCACTTGATCGTATGCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTTTAATCATACC
TCATTATGACCATTACCATAACATCAAATTTGAGTGGTTTGACGAAGGCCTTTATGAGGCACCTAAGGG
GTATACTCTTGAGGATCTTTTGGCGACTGTCAAGTACTATGTCGAACATCCAAACGAACGTCCGCATTC
AGATAATGGTTTTGGTAACGCTAGCGACCATGTTCGTAAAAATAAGGTAGACCAAGACAGTAAACCTGA
TGAAGATAAGGAACATGATGAAGTAAGTGAGCCAACTCACCCTGAATCTGATGAAAAAGAGAATCACGC
TGGTTTAAATCCTTCAGCAGATAATCTTTATAAACCAAGCACTGATACGGAAGAGACAGAGGAAGAAGC
TGAAGATACCACAGATGAGGCTGAAATTCCTCAAGTAGAGAATTCTGTTATTAACGCTAAGATAGCAGA
TGCGGAGGCCTTGCTAGAAAAA 
 pMRH3 ΔC-term PhtD Truncate Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVKEAVRKVGD
GYVFEENGVSRYIPAKDLSAETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGR
QVDFEALDNLLERLKDVPSDKVKLVDDILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPR
DITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKK
VPLDRMPYNLQYTVEVKNGSLIIPHYDHYHNIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNG
FGNASDHVRKNKVDQDSKPDEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKPSTDTEETEEEAEDTTDEA
EIPQVENSVINAKIADAEALLEK 
 pMRH3 ΔC-term PhtD Truncate Protein Sequence Minus His6 Tag 
GPSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLS
AETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVP
SDKVKLVDDILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHS
HWIKKDSLSEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVK
NGSLIIPHYDHYHNIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVRKNKVDQDS
KPDEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKPSTDTEETEEEAEDTTDEAEIPQVENSVINAKIADAEA
LLEK 
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A.1.5  pMRH4 5.3 kDa C-terminal PhtD Truncate Sequences 
 pMRH4 5.3 kDa C-terminal PhtD Truncate Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGGTAACAGATCCT
AGTATTAGACAAAATGCTATGGAGACATTGACTGGTCTAAAAAGTAGTCTTCTTCTCGGAACGAAAGAT
AATAACACTATTTCAGCAGAAGTAGATAGTCTCTTGGCTTTGTTAAAAGAAAGTCAACCGGCTCCTATA
CAG 
 pMRH4 5.3 kDa C-terminal PhtD Truncate Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPVTDPSIRQNAMETLTGLKSSLLLGTKDNNTISAEVDSLLALLKESQPAPIQ 
 pMRH4 5.3 kDa C-terminal PhtD Truncate Protein Sequence Minus His6 
Tag 
GPVTDPSIRQNAMETLTGLKSSLLLGTKDNNTISAEVDSLLALLKESQPAPIQ 
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A.1.6  pMRH6 34 kDa PhtD Truncate Sequences 
 pMRH6 34 kDa PhtD Truncate Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGTCAA
ACCATTGGGTACCAGATTCAAGACCAGAACAACCAAGTCCACAATCGACTCCGGAACCTAGTCCAAGTC
CGCAACCTGCACCAAATCCTCAACCAGCTCCAAGCAATCCAATTGATGAGAAATTGGTCAAAGAAGCTG
TTCGAAAAGTAGGCGATGGTTATGTCTTTGAGGAGAATGGAGTTTCTCGTTATATCCCAGCCAAGGAT
CTTTCAGCAGAAACAGCAGCAGGCATTGATAGCAAACTGGCCAAGCAGGAAAGTTTATCTCATAAGCTA
GGAGCTAAGAAAACTGACCTCCCATCTAGTGATCGAGAATTTTACAATAAGGCTTATGACTTACTAGCA
AGAATTCACCAAGATTTACTTGATAATAAAGGTCGACAAGTTGATTTTGAGGCTTTGGATAACCTGTTG
GAACGACTCAAGGATGTCCCAAGTGATAAAGTCAAGTTAGTGGATGATATTCTTGCCTTCTTAGCTCCG
ATTCGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGATGATGAGATTCAAGTA
GCCAAGTTGGCAGGCAAGTACACAACAGAAGACGGTTATATCTTTGATCCTCGTGATATAACCAGTGAT
GAGGGGGATGCCTATGTAACTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTTGTCTGAA
GCTGAGAGAGCGGCAGCCCAGGCTTATGCTAAAGAGAAAGGTTTGACCCCTCCTTCGACAGACCATCA
GGATTCAGGAAATACTGAGGCAAAAGGAGCAGAAGCTATCTACAACCGCGTGAAAGCAGCTAAGAAGG
TGCCACTTGATCGTATGCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTTTAATCATACC
TCATTATGACCATTACCATAAC 
 pMRH6 34 kDa PhtD Truncate Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVKEAVRKVGD
GYVFEENGVSRYIPAKDLSAETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGR
QVDFEALDNLLERLKDVPSDKVKLVDDILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPR
DITSDEGDAYVTPHMTHSHWIKKDSLSEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKK
VPLDRMPYNLQYTVEVKNGSLIIPHYDHYHN 
 pMRH6 34 kDa PhtD Truncate Protein Sequence Minus His6 Tag 
GPSNHWVPDSRPEQPSPQSTPEPSPSPQPAPNPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLS
AETAAGIDSKLAKQESLSHKLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVP
SDKVKLVDDILAFLAPIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHS
HWIKKDSLSEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVK
NGSLIIPHYDHYHN 
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A.1.7  pMRH7 PhtD Epitope Truncate Sequences 
 pMRH7 PhtD Epitope Truncate  Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGATCAAATTTGAG
TGGTTTGACGAAGGCCTTTATGAGGCACCTAAGGGGTATACTCTTGAGGATCTTTTGGCGACTGTCAA
GTACTATGTCGAACATCCAAACGAACGTCCGCATTCAGATAATGGTTTTGGTAACGCTAGCGACCATGT
TCGTAAAAATAAGGTAGACCAAGACAGTAAACCTGATGAAGATAAGGAACATGATGAAGTAAGTGAGCC
AACTCACCCTGAATCTGATGAAAAAGAGAATCACGCTGGTTTAAATCCTTCAGCAGATAATCTTTATAAA
CCAAGCACTGATACGGAAGAGACAGAGGAAGAAGCTGAAGATACCACAGATGAGGCTGAAATTCCTCA
AGTAGAGAATTCTGTTATTAACGCTAAGATAGCAGATGCGGAGGCCTTGCTAGAAAAA 
 pMRH7 PhtD Epitope Truncate Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVRKN
KVDQDSKPDEDKEHDEVSEPTHPESDEKENHAGLNPSADNLYKPSTDTEETEEEAEDTTDEAEIPQVENSVINA
KIADAEALLEK 
 pMRH7 PhtD Epitope Truncate Protein Sequence Minus His6 tag 
GPIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVRKNKVDQDSKPDEDKEHDEV
SEPTHPESDEKENHAGLNPSADNLYKPSTDTEETEEEAEDTTDEAEIPQVENSVINAKIADAEALLEK 
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A.1.8  PpmA (SP_0981) TIGR4 Natural Sequences 
 PpmA Nucleotide Sequence 
ATGAAGAAAAAATTATTGGCAGGTGCCATCACACTATTATCAGTAGCAACTTTAGCAGCTTGTTCGAAA
GGGTCAGAAGGTGCAGACCTTATCAGCATGAAAGGGGATGTCATTACAGAACATCAATTTTATGAGCAA
GTGAAAAGCAACCCTTCAGCCCAACAAGTCTTGTTAAATATGACCATCCAAAAAGTTTTTGAAAAACAAT
ATGGCTCAGAGCTTGATGATAAAGAGGTTGATGATACTATTGCCGAAGAAAAAAAACAATATGGCGAAA
ACTACCAACGTGTCTTGTCACAAGCAGGTATGACTCTTGAAACACGTAAAGCTCAAATTCGTACAAGTA
AATTAGTTGAGTTGGCAGTTAAGAAGGTAGCAGAAGCTGAATTGACAGATGAAGCCTATAAGAAAGCC
TTTGATGAGTACACTCCAGATGTAACGGCTCAAATCATCCGTCTTAATAATGAAGATAAGGCCAAAGAA
GTTCTCGAAAAAGCCAAGGCAGAAGGTGCTGATTTTGCTCAATTAGCCAAAGATAATTCAACTGATGAA
AAAACAAAAGAAAATGGTGGAGAAATTACCTTTGATTCTGCTTCAACAGAAGTACCTGAGCAAGTCAAA
AAAGCCGCTTTCGCTTTAGATGTGGATGGTGTTTCTGATGTGATTACAGCAACTGGCACACAAGCCTAC
AGTAGCCAATATTACATTGTAAAACTCACTAAGAAAACAGAAAAATCATCTAATATTGATGACTACAAAG
AAAAATTAAAAACTGTTATCTTGACTCAAAAACAAAATGATTCAACATTTGTTCAAAGCATTATCGGAAA
AGAATTGCAAGCAGCCAATATCAAGGTTAAGGACCAAGCCTTCCAAAATATCTTTACCCAATATATCGG
TGGTGGAGATTCAAGCTCAAGCAGTAGTACATCAAACGAATAG 
 PpmA Protein Sequence 
MKKKLLAGAITLLSVATLAACSKGSEGADLISMKGDVITEHQFYEQVKSNPSAQQVLLNMTIQKVFEKQYGSEL
DDKEVDDTIAEEKKQYGENYQRVLSQAGMTLETRKAQIRTSKLVELAVKKVAEAELTDEAYKKAFDEYTPDVT
AQIIRLNNEDKAKEVLEKAKAEGADFAQLAKDNSTDEKTKENGGEITFDSASTEVPEQVKKAAFALDVDGVSDV
ITATGTQAYSSQYYIVKLTKKTEKSSNIDDYKEKLKTVILTQKQNDSTFVQSIIGKELQAANIKVKDQAFQNIFTQ
YIGGGDSSSSSSTSNE 
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A.1.9  PpmA Expression Construct Sequences 
 PpmA Expression Construct Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGAAGAAAAAATTA
TTGGCAGGTGCCATCACACTATTATCAGTAGCAACTTTAGCAGCTTGTTCGAAAGGGTCAGAAGGTGC
AGACCTTATCAGCATGAAAGGGGATGTCATTACAGAACATCAATTTTATGAGCAAGTGAAAAGCAACCC
TTCAGCCCAACAAGTCTTGTTAAATATGACCATCCAAAAAGTTTTTGAAAAACAATATGGCTCAGAGCTT
GATGATAAAGAGGTTGATGATACTATTGCCGAAGAAAAAAAACAATATGGCGAAAACTACCAACGTGTC
TTGTCACAAGCAGGTATGACTCTTGAAACACGTAAAGCTCAAATTCGTACAAGTAAATTAGTTGAGTTG
GCAGTTAAGAAGGTAGCAGAAGCTGAATTGACAGATGAAGCCTATAAGAAAGCCTTTGATGAGTACACT
CCAGATGTAACGGCTCAAATCATCCGTCTTAATAATGAAGATAAGGCCAAAGAAGTTCTCGAAAAAGCC
AAGGCAGAAGGTGCTGATTTTGCTCAATTAGCCAAAGATAATTCAACTGATGAAAAAACAAAAGAAAAT
GGTGGAGAAATTACCTTTGATTCTGCTTCAACAGAAGTACCTGAGCAAGTCAAAAAAGCCGCTTTCGCT
TTAGATGTGGATGGTGTTTCTGATGTGATTACAGCAACTGGCACACAAGCCTACAGTAGCCAATATTAC
ATTGTAAAACTCACTAAGAAAACAGAAAAATCATCTAATATTGATGACTACAAAGAAAAATTAAAAACTG
TTATCTTGACTCAAAAACAAAATGATTCAACATTTGTTCAAAGCATTATCGGAAAAGAATTGCAAGCAGC
CAATATCAAGGTTAAGGACCAAGCCTTCCAAAATATCTTTACCCAATATATCGGTGGTGGAGATTCAAG
CTCAAGCAGTAGTACATCAAACGAATAG 
 PpmA Expression Construct Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPKKKLLAGAITLLSVATLAACSKGSEGADLISMKGDVITEHQFYEQVKSNPSAQQ
VLLNMTIQKVFEKQYGSELDDKEVDDTIAEEKKQYGENYQRVLSQAGMTLETRKAQIRTSKLVELAVKKVAEAE
LTDEAYKKAFDEYTPDVTAQIIRLNNEDKAKEVLEKAKAEGADFAQLAKDNSTDEKTKENGGEITFDSASTEVP
EQVKKAAFALDVDGVSDVITATGTQAYSSQYYIVKLTKKTEKSSNIDDYKEKLKTVILTQKQNDSTFVQSIIGKEL
QAANIKVKDQAFQNIFTQYIGGGDSSSSSSTSNE 
 PpmA Expression Construct Protein Sequence Minus His6 Tag 
GPKKKLLAGAITLLSVATLAACSKGSEGADLISMKGDVITEHQFYEQVKSNPSAQQVLLNMTIQKVFEKQYGSE
LDDKEVDDTIAEEKKQYGENYQRVLSQAGMTLETRKAQIRTSKLVELAVKKVAEAELTDEAYKKAFDEYTPDV
TAQIIRLNNEDKAKEVLEKAKAEGADFAQLAKDNSTDEKTKENGGEITFDSASTEVPEQVKKAAFALDVDGVSD
VITATGTQAYSSQYYIVKLTKKTEKSSNIDDYKEKLKTVILTQKQNDSTFVQSIIGKELQAANIKVKDQAFQNIFT
QYIGGGDSSSSSSTSNE 
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A.1.10 TktA (LSL_1946) L. salivarius Natural Sequences 
 TktA Nucleotide Sequence 
ATGTATGATCAAGTAGACCAATTGGGAGTAAATACTCTTAGAACATTATCAATCGACGCAATCCAAAGA
GCTAACTCAGGTCATCCAGGTTTACCAATGGGAGCGGCACCAATGGCATATGTCCTATGGACACGTCAT
TTAAAAATTAATCCTAAAACACATATGAACTGGGTAAATAGAGATAGATTTGTTTTATCGGCAGGACAT
GGTTCAGCTTTACTATATAGTTTGGCACATTTAGCTGGATATGATGTTTCAATGGATGATTTGAAGAAT
TTTAGAGAATGGAAATCTAATACACCAGGACATCCTGAATATGGTTGTACCGATGGAGTGGAAGCTACA
ACAGGGCCATTAGGTCAAGGAATTTCAATGGCTGTAGGAATGGCGATGGCTGAAGCTCATCTAGGTAA
GAAATTTAACCGTGAAGGTTACCCAGTAATGGATCATTATACATACGCTTTAATTGGCGATGGTGATTT
AATGGAAGGTGTCGCTAGTGAAGCAGCGTCATTGGCAGGTCATTTGAAATTAGGTAAGTTAATTGCTT
TGTATGATTCAAATGGAATTTCTTTAGATGGTAAAACTTCAGCATCATTTACAGAAAATGTAGGAGCTC
GTTTTGAAGCTTATGGCTGGCAATATATTCTAGTAGAAGATGGTTTCAATCTCGAAGAGATTGATAAAG
CAATTGTTCAAGCAAAAGCAGAAAGTGATAAGCCAACAATTATTGAAATAAAAACTACAATTGGTTATG
GTTCAGAAAATCAAGGTACACATAAAGTACATGGAAGTCCTCTTGGTGAAGAAGGAGTAGCACACGCTA
AAGAAGTATATAACTGGAATTATCCACCATTTACAGTACCTGAAGAAGTAAGTCAAAGATTTAAAGAAT
GCTTACAAGATAAGGGTGTTAAAGCAGAAAATAAGTGGAATGAAATGTTTGAAGCATATAAAAAAGAAT
ATTCAGATCTTGCACAAAAGTTTTCCGACGGCTTTTCTAACAAGGTTCCAAATACTCTTGGAGACATTTT
ACCACAATATGGAGAAGATGACAGTATCGCAACACGTGCAGCTAGTCAAAAAGCAATTAATGCTTTGGC
TAAAGAAGTATCATCACTTTGGGGTGGGGCAGCTGATTTAGCTAGTTCGAATAAAACAGTAATTGCTG
GAGAAGGTGATTTCCAACCTGAATCATATGAAGGAAGAAATATTTGGTTTGGGGTTCGAGAATTTGGA
ATGGCATGTGCGATGAATGGAATCATGTTACATGGAGGGACACGAATATTCGGAAGTACGTTCTTTGT
ATTTAGTGATTATTTAAAAGCGGCAATTCGTTTATCTGCCATTCAAAAATTACCAGTAATTTATGTTTTA
ACTCACGATTCAGTGGCAGTAGGAAAAGACGGTCCAACTCATGAACCAATTGAACAACTAGCAAGTTTA
AGAACGATTCCAAATGTCCAGGTATTTCGCCCAGCAGATGGAAATGAAACATCAGCAGCCTGGAAAGTG
GCATTAGAAACCTTAGATAAACCAACAATCTTAGTTTTGAGTCGCCAAAACTTAGATACACTACCAATTT
CAAAAGAAAAAGTTTTTGATGGGGTAGAAAAAGGTGGGTATGTAGTTCAAGGAGCTGAAAATGAAGCC
GATGGAATTTTGATTGCCACAGGTTCAGAAGTAGGTTTAGCTTTGAAAGCTAAAGAAGAACTACAAAAG
AAAGGTAAAGATGTAATTGTAGTTTCATTACCTAGTTGGGAAAGATTTGAAGCTCAAAGTGAAGAATAT
AAGAATACGGTCATCCCTCCAGAACTTAAGAAACGCATGACAATTGAAGCAGGTACAACATATGGTTGG 
GCTAAATATGCAGGAGATCATGGAGTGATGATAGGGATAGATGAATTCGGAATGTCAGCTCCAAGTGA
CATAGTCCTAAGAGAACTAGGAATGAGTGTAGAAAATATCGTTGATAAATATTTGGAAAAATAA 
 
TktA Protein Sequence 
MYDQVDQLGVNTLRTLSIDAIQRANSGHPGLPMGAAPMAYVLWTRHLKINPKTHMNWVNRDRFVLSAGHGS
ALLYSLAHLAGYDVSMDDLKNFREWKSNTPGHPEYGCTDGVEATTGPLGQGISMAVGMAMAEAHLGKKFNR
EGYPVMDHYTYALIGDGDLMEGVASEAASLAGHLKLGKLIALYDSNGISLDGKTSASFTENVGARFEAYGWQY
ILVEDGFNLEEIDKAIVQAKAESDKPTIIEIKTTIGYGSENQGTHKVHGSPLGEEGVAHAKEVYNWNYPPFTVPE
EVSQRFKECLQDKGVKAENKWNEMFEAYKKEYSDLAQKFSDGFSNKVPNTLGDILPQYGEDDSIATRAASQKA
INALAKEVSSLWGGAADLASSNKTVIAGEGDFQPESYEGRNIWFGVREFGMACAMNGIMLHGGTRIFGSTFFV
FSDYLKAAIRLSAIQKLPVIYVLTHDSVAVGKDGPTHEPIEQLASLRTIPNVQVFRPADGNETSAAWKVALETLD
KPTILVLSRQNLDTLPISKEKVFDGVEKGGYVVQGAENEADGILIATGSEVGLALKAKEELQKKGKDVIVVSLPS
WERFEAQSEEYKNTVIPPELKKRMTIEAGTTYGWAKYAGDHGVMIGIDEFGMSAPSDIVLRELGMSVENIVDKY 
LEK 
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A.1.11 TktA Expression Construct Sequences 
TktA Expression Construct Nucleotide Sequence 
ATGGCACACCATCACCACCATCACAGCAGCGGTCTGGAAGTTCTGTTTCAGGGCCCGTATGATCAAGTA
GACCAATTGGGAGTAAATACTCTTAGAACATTATCAATCGACGCAATCCAAAGAGCTAACTCAGGTCAT
CCAGGTTTACCAATGGGAGCGGCACCAATGGCATATGTCCTATGGACACGTCATTTAAAAATTAATCCT
AAAACACATATGAACTGGGTAAATAGAGATAGATTTGTTTTATCGGCAGGACATGGTTCAGCTTTACTA
TATAGTTTGGCACATTTAGCTGGATATGATGTTTCAATGGATGATTTGAAGAATTTTAGAGAATGGAAA
TCTAATACACCAGGACATCCTGAATATGGTTGTACCGATGGAGTGGAAGCTACAACAGGGCCATTAGG
TCAAGGAATTTCAATGGCTGTAGGAATGGCGATGGCTGAAGCTCATCTAGGTAAGAAATTTAACCGTG
AAGGTTACCCAGTAATGGATCATTATACATACGCTTTAATTGGCGATGGTGATTTAATGGAAGGTGTCG
CTAGTGAAGCAGCGTCATTGGCAGGTCATTTGAAATTAGGTAAGTTAATTGCTTTGTATGATTCAAATG
GAATTTCTTTAGATGGTAAAACTTCAGCATCATTTACAGAAAATGTAGGAGCTCGTTTTGAAGCTTATG
GCTGGCAATATATTCTAGTAGAAGATGGTTTCAATCTCGAAGAGATTGATAAAGCAATTGTTCAAGCAA
AAGCAGAAAGTGATAAGCCAACAATTATTGAAATAAAAACTACAATTGGTTATGGTTCAGAAAATCAAG
GTACACATAAAGTACATGGAAGTCCTCTTGGTGAAGAAGGAGTAGCACACGCTAAAGAAGTATATAACT
GGAATTATCCACCATTTACAGTACCTGAAGAAGTAAGTCAAAGATTTAAAGAATGCTTACAAGATAAGG
GTGTTAAAGCAGAAAATAAGTGGAATGAAATGTTTGAAGCATATAAAAAAGAATATTCAGATCTTGCAC
AAAAGTTTTCCGACGGCTTTTCTAACAAGGTTCCAAATACTCTTGGAGACATTTTACCACAATATGGAG
AAGATGACAGTATCGCAACACGTGCAGCTAGTCAAAAAGCAATTAATGCTTTGGCTAAAGAAGTATCAT
CACTTTGGGGTGGGGCAGCTGATTTAGCTAGTTCGAATAAAACAGTAATTGCTGGAGAAGGTGATTTC
CAACCTGAATCATATGAAGGAAGAAATATTTGGTTTGGGGTTCGAGAATTTGGAATGGCATGTGCGAT
GAATGGAATCATGTTACATGGAGGGACACGAATATTCGGAAGTACGTTCTTTGTATTTAGTGATTATTT
AAAAGCGGCAATTCGTTTATCTGCCATTCAAAAATTACCAGTAATTTATGTTTTAACTCACGATTCAGTG
GCAGTAGGAAAAGACGGTCCAACTCATGAACCAATTGAACAACTAGCAAGTTTAAGAACGATTCCAAAT
GTCCAGGTATTTCGCCCAGCAGATGGAAATGAAACATCAGCAGCCTGGAAAGTGGCATTAGAAACCTTA
GATAAACCAACAATCTTAGTTTTGAGTCGCCAAAACTTAGATACACTACCAATTTCAAAAGAAAAAGTTT
TTGATGGGGTAGAAAAAGGTGGGTATGTAGTTCAAGGAGCTGAAAATGAAGCCGATGGAATTTTGATT
GCCACAGGTTCAGAAGTAGGTTTAGCTTTGAAAGCTAAAGAAGAACTACAAAAGAAAGGTAAAGATGTA
ATTGTAGTTTCATTACCTAGTTGGGAAAGATTTGAAGCTCAAAGTGAAGAATATAAGAATACGGTCATC
CCTCCAGAACTTAAGAAACGCATGACAATTGAAGCAGGTACAACATATGGTTGGGCTAAATATGCAGGA
GATCATGGAGTGATGATAGGGATAGATGAATTCGGAATGTCAGCTCCAAGTGACATAGTCCTAAGAGA
ACTAGGAATGAGTGTAGAAAATATCGTTGATAAATATTTGGAAAAATAA 
 
TktA Expression Construct Protein Sequence With His6 Tag 
MAHHHHHHSSGLEVLFQGPYDQVDQLGVNTLRTLSIDAIQRANSGHPGLPMGAAPMAYVLWTRHLKINPKT
HMNWVNRDRFVLSAGHGSALLYSLAHLAGYDVSMDDLKNFREWKSNTPGHPEYGCTDGVEATTGPLGQGIS
MAVGMAMAEAHLGKKFNREGYPVMDHYTYALIGDGDLMEGVASEAASLAGHLKLGKLIALYDSNGISLDGKT
SASFTENVGARFEAYGWQYILVEDGFNLEEIDKAIVQAKAESDKPTIIEIKTTIGYGSENQGTHKVHGSPLGEEG
VAHAKEVYNWNYPPFTVPEEVSQRFKECLQDKGVKAENKWNEMFEAYKKEYSDLAQKFSDGFSNKVPNTLG
DILPQYGEDDSIATRAASQKAINALAKEVSSLWGGAADLASSNKTVIAGEGDFQPESYEGRNIWFGVREFGMAC
AMNGIMLHGGTRIFGSTFFVFSDYLKAAIRLSAIQKLPVIYVLTHDSVAVGKDGPTHEPIEQLASLRTIPNVQVFR
PADGNETSAAWKVALETLDKPTILVLSRQNLDTLPISKEKVFDGVEKGGYVVQGAENEADGILIATGSEVGLAL
KAKEELQKKGKDVIVVSLPSWERFEAQSEEYKNTVIPPELKKRMTIEAGTTYGWAKYAGDHGVMIGIDEFGMS
APSDIVLRELGMSVENIVDKYLEK 
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TktA Expression Construct Protein Sequence Minus His6 Tag 
GPYDQVDQLGVNTLRTLSIDAIQRANSGHPGLPMGAAPMAYVLWTRHLKINPKTHMNWVNRDRFVLSAGHG
SALLYSLAHLAGYDVSMDDLKNFREWKSNTPGHPEYGCTDGVEATTGPLGQGISMAVGMAMAEAHLGKKFN
REGYPVMDHYTYALIGDGDLMEGVASEAASLAGHLKLGKLIALYDSNGISLDGKTSASFTENVGARFEAYGWQ
YILVEDGFNLEEIDKAIVQAKAESDKPTIIEIKTTIGYGSENQGTHKVHGSPLGEEGVAHAKEVYNWNYPPFTVP
EEVSQRFKECLQDKGVKAENKWNEMFEAYKKEYSDLAQKFSDGFSNKVPNTLGDILPQYGEDDSIATRAASQK
AINALAKEVSSLWGGAADLASSNKTVIAGEGDFQPESYEGRNIWFGVREFGMACAMNGIMLHGGTRIFGSTFF
VFSDYLKAAIRLSAIQKLPVIYVLTHDSVAVGKDGPTHEPIEQLASLRTIPNVQVFRPADGNETSAAWKVALETL
DKPTILVLSRQNLDTLPISKEKVFDGVEKGGYVVQGAENEADGILIATGSEVGLALKAKEELQKKGKDVIVVSLP
SWERFEAQSEEYKNTVIPPELKKRMTIEAGTTYGWAKYAGDHGVMIGIDEFGMSAPSDIVLRELGMSVENIVDK
Y 
LEK 
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A.2  DNA And Protein Molecular Weight Standards 
A.2.1  DNA Molecular Weight Standards 
 1Kb Plus DNA Ladder (Invitrogen) 
1Kb Plus DNA ladder (figure A.1) is supplied at a concentration of 1µg/µl and 
can be used to size DNA products ranging from 100bp – 12Kb. A working stock 
was made by diluting the marker 1 in 10 to a final concentration of 0.1µg/µl 
with 1xDNA loading dye. 0.3µg marker was used when running agarose gels 
for DNA analysis. 
 
Figure A. 1: 1Kb Plus DNA ladder  
(Image reproduced from Invitrogen product documentation) 
 198 
A.2.2  Protein Molecular Weight Standards 
 SeeBlue® Plus2 Pre-Stained Standards (Invitrogen) 
SeeBlue® Plus2 molecular weight standards (figure A.2) are supplied as a pre-
stained solution of 12 proteins of known molecular weight for visualisation of 
sample migration and estimation of molecular weight by SDS-PAGE analysis. 
5µl of SeeBlue® Plus2 standards were run for 15-lane 4-12% Bis-Tris SDS gels. 
All SDS gels were run in 1xMES buffer. 
 
Figure A. 2: SeeBlue Plus2 protein molecular weight standards 
(Image reproduced from Invitrogen product documentation) 
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A.3  Selected Standard Operating Protocols (SOPs) 
Devised By The Mitchell Group 
A.3.1  Preparation Of Pneumococcal Genomic DNA 
Notes 
To avoid contamination it is best to use filter tips throughout this work. 
It may be useful to prepare DNA from sterile medium in parallel wit proper 
samples to confirm the absence of contamination during the process e.g. 
when investigating the presence/absence of gene(s) in several strains at one 
time. 
Autoclave buffers beforehand to limit contamination of samples. 
Protocol 
1. Grow culture. An overnight culture of 20ml BHI typically gives 
sufficient yield for most purposes. Aseptically streak a loopful onto a 
BAB plate and add optochin disc (incubate O/N, this will confirm the 
purity and identity of the culture). 
2. Spin down culture, 4000rpm, 15mins, 4oC. Sometimes culture doesn’t 
pellet well after first spin. If so, a second spin as above usually works. 
3. Remove supernatant. Pellet is fragile so be careful not to disturb cells. 
4. Resuspend pellet in 1ml lysis buffer (see below). 
5. Transfer to eppendorf and incubate at 37oC for 1hr. 
6. Add proteinase K to final concentration of 100µg/ml (5µl/ml from a 
20mg/ml stock). 
7. Incubate in H2O bath at 50oC for 3hrs. 
8. Add RNase A to a final concentration of 20µg/ml (2µl/ml of a 10mg/ml 
stock).*** 
9. Incubate at 37oC for 30mins. 
10. Add equal volume of phenol:chloroform:IAA (25:24:1). Due to volume 
involved may have to split samples into two tubes. Several types of 
eppendorf are not suitable for use with phenol (they degrade/melt 
leading to loss of sample and phenol contamination of lab equipment). 
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If in doubt, cryotubes are usually fine. Take from the lower phase of 
the phenol:chloroform:IAA solution or mix well first. 
11. Mix by inverting the tubes sharply several times. Vortex mixing is not 
required and may cause shearing of the DNA and loss of quality. 
12. Spin at 13000rpm, 3mins. 
13. Remove as much of the upper phase as possible without disturbing the 
lower phase, and add to fresh eppendorf. Pool samples if previously 
split. 
14. Add 0.2 volumes 10M ammonium acetate (e.g. 20µl to 100µl). 
15. Add ~600µl absolute ethanol (analytical reagent grade) 
16. Gently invert the tubes and the ‘clouds’ of DNA often but not always 
become visible. 
17. Spin for 30mins at 13000rpm. This pellets the DNA (It may be useful to 
put all the tubes in at the same angle so you know where the pellet 
will be). 
18. Remove supernatant. Be careful to leave DNA pellet. 
19. Air-dry for 15-20mins upside-down on a paper towel. Over-drying may 
make it hard to re-dissolve the DNA. 
20. Remove any remaining ethanol. 
21. Re-suspend in TE buffer (100-300µl). If gently pipetting up and down to 
re-suspend take care not to remove DNA. 
22. Incubate in 65oC H2O bath for 10mins. Gently flick bottom of tube with 
fingers every few minutes to help dissolve DNA. As well as helping to 
dissolve the DNA it may also inactivate DNase present in the sample. 
23. Store at 4oC. Store at -20oC long-term, but avoid frequent freeze 
thawing, which leads to shearing of the DNA (store in small aliquots). 
Lysis Buffer (1ml. Make up fresh before use) 
10µl 1M Tris pH 8.0, 200µl 500mM EDTA, 50µl 10% SDS (w/v), 740µl ddH2O 
***RNase must be boiled to ensure it is DNase free. 
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A.3.2  Western Blot 
Buffers 
Transfer Buffer: 25ml 1xNuPAGE transfer buffer (Invitrogen), 50ml methanol, 
425ml dH2O. 
Tris NaCl pH7.4: Tris base 1.2g, NaCl 8.7g. Make to 1L with dH2O and pH with 
800µl conc. HCl. 
Developer: Dissolve 30mg 4chloro-1-napthol in 10ml methanol, add 40ml Tris 
NaCl pH7.4, add 30µl H2O2 (30% w/v) 
Day 1 
1. Run samples on SDS-PAGE 
2. Equilibrate gel for 30mins in transfer buffer 
3. Cut 2 x (gel size) filter paper and 1 x membrane per blot 
4. Soak membrane, filter-paper and pads in transfer buffer. 
5. Assemble cassette as follows: pads/paper/gel/membrane/paper/pads. 
Place in gel-tank and fill with transfer buffer. Surround with cold 
water to keep cool. 
6. Blot at 30V for 1hr using Xcell II blotting module (Invitrogen). 
7. Transfer membrane to 3% skimmed milk (1.5g in 50ml Tris NaCl pH 7.4) 
and block O/N at 4oC. 
Day 2 
1. Transfer membrane to 3% skimmed milk containing 1/x dilution of 1o 
antibody* 
2. Shake at 37oC for 2-3hr 
 202 
3. Wash x 4 with 40ml Tris NaCl pH7.4 for 5mins 
4. Transfer membrane to 3% skimmed milk containing 1/x dilution of 2o 
antibody* (HRP labelled) 
5. Shake at 37oC for 1hr 
6. Wash x 4 with 40ml Tris NaCl pH7.4 for 5mins. 
7. Develop in dark and stop with dH2O 
X = dilution factor appropriate for Ab being used – 1o Ab should be titrated, 
instructions for use of 2o Ab are provided by supplier. 
* Ab solutions can be stored at -20oC and reused. 
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A.4  Molecular Biology Kit Protocols 
N.B. All buffers used were supplied with the relevant kits. In all cases, the 
supplied elution buffer was substituted with DNase/RNase free PCR grade 
H2O.  
13,000rpm = 17,900 x g 
A.4.1  QIAquick® PCR Purification Kit Protocol 
• Add 5 volumes of buffer PB to 1 volume of the PCR sample and mix. 
• Place a QIAquick spin column in a provided 2ml collection tube. 
• To bind DNA, apply the sample to the QIAquick column and centrifuge 
at 13,000rpm for 30-60secs.  
• Discard flow-through. Place QIAquick column back into the same tube. 
• To wash, add 0.75ml buffer PE to the QIAquick column and centrifuge 
at 13,000rpm for 30-60secs. 
• Discard flow-through and place the column back in the same tube. 
Centrifuge the column for an additional 1min. 
• Place the QIAquick column in a clean 1.5ml microcentrifuge tube. 
• To elute DNA, add 50µl warmed sterile DNase/RNase free H2O to the 
centre of the QIAquick membrane, let stand for 1min, then centrifuge 
at 13,000rpm for 1min. 
 
A.4.2  QIAquick® Gel Extraction Kit Protocol 
• Excise the DNA fragment from the agarose gel with a clean, sharp 
scalpel. 
• Weigh the gel slice in a colourless tube. Add 3 volumes of buffer QG to 
1 volume of gel (100mg ~ 100µl). 
• Incubate at 50oC for 10min (or until the gel slice has completely 
dissolved). To help dissolve gel, mix by vortexing every 2-3min during 
the incubation. 
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• After the gel slice has dissolved completely, check that the colour of 
the mixture is yellow (similar to buffer QG without dissolved agarose). 
• Add 1 gel volume of isopropanol to the sample and mix. Do not 
centrifuge the sample at this stage. 
• Place a QIAquick spin column in a provided 2ml collection tube. 
• To bind DNA, apply the sample to the QIAquick column and centrifuge 
at 13,000rpm for 1min. 
• Discard flow-through and place QIAquick column back in the same 
collection tube. 
• Recommended: Add 0.5ml of buffer QG to QIAquick column and 
centrifuge at 13,000rpm for 1min. This will remove all traces of 
agarose. 
• To wash, add 0.75ml of buffer PE to the QIAquick column and 
centrifuge at 13,000rpm for 1min. 
• Discard the flow-through and centrifuge the QIAquick column for an 
additional 1min at 13,000rpm. 
• Place the QIAquick column into a clean 1.5ml microcentrifuge tube. 
• To elute DNA add 50µl warmed sterile DNase/RNase free H2O to the 
centre of the QIAquick membrane, let stand for 1min, then centrifuge 
at 13,000rpm for 1min. 
 
A.4.3  QIAprep® Miniprep Kit Protocol  
Note 
This protocol is designed for purification of up to 20µg of high-copy plasmid 
DNA from 1-5ml overnight cultures of E. coli in LB medium. 
Procedure 
• Resuspend pelleted bacterial cells in 250µl buffer P1 and transfer to a 
microcentrifuge tube. 
• Add 250µl buffer P2 and mix thoroughly by inverting the tube 4-6 
times. Mix gently by inverting the tube. Do not vortex, as this will 
result in shearing of genomic DNA. If necessary, continue inverting the 
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tube until the solution becomes viscous and slightly clear. Do not allow 
the lysis reaction to proceed for more than 5min. 
• Add 350µl buffer N3 and mix immediately and thoroughly by inverting 
the tube 4-6 times. To avoid localised precipitation, mix the solution 
thoroughly immediately after addition of buffer N3. The solution 
should become cloudy. 
• Centrifuge for 10min at 13,000rpm in a table-top microcentrifuge. A 
compact white pellet will form. 
• Apply the supernatants from step 4 to the QIAprep spin column by 
decanting or pipetting. 
• Centrifuge at 13,000rpm for 30-60secs. Discard the flow-through. 
• Recommended: Wash the QIAprep spin column by adding 0.5ml buffer 
PB and centrifuging at 13,000rpm for 30-60secs. Discard the flow-
through. This step is necessary to remove trace nuclease activity. 
• Was the QIAprep spin column by adding 0.75µl buffer PE and 
centrifuging at 13,000rpm for 30-60secs. 
• Discard the flow-through, and centrifuge for an additional 1min to 
remove residual wash buffer. 
• Place the QIAprep spin column into a clean 1.5ml microcentrifuge 
tube. To elute DNA add 50µl warmed sterile DNase/RNase free H2O to 
the centre of the QIAquick membrane, let stand for 1min, then 
centrifuge at 13,000rpm for 1min. 
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A.5  Protein Manipulation Protocols 
A.5.1  PD-10 Desalting Column Protocol 
N.B. The following is a copy of the Gravity Protocol for buffer exchange of 
proteins from the instruction documentation supplied by the 
manufacturer (GE Healthcare) with the product. 
1. PD-10 desalting column preparation 
• Remove the top cap and pour off the column storage solution 
• Cut the sealed end of the column at notch 
2. Column equilibration 
• Fill up the column with equilibration buffer and allow the equilibration buffer to 
enter the packed bed completely 
• Repeat 4 times 
• Discard the flow-through 
 Note: about 25ml equilibration buffer should be used in total for all  three steps 
3. Sample application 
• Add maximum 2.5ml of sample to the column 
• For sample volumes less than 2.5ml, add equilibration buffer to adjust the volume up 
to 2.5ml after the sample has entered the packed bed completely 
• Let the sample or equilibration buffer enter the packed bed completely 
• Discard the flow-through 
4. Elution 
• Place a test tube for sample collection under the column 
• Elute with 3.5ml buffer and collect the eluate. 
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A.5.2  Ni-Affinity IMAC Template 
N.B. These templates are replicated from the ÄKTAprime plus cue cards. 
 
Total separation time = 74 min + sample application time. 
 
A.5.3  Anion Exchange Chromatography Template 
 
Total separation time = 63 mins + sample application time. 
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Expression, Purification, Crystallisation and Preliminary Diffraction Data 
For PpmA, A predicted Cis-Trans Isomerase From The Pathogenic Bacteria 
Streptococcus pneumoniae 
 
Matt Horsham1, Neil W. Isaacs2, Tim Mitchell1 and Alan Riboldi-Tunnicliffe3* 
1FBLS I&I, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA 
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G12 8TA 
3 Australian Synchrotron, 800 Blackburn Rd Clayton, VIC 3168, Melbourne, Australia 
 
1. Abstract 
 
 The surface associated protein PpmA (Putative Protease Maturation Protein 
A) from the human pathogen Streptococcus pneumoniae has been 
recombinantly expressed using an Escherichia coli expression system. Purified 
PpmA from S. pneumoniae has been crystallised utilising the sitting-drop 
vapour diffusion technique. The crystals, which appear as large plates belong 
to the space-group P212121 with unit cell parameters a=65.0Å, b=105.0Å, 
c=120.0Å, α=β=γ=90.0o. The crystals show diffraction to beyond 2.5 
Angstroms resolution. 
 
2. Introduction 
 
 S. pneumoniae is a common commensal bacteria found in the nasopharynx of 
the vast majority of the human population. A gram positive facultative 
anaerobe, it can however cause a variety of diseases ranging from mild 
(otitis-media) to life-threatening (pneumonia, meningitis) when relocated to 
an atypical niche within the body. 
 Current available pneumococcal vaccines in use are either the 23-valent 
capsular polysaccharide vaccine, or a 7-valent capsular polysaccharide - 
protein conjugation vaccine, where the capsular polysaccharide elements are 
linked to a carrier protein such as diphtheria toxoid. However, the latter 
technique is limited by the number of capsular polysaccharides that can be 
successfully conjugated to the carrier-protein, raising the possibility of a 
population shift to strains not encompassed by the current vaccine, whilst the 
former method is less effective in the major at risk groups where the immune 
system is underdeveloped or weakened182. As a result there has been 
increased interest in the possibility of developing a protein-based vaccine 
which could overcome current vaccine limitations65. 
 S. pneumoniae produces two proteins which exhibit homology to peptidyl-
prolyl isomerases (PPIases) of which the putative proteinase maturation 
protein A (PpmA) is one; the other being streptococcal rotamase A (SlrA)156. 
These PPIases are responsible for the cis-trans isomerisation of proteins at 
proline residues, aiding protein folding183. PpmA shows homology to PrtM, a 
PPIase from lactic acid bacteria. However PpmA has not been shown to have 
any PPIase activity, nor is it currently known which protein PpmA activates156, 
157. It has been shown that in a murine model, absence of PpmA results in 
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decreased virulence of the pneumococcus mediated by a decrease in the 
ability of adherence and an increase in susceptibility to opsonophagocytosis 
in PpmA deficient pneumococci157. PpmA is widely conserved throughout 
various strains of S. pneumoniae157 making it a possible candidate for 
inclusion in a novel protein-based pneumococcal vaccine.  
 
3. Materials and methods 
 
3.1 Protein expression and purification 
 
 The gene coding for PpmA was amplified from gDNA of the TIGR4 strain of S. 
pneumoniae by PCR. The obtained PCR product was cleaned using a PCR 
Purification Kit (Qiagen) and cloned into the expression vector pOPINF119 
using the InFusion cloning system (Clontech)125 in-frame with an N-terminal 
His6 tag separated by a HRV-C3 protease cleavage site. The plasmid was 
transformed into competent E.coli DH5-α cells (Invitrogen) and grown at 37oC 
on LB agar plates supplemented with 54µg/ml carbenicillin. A single colony 
was used to inoculate 50ml of LB supplemented with 54µg/ml carbenicillin, 
and the culture was grown overnight in a shaking incubator operating at 37oC 
and 170rpm. Plasmids, harvested from the overnight culture using the Qiagen 
Plasmid Miniprep kit (Qiagen), were transformed into the protein expression 
strain E.coli Rosetta 2(DE3)pLysS and grown at 37oC on LB agar plates 
supplemented with 54µg/ml carbenicillin. A single colony was used to 
inoculate 50ml of LB supplemented with 54µg/ml carbenicillin and 34µg/ml 
chloramphenicol, and the culture was grown overnight in a shaking incubator 
at 37oC and 170rpm. Two 500ml cultures of LB media were each inoculated 
with 5ml of the starter culture and incubated in a shaking incubator at 37oC 
and 170rpm until an O.D600 of 0.6 was reached. Cultures were then induced 
by addition of 0.5ml 1M isopropyl-β-D-1-thiogalactopyranoside (IPTG), and 
incubated at 22oC for the remainder of the 24-hour period. Cells were 
harvested at 4000g for 30mins at 4oC and re-suspended in 50ml buffer A 
(50mM Tris-HCl pH7.5, 500mM NaCl, 20mM Imidazole) supplemented with 
0.1% Tween. Cells were lysed by passing 5 times through a French Pressure 
Cell set at 950psi. The cell lysate was centrifuged at 6500g for 30mins at 4oC 
and the supernatant then centrifuged at 40000g for a further 30mins at 4oC. 
The resulting supernatant was filtered through a 0.2µm syringe filter. The 
cleared cell lysate was then applied to a 1ml HisTrap HP Nickel affinity 
column (GE Healthcare) and the protein was eluted from the column with 
buffer B (50mM Tris-HCl pH7.5, 500mM NaCl, 500mM Imidazole) on an Äkta 
PrimePlus (GE Healthcare) using a linear gradient. The purified protein was 
transferred back into buffer A using a PD-10 Desalting Column (GE 
Healthcare) to remove excess imidazole. The Ni-affinity purified batch of 
PpmA was divided into two equal aliquots; one retained the His6 tag during 
crystal trials, whilst the other had the tag removed. Cleavage of the His6 tag 
was performed overnight at 4oC by addition of 2µl HRV-C3 protease, 
Dithiothrietol (DTT) and EDTA at a final concentration of 10mM and 1mM 
respectively. Reverse IMAC was used to separate the pure PpmA from the 
cleaved His-tags. Purified PpmA was concentrated for crystal trials using 
centrifugal concentrators with a MWCO of 10kDa (Millipore). Concentrated 
PpmA was then used to set up crystal trials. 
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3.2 Crystallisation and data-collection 
 
 Recombinantly expressed, purified PpmA protein was subjected to crystal 
trials at concentrations of 30mg/ml and 16mg/ml using the sitting-drop 
vapour diffusion technique mixing a 1:1 ratio of protein to reservoir solution, 
stored at 20oC and monitored for crystal growth. Screening for crystals 
showed crystals to be present in around 50% of conditions from PEG/Ion 
screen (Hampton Research). The higher concentration of PpmA produced 
showers of small micro-crystals all in a large crystalline mass. The lower 
protein concentration produced single plates varying in size (Fig1). Crystals 
grew within a varying period of 2 days - 2 weeks. Crystals were flash cooled 
in a liquid nitrogen stream at 110K, cryo-protected with dried paraffin oil184 
and tested for protein diffraction in-house on a Rigaku 007 x-ray generator 
(Rigaku). Following further optimisation of crystallisation conditions the best 
crystal was obtained from the condition comprising 31% w/v PEG 4000, 0.18M 
ammonium acetate and 0.1M sodium acetate. The crystal showed diffraction 
to beyond 2.5Å resolution (Fig2). Good, clean diffraction was obtained when 
shooting through the large, flat face of the crystal, but diffraction quality 
decreased greatly when shooting along the thin edge. Despite this, a full 
dataset was collected and it was possible to successfully index the crystal.  
 Indexing of the PpmA crystal was performed using the crystallographic 
program MOSFILM.134 Spots were picked by hand over 10 images due to poor 
diffraction quality in a number of the images. The preliminary data-collection 
statistics for this crystal are given in Table 1.  
 
  
   
Resolution (Å)  2.5Å 
Space group  P212121 
Unit cell parameters (Å, o)  a= 65.0, b=105.0, 
c=120.0, 
α=β=γ=90.0 
   
 
Table 1 Preliminary data collection statistics for single crystal of PpmA 
 
     
Fig1 Crystals of PpmA from S. pneumoniae    Fig2  In-house diffraction image for PpmA shot at 
       0o rotation (crystal shot through large flat  
       surface)               
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4. Results and discussion 
 
 We have successfully crystallised the pneumococcal protein PpmA using an E. 
coli recombinant expression system. PpmA crystals grew over a period of days 
using the sitting-drop vapour diffusion method. Crystals were present as thin 
plates, which show diffraction to beyond 2.5Å. Indexing of the crystal has 
been possible, showing PpmA to belong to the space-group P212121, with unit-
cell dimensions a=65.0Å, b=105.0Å c=120.0Å, α=β=γ=90.0o. Estimation of 
solvent content of the PpmA crystals by derivation of the Matthews co-
efficient suggests 2 molecules of PpmA per asymmetric unit. This suggests 
that PpmA is present as a dimer; previous experiments in our lab using gel-
filtration studies confirm this to be true. Attempts are ongoing at present to 
obtain phases and improve crystal quality for PpmA, which will be required to 
determine the crystallographic structure of PpmA from S. pneumoniae.  
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